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ABSTRACT 
Although many efforts have been done in understanding the aetiology of 
rheumatoid arthritis (RA), the Epstein-Barr Virus (EBV) remains one of 
the strongest candidates to be investigated as possible environmental 
factors in inducing RA. Of relevance, a high percentage of RA patients are 
characterised by a strong immune response to EBV, with high blood DNA-
viral load and circulating cross-reactive (auto)antibodies reacting against 
self-citrullinated antigens (ACPA) and viral proteins.  
Due to its lymphotropic behaviour, EBV might be able to rescue an 
autoreactive B cell phenotype and thus eludes the immune system 
checkpoints. Also, the virus and the infected B cells have been proposed as 
a possible source of citrullinated epitopes triggering the disease.  
To obtain long-standing EBV-infected B cells, I setup an in vitro co-culture 
system whereby RA fibroblasts-like synoviocytes (RA-FLS) obtained from 
synovial fluid and synovial tissue of patient were cultured with CD19+B 
cells for 28 days. RA-FLS were used as feeding environment for the 
CD19+B cells obtained from ACPA+ RA patients and healthy donor. CpG 
was added to induce plasmacells differentiation to test the presence of 
ACPA antibodies. B cells were then recovered, and analysed trough 
fluorescence activated cell sorting (Facs). Finally, molecular biology 
analysis has been performed to detect and quantify specific EBV-related 
gene such as the BamH1-W repeat region. Also, RA-FLS were recovered 
in order to investigate any possible modification induced by the CD19+B 
cells in the system.  
Preliminary data suggested that the EBV+ CD19+B cells population has a 
higher proliferation rate when incubated with RA-FLS, although this is not 
exclusive of RA patient since such proliferation was detected also in 
healthy donor. Nevertheless, this might reflect an in vivo mechanism in 
6 
which the EBV+ CD19+B cells from the peripheral compartment might 
find a preferential proliferating niche in the synovium, due to the RA-FLS. 
Furthermore, I am proposing a new method to obtain naturally EBV+ RA-
CD19+B cells in order to develop a better tool to study the role of the virus 
in RA pathogenesis. 
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CHAPTER 1 INTRODUCTION 
 




Rheumatoid arthritis (RA) is the most common inflammatory erosive 
polyarthritis affecting 1% of the general population and half-million of 
people in the UK. The disease is characterized by a chronic inflammation 
which affects mainly the synovial joints and leads to strong synovial 
alterations (Fig.1.1).  
At the peripheral blood level one of the hallmarks of the disease is an 
autoreactive B cell dysregulation that can results in the production of 
autoantibodies, such as those against citrullinated proteins (ACPA) which 







Figure 1.1 Normal joint compared to rheumatoid arthritis joint. In a healthy joint 
(a) the synovial membrane appears thin with a single cell layer. In a rheumatoid one (b) cells 
in the synovial membrane become activated and hyperproliferative, increasing the thickness 
and developing into the characteristic “pannus”, which then interfere with bone and cartilage. 
From: Strand, V., R. Kimberly, and J.D. Isaacs, Biologic therapies in rheumatology: lessons 





Referring to Dr Wasserman’s paper, in 2010 the American College of 
rheumatology (ACR) and the European Leagues against Rheumatism 
(EULAR) created new classification criteria for RA, aiming to diagnose the 
disease earlier in patients who may not meet the older 1987 ACR 
classification. The most important changes have been the exclusion of 
features present in well-established  RA but not in early RA cases, such as 
the presence of nodules or radiographic erosive changes, together with the 
evidence of symmetric arthritis [2]. A comprehensive list of these updated 
criteria is available in Table 1.1. It is important to mention the contribution 
from Dutch researchers whom analysis system has been developed in order 
to predict and identify those patients with undifferentiated arthritis who 
will, eventually, develop RA (Table 1.2). 
Clinical aspects  
 
Pain and stiffness in multiple joints are the typical clinical presentations in 
RA patients. Most involved joints are the wrists, the proximal 
interphalangeal and metacarpophalangeal of the hands. Also, the 
metatarsophalangeal joints of the feet are commonly targeted. Through the 
DAS28 – where DAS stands for “disease activity” and 28 refers to the 
joints that are examined in this assessment - the disease activity can be 
monitored from baseline through the radiological progression [3].  Visual 
and tactile joint examination may reveal swelling and thickening of the 
synovia due to synovitis. Patients usually present also with prolonged 
morning stiffness, weight loss and systemic symptoms of fatigue. For a 
detailed list of extra-articular symptoms refer to Table 1.3. 
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Table 1.1. The 2010 American College of Rheumatology/European League 
Against Rheumatism Classification Criteria for RA. From Diagnosis and 
Management of Rheumatoid Arthritis, Amy Wasserman, 2011, readapted from 2010 
rheumatoid arthritis classification criteria: an American College of Rheumatology/European 
League Against Rheumatism collaborative initiative, Aletaha D, Neogi T, Silman AJ, et al.  
Ann Rheum Dis. 2010 [4]. 
 24 
 
Table 1.2. Clinical rule for predicting the Risk of RA Patients with 
undifferentiated arthritis. From Diagnosis and Management of Rheumatoid Arthritis, 
Amy Wasserman, 2011, readapted from A prediction rule for disease outcome in patients with 
recent-onset undifferentiated arthritis, Arthritis Rheum, van der Helmvan Mil, 2007, with 
scoring information from reference 5 [2] [5, 6].  
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ORGAN Clinical presentation  







rheumatoid nodules, serositis  
Neurological 
Mononeuritis multiplex, 
peripheral neuropathy  






vasculitis, osteoporosis  












Based on the most recent analysis, RA is estimated to affect between 0.24 
and 1% of the global population. More specifically the incidence of the 
disease in Europe and United States (where it has been more thoroughly 
studied) is estimated to be approximately 40 per 100’000 persons with 
women having usually twice the chance of getting RA compared to men 
(lifetime risk: women 3.6% vs men 1.7) [7] [8].  Of notice the Pima Native 
Americans population has a 10.3 times higher risk of developing the 
disease than the global population [9]. In Nigeria and in less developed 
parts of Africa, RA is almost undetectable, whereas prevalence rates rise to 
nearly 1% in black populations in urban areas, further suggesting some sort 
of environmental factor in the etiology of the disease.  
Etiology  
 
Similar to many autoimmune diseases, RA has several levels of complexity 
with a multifactorial etiology. There is evidence that both genetic and 
environmental factors are involved. 
 
Genetic Factors and the Shared Epitope hypothesis in RA  
 
RA has been widely studied in familial clustering and, specifically, in twin 
studies (monozygotic VS dizygotic). These large genetic screening in 
North Europe have allowed to find a concordance rates for RA of 12.3% 
and 15.4% in monozygotic twins, while these values dropped to 3.5% in 
dizygotic twins. This has led to a final estimation of heritability for RA 
around 65% [10]. 
In order to understand and identify possible susceptibility loci in 1989 
Deighton et al have been performed for RA whole genome scans using 
multi-locus nonparametric linkage analysis. The final result showed that 
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human leukocyte antigen (HLA) region was the only one with statistical 
significance in term of linkage. Other authors have then connected the 
HLA to an higher risk, accounting for 30%-50% of all genetic 
susceptibility in RA [10, 11].  This was further refined by Stastny, who 
hinted a stronger association with a specific HLA gene, the β-chain of the 
HLA-DR molecule, expressed on the surface of antigen-presenting cells 
(APC). In the late 1990s Gregersen et al managed to completely sequence 
the HLA-DRB1 loci, and, for the first time, they proposed the “shared 
epitope (SE) theory”, trying to explain the association between RA and the 
HLA-DR: several alleles present in the HLA-DRB1 would account for  
susceptibility alleles trough a homologous amino acid sequence in the third 
hypervariable region of the first domain of the molecule [12]. At a 
molecular level, the region of interests spans from position 70 to position 
74, having either a glutamine (Q), a Lysine (K) or an arginine (R) at 70 and 
Alanine(A) at 74 (70QRRAA74 or 70KRRAA74 or 70RRRAA74). Specifically, 
these aminoacid sequence can be encoded by several DR: the HLA-DR4 
(DRB1*0401, *0404, and *0405), HLA-DR1 (DRB1*0101 and *0102), 
and HLA-DR10 (DRB1*1010) and this motif constitute an α-helical 
domain creating one side of the antigen binding pocket. This has led 
researchers to speculate that the mechanism of association might rely on 1) 
antigen presentation of arthritogenic antigens [13], 2) the selection of T cell 
repertoire [14]  3) a disrupted generation of functional T regulatory cells 
(Treg) [15].  In contrast Zanelli et al described that sequences having 
aspartic acid (D) and glutamic acid (E) in position 70 and 71 (70DERAA74) 
which is expressed by certain HLA-DR alleles (DRB1*0103, *0402, 
*1102, *1103, *1301, *1302) have actually a protective effect. They also 
refined the haplotypes connected to RA by showing that susceptibility to 
the disease is not exclusively related to DR alleles alone but more likely to  
both HLA-DQ-DR alleles [16]. A more thorough classification of the 
HLA-DR SE component has been proposed by Tezenas du Montcel in 
2005, where she divided the alleles in 3 subgroups (S2, S3P, and L) 
according to their susceptible/protective  phenotype [17].  
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It has been to be mentioned that the SE association it is not exclusive of 
RA but has been found in other autoimmune diseases, such as type I 
diabetes (T1DM) [18]. Adding more complexity, around 20% of RA 
patients are SE negative, making a direct connection less plausible. 
However a study have shown a possible link between this negativity and 
HLA-DR4 coding non-inherited maternal antigens (NIMAs) in women 
with the onset of the disease in child-bearing age (<45 years), but not in 
older women or in men [19]. The possible mechanism could be explained 
by maternal and fetal microchimerism, a phenomenon that takes place 
during pregnancy and in which the mother and the foetus can interchange 
cells and soluble antigens, developing tolerance. Intriguingly maternal 
microchimerism has been associated also to autoimmunity [20]. 
It is fascinating that the presence of these alleles has been strongly related 
to the production of autoreactive antibodies, which are present in 70% of 
RA patient. Indeed, ACPA seropositivity is more strongly related to SE-
positive patient and rarely detected in SE-negative [21], with allele-dose 
effect on antibody production: Snir et al. showed that RA patients carrying 
double SE alleles produce higher levels of ACPA (specifically anti-CCP 
antibodies, anti-citrullinated fibrinogen and anti-CEP-1) compared to those 
patient who are carrying a single SE or no allele at all [22, 23].  
It has since then been hypothesized that this strong association might be the 
evidence of a SE-restricted presentation of citrullinated of antigens model. 
Nevertheless, despite these results, a direct connection between the SE and 
the specific peptide binding and presentation of citrullinated antigens or 
restricted T cell response to citrulline has been difficult. These topics are 
further expanded in the “Autoantibodies in RA: ACPA and RF” and in 
“EBV molecular mimicry” chapters.  
All these connections have led to the speculation of several etiological 
model for RA based on this peculiar mechanism. An example can be the 
fact that the QKRAA sequence expressed by the HLA-DRB1*0401 shares 
sequence homology with EBVgp110, which is usually targeted by the 
immune response during infection [24].   
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It has to be mentioned that other genes have been found to be associated 
with RA: Genome wide association studies (GWAS) and single nucleotide 
polymorphism analysis (SNP) have highlighted elements such as ligands 
and transcriptional factors (CD40 or STAT4) [25], molecules involved in 
interaction between T and APC such as cytotoxic T-lymphocyte-associated 
protein 4, (CTLA4), chemokines (CCL21) or signals related to the 
activation of T cells (PTPN22) [26]. Nevertheless, they represent less than 
5% of the overall genetic contribution compared to HLA genes. 
 
Environmental factors in autoimmunity and in autoinflammatory 
diseases: a wider perspective for RA: 
 
Current evidences and studies have shown that genetic predisposition can 
account for only a 30% of autoimmune diseases. Recent works have shown 
that the environment plays a much more fundamental role in triggering and 
shaping an autoimmune response at a given specific period of time [27]. It 
is very likely that the presence of both genetic and multiple environmental 
factors it is necessary for the break of immune tolerance which then result 
in the immune system attacking the host. Most of these factors have been 
elegantly described by Anaya et al in the review “The Autoimmune 
Ecology”, and some of them will be reported here. This work defines the 
term “exposome”, which is the whole range of factors to whom a subject 
can be exposed during the lifespan that can lead to autoimmunity. These 
can be both internal (e.g.  viruses or bacteria) and external (e.g. lifestyle, 
climate, exposure to contaminant, air pollution) and interact at different 
levels of the immune system, such as the innate or adaptive immunity, or 
trough epigenetic and post-translational modifications. For some other 
factors we still do not have functional mechanisms but strong 
epidemiological association. Some of the most important will be 
summarised here but a complete list is beyond the purpose of this thesis 
and can be consulted on the review [28].  
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Toll like receptors (TLRs), as essential crossroads for the innate system, 
are important in dealing with treats, defined as PAMPs (pathogen-
associated molecular patterns) or DAMPS (damage-associated molecular 
patterns). Upon activation, TLRs can upregulate chemokines and cytokines 
and define the duration and the extent of the inflammatory response. For 
their role, overactivation of these pathways has been often hypothesized to 
be linked to autoimmunity [29]. High mobility group box 1 (HMGB1) - a 
protein which is usually localized inside the cells - can act as a DAMP 
when released and can work in synergy with PAMPs such 
lipopolysaccharide (LPS), double stranded DNA or RNA (dsDNA, 
dsRNA), eventually inducing expression of prostaglandin that promote 
inflammation in arthritis [30]. Another example are peptidoglycans, which 
can be released from bacteria and then bind nod like receptors (NLRs) or 
TLR2. Particularly, it has been found to be increased in cells isolated from 
RA synovial tissue, such as macrophages or DCs [31]. Molecule released 
from dying cells upon ultraviolet irradiation have been reported to induce 
DAMP and being connected to immune responses. Also, in SLE, nuclear 
material and dsDNA released from necrotic cells can also become self-
antigens, and activate the TLR9 signal cascade which leads to 
autoantibodies production [32].  In addition, organ culture from synovial 
biopsies of RA patients have been found to express TLR2 and TLR 4 and 
to release TLR endogenous ligands in a process that can contribute to 
inflammation and arthritis [28]. 
Regarding the adaptive system, failure in the numerous checkpoints of B 
cell activation can leads to possible autoimmune mechanisms. Errors 
during the somatic hypermutation (SHM) can break self-tolerance leading 
to the production of autoreactive clones which can – if not inactivated - 
either produce autoantibodies or present autoantigens to T cells and 
produce inflammatory cytokines [33]. Estrogen and prolactin, two 
important sex hormones, have been reported to directly activate 
autoreactive B cells. Indeed, sex hormones are investigated as one of the 
main culprits in SLE for the predominance observed in female [34]. 
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Furthermore, it has also been shown that women that undergoes hormonal 
replacement therapy have a higher odd of developing the disease [35]. As 
SLE, Sjogren Syndrome (SS)  is also highly prevalent in women: males 
affected by the disease have usually less anti-ro antibodies and Raynaud’s 
phenomena compared to the other sex [36], but they have an higher risk of 
lymphoma and neurological disorder [37]. 
Another element that can activate B cells is 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), an environmental factor released by incineration of several 
material - one these to be cigarettes smoking - and that has been widely 
associated with autoimmunity: animal model exposed to TCDD during 
prenatal development showed an increase in autoantibodies and 
autoimmune kidney lesions [38].  
Regarding T cells, the most studied case in autoimmunity regard a subset 
of T helper cells that strongly participate in autoimmune conditions, which 
are the Th17. There are strong connection between the development of this 
subset and interaction with commensal bacteria  in the intestine, all leading 
to a strong immune response and autoimmunity [39]. 
At the epigenetic level the best studied case in autoimmunity is probably 
SLE, where several environmental agents - cigarette smoke, mercury 
ultraviolet light, viral infections and medication - are known to induce 
oxidative stress, resulting in a reduction of DNA methyltransferase 1 
(DNMT1) and consequent DNA methylation in CD4+ T cells that promote 
autoimmunity [40]. 
Several other environmental factors have been connected to this topic 
based on a wider epidemiological association. As previously mentioned, 
cigarette smoking is of those. It has been associated with an higher odd of 
developing SLE [41] and has been connected to seropositive RA 
(ACPA/Rheumatoid factor) in Caucasian and Latina Americans [42].  
Smoking can also be directly linked to the SE and specific gene-
environment interactions [43, 44] . For instance, it has been demonstrated 
that smoking can induce protein citrullination in lung macrophages among 
persons with the SE [45]. This hypothesis is reinforced by a study in which 
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– using  HLADRB1*0401 transgenic mice – it has been reported that 
citrullination of certain peptides rather than other have made them more 
prone to be mounted and presented on  HLA class II molecules with the 
HLA-SE, leading to a very specific immune response to citrullinated self-
antigens [46] . 
Also, habits such as alcohol and coffee consumption have showed 
association with seropositive RA [47].   
Vitamin D deficiency - a crucial molecule for the immune system - has 
been associated with several autoimmune diseases, such as multiple 
sclerosis (MS), SLE, RA, inflammatory bowel disease and T1DM. These 
disease  become more common as the distance from the equator increases 
and this has been related to diminished sun exposure [28].  
Regarding organic solvents, chronic exposure to these potentially harmful 
agents has been associated as well with MS [48] and systemic sclerosis 
[49]. 
The economic status might be a factor of influence as well in this topic. It 
has been reported that in the US, African American develop MS at a 
younger age compared to European and Hispanic. This was matching with 
lower socioeconomical position that can result in difficulties in accessing 
neurology consultation [50].  
The last environmental factors to be covered are microbial agents. The 
concept of a microbe triggering an autoimmune disease has been proposed 
since the 1870s [51], leading to an enormous amount of research in this 
direction, very often characterized by conflictual results. In particular, in 
RA, it does not look like a single microorganism can trigger the disease but 
rather a combination of bacterial and viral factor [52]. Also, it might be that 
a certain microorganism can trigger the disease only in a subset of cases or 
in cooccurrence with other clinical manifestation, such as psychological 
stress or microtrauma [53]. A crucial conceptual difference - as defined by 
Arleevskaya – is between the acquired and the innate hypothesis. In the 
first case the single event of infection might lead to autoimmunity, while in 
the second one, a genetical predisposition would make a certain group of 
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patients more susceptible to a specific microorganism [54]. Among the 
group relate to the acquired hypothesis the most interesting are 
Porphyromonas gingivalis (P. gingivalis) [55] which, as discussed later, is 
responsible for periodontal disease and can directly citrullinate human 
proteins. 
Regarding those included in the innate hypothesis there are: Proteus 
mirabilis (P. mirabilis) [56], Mycobacterium tuberculosis [57], 
Mycoplasma [58], human retrovirus 5 [59], alpha virus [60], 
Cytomegalovirus [61], Rubella virus [62], parvovirus B19 [63], and the 
ubiquitous Epstein Barr Virus (EBV) [64]. The latter has been extensively 
and yet inconclusively investigated since the 1980’s as a contributor to RA 
and is the focus of my PhD project.  The virus has a strong connection not 
only to RA but to autoimmunity in general and specifically in MS and 
SLE. This topic will be discussed on the EBV chapter. 
So far has been difficult to connect a single infectious agent as the cause of 
RA due to lack of consistent data and large microbial screening. Despite 
these controversies, new evidences are emerging regarding a novel role for 
EBV in the disease as I will discuss in the relevant section. 
 
Immunopathogenesis in RA 
  
As above mentioned, one of the hallmarks of the disease is a strong 
alteration of the synovial architecture. Stromal cells, in particular fibroblast 
like synoviocytes (FLS), can be activated and they are usually responsible 
for tissue invasion and matrix degradation. Contextually, the infiltration in 
the synovia of different immune cells subsets, such as B cells, T cells and 
macrophages can be found. Histologically, the difference in the grade of 
infiltration has been developed to characterize and stratify the disease in 
further subsets. Indeed several related works have been published by 
Pitzalis, Humby, Riberio and Lewis identifying three different” 
pathotypes” [65-67]: 1) lympho-myeloid, with abundance of B cells and 
plasmacells 2) diffuse -myeloid, with a predominance of myeloid cells and 
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a low percentage of B cells 3) pauci-immune, characterised by a prevalence 
of stromal cells and virtually no immune cells infiltrate.  
Among those patients with clear synovial immune cell infiltration: i) 50% 
of the cases are characterized by predominant monocytes and macrophage 
but also T cells; ii) 25% expose sign of B cells and T cells without a clear 
organization; iii) the last 25% present with organized tertiary lymphoid 
organs (TLO),  also called ectopic lymphoid structure (ELS), where B and 
T cell follicles are further clustered thanks to presence of CD21+ follicular 
dendritic cells (FDCs) [68]. Interestingly, this peculiar organisation has 
been described also in other autoimmune or inflammatory conditions as 
well as different type of solid cancers: the most important have been listed 
in Table 1.4 (the complete list can be consulted on the review from 2014  











Table 1.4. Human chronic inflammatory diseases with ectopic lymphoid 
structures. This table has been readapted from “Ectopic lymphoid-like structures in 
infection, cancer and autoimmunity, Costantino Pitzalis, Gareth W. Jones, Michele 
Bombardieri1 and Simon A. Jones, 2014” 
CCL, CC-chemokine ligand; CNS, central nervous system; CSR, class-switch recombination; 
CXCL13, CXC-chemokine ligand 13; CXCR5, CXC-chemokine receptor 5; EGC, ectopic 
germinal center; HCV, hepatitis C virus; LT, lymphotoxin; LTβR, lymphotoxin-β receptor; 
SLE, systemic lupus erythematosus; SSA/Ro, Sjögren’s syndrome antigen A 
(ribonucleoprotein autoantigen); SSB/La, Sjögren’s syndrome antigen B (autoantigen La); 
TAA, tumour-associated antigen. 
Condition Location 
Antigen recognized 
by cells in ELS/TLO 
Other known function 
of ELS/TLO in 
disease 
Autoimmune Diseases  





In situ B cell differentiation  
Ongoing CSR 
Autoantibody secretion 






In situ B cell differentiation  
Ongoing CSR 
Autoantibody secretion 
Multiple Sclerosis CNS Myelin and other neuronal 





Plasma cell anti-insulin 
Reactivity observed 
Unknown 




tial of the 
kidneys 
 Immunoglobulin repertoire 
analysis reveals B cell clonal 
expansion and ongoing 
somatic hypermutation 
Cancer  
Primary cancers Lung 
Breast 
Colon 
TAA In situ antigen-driven B cell 
proliferation, somatic 
hypermutation and affinity 
maturation 
Infection  
HCV Liver Unknown B cell clonal expansion 
Elevated CXCL13 expression 
systemically and locally 
Helicobacter pylori Gastric 
mucosa 
Unknown CXCR5-CXCL13 dependent  
Local T cell priming and 
support 
T helper 17 cells 
IgG and IgA Immune 
response 
Mycobacterium tuberculosis Lung Unknown Priming of antigen specific 
Thelper 1 cells 
CCL19 and CCL21 
expression 
Accumulation of T follicular 
helper like cells 
Environmental     
Cigarette smoke  Lung Unknown Dependent on LTab and 
LTbR 
CXCL13 and CCL19 
expression 
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Secondary and tertiary lymphoid organs: 
  
In the human body the immune response is mainly orchestrated by complex 
and organized structures which are classified into primary and secondary 
lymphoid organs. Primary lymphoid organs comprehend the thymus and 
the bone marrow, and their main function is to produce and select naïve 
lymphocytes (B and T) with high diversity in their receptors. Conversely, 
secondary lymphoid organs (SLO) comprehend lymph nodes, spleen and 
very specific tissue in the mucosa such as the Peyer’s patches.  
The main role of these organs is it to allow recirculation of white blood 
cells and to regulate the encounter between the antigen (trough APC) and 
the final effectors of the immune system. In order to perform these 
activities, SLOs are characterised by a fine architecture which allows 
precise immune cells trafficking and compartmentalization and are 
anatomically segregated thanks to the capsule. Inside, this system is 
sustained by a network of stromal cells and crossed by an intricated and 
specialised vascular and canalicular system, including the afferent and 
efferent lymphatic system, and specialised blood vessels called the high 
endothelial venules (HEV) [70-73]. Trough HEVs, naïve lymphocytes 
expressing L-selectin can access the lymph node from the blood and 
localize in specific areas: B cells localize into the B cell zones (defined as 
follicles) in the cortex region - closer to the capsule - while the T cells 
localise into the T cells zones, (also defined as paracortex), which is more 
central to the organ. In normal lymphoid conditions, B cells follicles tend 
to appear close to follicular dendritic cells (FDC) and HEVs and to be 
surrounded by T cells. Follicles are then divided into germinal centres 
(GC), whereas - during an immune response – further 
compartmentalization can be identified: upon activation naïve B cells enter 
the germinal center and start to proliferate, while undergoing cycles of 
SHM (dark zone); these centroblast can then move to the light zone, 
becoming centrocytes, which are cells in a state of active apoptosis 
competing for survival signals. The highest the affinity induced during the 
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SHM, the strongest the binding to FDC and T follicular Helper cells (TFH) 
and the chances for a specific cell to be rescued from the anergetic or 
apoptotic program. Therefore, the main TFH role is to help the selection of 
affinity matured B cells clones. Also, these two areas are surrounded by the 
mantle zone, an enriched T cells area.  
More in particular, this peculiar segregation is possible thanks to 
differentiated gradients of specific cytokines and chemokines produced by 
the stromal cells network. For instance: T cell who express CCR7 binds 
CCL19/CCL21; centroblast in the dark zone express high level of CXCR4 
which binds CXCL12 produced by reticular cells, while centrocytes in the 
light zone express CXCR5, which binds CXCL13 produced by the FDCs 
[74]. 
TLOs can appear during injury or inflammation and resolve at the end of 
the response. Nevertheless chronic inflammation can stabilize these 
structures, allowing the acquisition of SLO features [75]. SLOs and TLOs 
share similarities in term of segregation of T/B cells areas, and for the 
appearance of vascular structure analogues to HEV. B cells are divided in 
the same different areas present in the germinal center where they 
proliferate, usually close to CD21+ FDC. Plasmablast and plasmacells can 
accumulate around the T and B areas. A major difference between SLOs 
and TLOs is the absence of the surrounding capsules. The main function of 
the capsule is to allow antigen presentation in an isolate environment, 
while in TLOs the immune cells are directly exposed to all the external 
signal of the inflamed tissue. These alterations might lead to abnormal T 
and B cells activation and presentation of autoreactive antigens (such as 
citrulline). Another main difference is that molecules that are usually 
strictly produced and regulate only during development in SLOs, are again 
expressed and activated de novo in TLOs. The most important are 
lymphotoxin-alpha (LT-a) and lymphotoxin beta (LT-b) , produced by the 
B cells, which usually stimulate the expression of other fundamental 
cytokines crucial for organization and compartmentalization of the EGCs 
(e.g. CXCL12, CXCL13, CC19 and CCL21) [76]. A peculiar subset of 
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activated synovial fibroblasts has been recently described as one of the 
major sources of CXCL13 inside the inflamed joint [77]. An example of a 








Figure 1.2. Synovial TLO (previous page). Schematic representation of a synovial TLS showing full feature as a secondary lymphoid organ. T cells and B cells are 
segregated in different areas; cluster of germinal center B cells in the B cell rich area; network of follicular dendritic cells (FDC) derived by stromal cells, who support 
ectopic GC development; lining layer formed by synovial fibroblasts; development of high endothelial venules (HEVs) at the T rich area; localization of B cells and after 
activation GC B cells and final differentiation into hypermutated and class switched plasmacells. In autoimmune diseases plasmacells can then produce a consistent titer of 
autoreactive antibodies, such as ACPA and anti-RO, as demonstrated by immunofluorescence showing colocalization of this cells (CD138) with citrullinated antigens and 
RO52. (T Cells (T); Antigen presenting cells (APC); B cells (B), T follicular helper, Plasmacells (PC), Somatic Hypermutation (SHM), Class witching Recombination 
(CSR)) [75] (CC BY-SA 3.0).
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B cells development and affinity maturation in normal conditions and 
in RA 
 
Hematopoietic stem cells (HSC) in the bone marrow are precursor for both 
T and B cells. While progenitors of the T cells lineage migrate to thymus to 
finish to complete maturation, B cells development takes place almost 
entirely in the bone marrow, where niches created by stromal cells provide 
growth factors, cytokines and survival signals. Then, these signals allow 
the B cells precursor to survive and further differentiate, going through 
different stages (pro-B, pre-B and then, finally, immature B cells) each 
characterised by specific surface markers and by continuous rearrangement 
of the immunoglobulin (Ig) heavy (H) and light (L). Once this primary 
rearrangement is completed, the pre-B cell receptor (pre-BCR) is expressed 
for the first time. The pre-BCR is formed by the µ chain and, after another 
rearrangement of the Ig L genes, the B cells evolve into IgM+ immature B 
cells. The last step in this is the final maturation, where the cells become 
IgM+/IgD+ mature. There is a very refined system of checkpoints and 
selection in this process, but defects in the maturation pathway can lead to 
several issues, such as autoimmunity, primary immunodeficiencies or 
cancer. 
Once the resting mature IgM+/IgD+ cells are present in follicles inside the 
SLO, they can become activated by process orchestrated by T helper cells 
and APCs.  
In GC, B cells undergo cycles of SHM of the immunoglobulin variable 
heavy and light (VH and VL) genes in order to achieve affinity maturation 
and class-switch recombination (CSR) of the immunoglobulin (Ig) genes 
and then finally differentiate into memory cells or plasmacells. The latter 
can then produce a higher titre of autoreactive antibodies (Fig. 1.2).  It is 
important to mention that each of these steps previously mentioned it is 
defined but expression of specific markers, which are now very well 
characterized (Fig. 1.3). 
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In this context, the enzyme activation-induced cytidine deaminase (AID) 
has been proven to initiate SHM by introducing single point mutation in 
WRC (W=A/T, A/G) motifs, or so-called mutational hotspot [78]. This 
allows the B cells, through several cycles of proliferation, to acquire new 
mutations, and trough this mechanism to generate an incredible diversity.  
Also, for the IgM+/IgD+ to switch for their final function as effector into 
IgG, IgA and IgE. CSR can take place inside or outside the germinal center 
and a recent work from Roco, Vinuesa et al revised previously held 
assumptions regarding CSR. Using an immunization model in which mice 
have received transferred B cells specific for hen egg Lysozime (HEL), 
they found that CSR predominantly happen even before the GC or any kind 
of extrafollicular differentiation [79].  
 
There is now conclusive evidence that B cells plays a fundamental role in 
the RA synovium [75]. Indeed, my group demonstrated that B cells 
actively undergo CSR within RA synovium. Humby et al identified the 
presence of circular transcript (obtained during CSR from IgM to IgG) in 
AID+ CD21+ RA synovium, supporting the presence of autoreactive 
plasmacells and high affinity IgG autoantibodies against several 
citrullinated antigens.  
Crucial experiments by different groups have demonstrated that V gene 
repertoire of B cells obtained from the synovium – both from RNA extracts 
and microdissection – frequently display on oligoclonal repertoire with 
highly mutated V regions, which is usually a hint for local antigen-driven 
GC reaction. The direct evidence that in situ diversification in the RA 
synovium may allow B cells proliferation has been provided by my group, 
showing high AID level expression in B cells aggregates in close contact 
with FDC inside the synovial environment [80]. This expression seems to 





Figure 1.3. B cell development and surface markers expression. Here the expression of different surface markers during B cell development is shown (from “B-cell 
targeting in rheumatoid arthritis and other autoimmune diseases, Edwards, J.C. and G. Cambridge, Nat Rev Immunol, 2006. 6(5): p. 394-403”) [81].
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Autoantibodies in RA: RF and ACPA 
 
Many autoantibodies have been connected to RA in the last 70 years, 
including RF, ACPA and, more recently, anti-carbamylated protein 
antibodies (anti-CarP) and anti-acetylated protein antibodies. Accordingly, 
to the presence of RF and/or ACPA, RA patients can be divided and 
stratified into seropositive and seronegative. The formation of these 
autoantibodies has been connected with both environmental (smoking) or 
genetic (shared epitope) factors. Interestingly, in some cases these 
autoantibodies can be detected many years prior to the onset of the disease, 
and this might suggest some sort of etiological trigger in which the first 
autoantibodies appear in predisposed hosts years before an established 
inflammatory arthritis [82]. Focusing on the antigens targeted by these 
autoreactive autoantibodies a vast spectrum of elements has been 
discovered, including stress protein, enzymes, nuclear proteins, cartilage 
components and, most importantly, several citrullinated antigens 
(Table1.5). This demonstrates that RA is not characterised by response to a 
single antigen but by a mixture of different autoreactive elements - 
connected both to B and T cells – and this mixture may vary during the 
course of the disease and differ from patient to patient [83].  
First evidence that serum from RA patients contained some sort of 
biological marker activating the agglutination of sheep red corpuscles, thus 
characterized by autoreactivity, was provided in a pivotal study in 1940 by 
Norwegian Dr Erik Waaler [84]. Dr Waaler first described the RF which 
was later redescribed in 1948 by Dr Harry Rose, who also developed an 
accurate diagnostic test. Nowadays this test is still referred as the Waaler-
Rose Test and allowed the discovery that RF is directed to the FC region of 
IgG [85]. Usually RF manifest as an IgM , but also IgG and IgA have been 
described [86]. 
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RF is considered to be high in serum when above 20 IU/mL and this 
usually occurs in 80% of RA cases. Higher levels of RF are clinically 
connected to a greater probability of destructive articular disease. RF has 
low specificity for RA being present in up to 50% of Sjögren's syndrome 
patients and in other autoimmune and infectious diseases. Intriguingly, RF 
it is also found in Epstein–Barr virus or Parvovirus infection and in 5 to 
10% of healthy persons, especially in elderly people. 
Although a direct pathophysiological connection has still been difficult to 
made (this will be discussed later) there is a clear association between RF 








Autoantigen Disease Tissue Localisation 
Filaggrin RA Epidermis 
Vimentin RA Mesenchymal cells 
⍺ Enolase RA Synovium 
Fibrinogen RA Serum 
Collagen Type I, II RA Synovium 
Fibronectin RA Extracellular matrix 
Myelin basic protein MS Neuron sheath 
Eukaryotic translation 
initiation factor 4G1 
RA Cytoplasm 







Histones FS Neutrophil Extracellular traps 
 
Table 1.5. List of Citrullinated autoantigens. Readapted from “Citrullination of 
autoantigens implicates NETosis in the induction of autoimmunity, Nishant Dwivedi, Marko 
Radic, Annals of Rheumatic Disease, 2014”[87]. Felty’s syndrome (FS), rheumatoid arthritis 
(RA)
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Another mechanism in which RF can contribute to the disease is by 
formation of immunocomplexes and complement fixation. The former has 
been demonstrated in a K/BxN mouse model where the development of an 
inflammatory arthritis is directly connected to the formation of complexes 
between autoantibodies and glucose-6-phosphate isomerase [88]. There is 
evidence that the autoreactivity potential of RF manifests both by self-
association and by increasing the arthritogenicity of other autoantibodies, 
such as ACPA [89, 90].  
In 1993, another important discovery was made when Serre et al described 
filaggrin as a target antigen of RA-specific anti-keratin antibodies (AKAs). 
Further examination led to a deeper understanding that AKAs – but also 
other RA-specific autoantibodies known as anti-perinuclear factors (APFs) 
and anti-Sa antibodies – bind to peptides containing citrulline as common 
antigenic element, nowadays commonly referred as ACPA [91-93]. 
Citrullination (or deimination) is a reaction mediated by peptidyl-arginine 
deiminase (PAD) enzymes, which convert the amino acid arginine into 
citrulline. This modification occurs post-translationally and usually happen 
in several normal physiological conditions, including maturation of the 
epidermis [82].  
There is a strong association between the presence of the shared epitope 
and the level of ACPA in the serum of RA patients, and this has led to 
speculation that peptides presented by SE-containing alleles might be more 
frequently citrullinated. Indeed, Hill et al have shown in 2002 that the 
conversion of arginine to citrulline allows for a high-affinity peptide 
interaction in the MHC class II molecule when the rheumatoid arthritis-
associated HLA-DRB1*0401 is present [94]. This has been further 
confirmed by a cutting-edge paper in which crystal structure studies have 
shown that the HLA-DRB1 beta chain antigen preferentially bind 
citrullinate antigens compared to other alleles that bind both arginine or 
citrulline [95]. Nevertheless, a final culprit regarding the exact binding-
motif of the SE molecules in vivo has still been difficult to identify. 
Interestingly, it has been shown that the SE allele is able to interact with 
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surface calreticulin (CRT), a molecule with a strong connection with 
citrullination and arthritis. In several works by Ling and De Almeida it was 
shown that the interaction between SE and CRT is able to skew the 
immune response to a Th17 subset and to a reduction of Treg [96, 97]. 
Furthermore, in my lab, Corsiero et al identified synovial B cell–derived 
RA-monoclonal antibodies (obtained from ELS+ RA synovium tissue) able 
in vitro to react toward FLS-derived CRT, showing that this might be a 
mechanism contributing to the local autoimmune response [98]. 
Recently, strong connections have been added between ACPA production 
and the microbiome, in particular regarding the association between 
periodontitis and RA. P. gingivalis is the main causative agent for 
periodontitis and his bacterial PAD might contribute to an increase of 
citrullinate antigen [99]. In addition, ACPA can bind alpha enolase derived 
from this bacterium and this cross reaction might produce an inflammatory 
immune response that can trigger the disease. Nevertheless, citrullination 
pathway of P. gingavalis PAD differs strongly from the human PAD, so 
further experiments are needed to establish the relevance of bacterial PAD 
in the breach of tolerance to citrullinated antigens [100]. 
 
The pathogenic potential of autoantibodies 
 
While the clinical relevance and diagnostic value of autoantibodies have 
been an uncontroversial dogma in RA, their direct role in the 
pathophysiology has been difficult to proof. Nevertheless, in the last 20 
years several papers have cast light in this direction, finally connecting 
these molecules to the inflammatory cascade leading to joint damage. One 
of the lines of evidence come from the fact that rituximab depletion of B 
cells greatly improves patients conditions, and this is even more marked in 
ACPA+ and RF+ patients, indirectly suggesting a major contribution of the 
autoantibodies in RA [82, 101]. In this section I will discuss some of the 
possible pathogenic roles of ACPA (Fig 1.4). 
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The first one is connected to the binding of FC receptors on effector 
immune cells, normally a physiological interaction between the antibodies 
and the immune cells to mount protective immune responses. Specifically, 
immunocomplexes containing citrullinated fibrinogen can stimulate 
macrophage activation through FcγR engagement leading to increased TNF 
secretion [102, 103]. 
The damaging effect of immunocomplexes appears to be increased when in 
synergy with RF-IgM or RF-IgA, as supported also by epidemiological 
studies [104]. Furthermore, ACPA can directly bind and activate 
monocytes on GRP78, a citrullinated surface receptor, triggering NF-kB 
activation and leading to the production of inflammatory cytokines as well 





















Figure 1.4. Pro-inflammatory and osteoclastogenic roles of autoantibodies in rheumatoid arthritis: From “Frontiers in Medicine, Bugatti, Manzo, Montecucco and 
Caporali, 2018: The multiple effects of anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) on macrophages (A) and osteoclasts (B) are shown. 
Collectively, ACPA are able to stimulate cytokine production by macrophages both through the interaction of their Fc tail with stimulating Fcγ receptors, and through Fab-
mediated recognition of membrane citrullinated proteins such as GRP78. Pentameric class M RF potentiates ACPA-induced inflammation likely via activation of the 
complement cascade (A). ACPA are also able to promote osteoclast differentiation and activation through similar mechanisms mediated by their Fc and Fab portions. Again, 
clinical studies indicate that RF, especially at high titres, amplifies ACPA-mediate bone damage (B)”[106] .
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The latter can be activated in RA by ACPA through both the classical 
pathway (initiated by C1q) and the alternative pathway (initiated by C3) 
but not the lectin pathway [107]. Indeed the synovial fluid of RA patients 
shows low C1q and C3 together with an increase of cleavage products, 
indicating a strong complement activation [108].  
Another important feature in RA is the augmented generation of neutrophil 
extracellular traps (NETs) from both circulating and synovial fluid 
neutrophils. Indeed, both ACPA and RF have shown to strongly influences 
this mechanism. NETs formation is an elegant physiological event where 
neutrophils protrude condensed chromatin to trap and kill pathogens. The 
link between NETs and ACPA production is extremely interesting as 
during NETtosis, chromatin decondensation requires the 
hypercitrullination of histone proteins, leading to excessive exposure of 
citrullinated antigens that may lead to the production of ACPA. 
Interestingly Pratesi and Migliorini have provided evidence that ACPA can 
in turn stimulates NETtosis and target NETs antigen, fuelling the ongoing 
ACPA production, opening the scenario to a process that might 
continuously renovate itself, leading to a systemic non-resolving response 
[109]. My group has  demonstrated that monoclonal antibodies obtained 
from synovial fluid B cells of RA ACPA+ patients have a strong reactivity 
against citrullinated histones produced during NETs formation [110]. Some 
studies have also connected NETs and RA-FLS, but this will be discussed 
later. Recent experiments have shown that IgA-RF immune complexes can 
result in an increased NETosis [111, 112]. 
RA patients who are RF+ or ACPA+ are usually affected by a more severe 
form of RA, with enhanced joint destruction [113, 114]. Several works 
have shown that ACPA are able to interact with FcγR on osteoclasts, both 
in vitro and in vivo, and also to induce their differentiation from osteoclast 
progenitors. In 2016, Krishnamurthy et al have identified a novel IL-8 
dependent molecular mechanism that link ACPA to osteoclasts and direct 
bone erosion, by showing that IL-8 antagonist can rescue bone destruction. 
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In this context ACPA seem able to bind citrullinated vimentin on 
osteoclasts surface [22]. As with immunocomplexes, osteoclasts activation 
- and thus degradation of bone - seems to be increased when RF and ACPA 
are present in combination, as supported by increased radiographic 
progression in double positive RA patients [106].  
Recent works have also suggested a direct role for ACPA in promoting 
pain. Wigerblad et al injected murinised monoclonal ACPA in a B10.RIII 
mice mouse model managing to trigger a directly induced pain response. 
This mechanism seems to require the binding of autoantibodies to marrow 
osteoclast precursor, which would in turn lead to the production of the IL-8 
murine analogue CXCL1 [115]. This novel work shows how ACPA can 




The role of FLS and their interactions with immune cells 
 
As already mentioned, B cell activation is sustained by a network of FDCs  
that have the same phenotype and functional capacity as FDCs in lymphoid 
organs and which are derived from locally differentiating stromal cells, 
probably FLS [116]. It has long been known that FLS play a fundamental 
role in the pathogenesis of RA either producing a wide array of pro-
inflammatory mediators (cytokines and chemokines) or directly 
contributing to local cartilage destruction due to their neoplastic-like 
behaviour in terms of tissue invasion and matrix degradation [117]. It has 
now been extensively shown that resident joint tissue synovial fibroblasts - 
but also dermal, gingival and intestinal - can exert immunological 
functions. Indeed they display several immune characteristics like 
expression of innate immune receptors, i.e. TLR [118, 119], production of 
cytokines and chemokines in the presence of pathogens or trauma, ability 
to process antigens and expression of major histocompatibility complex 
(MHC) receptors [120]. In a healthy joint, synovial fibroblast are the most 
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abundant cells, constituting one of the crucial elements in both lining and 
sublining layer, the latter presenting with a normal thickness of 1-2 cells. 
They are the major contributor to the lubrication and integrity of the 
cartilage, thanks to the production of several components of synovial fluid, 
such as the extracellular matrix (ECM). These mesenchymal cells, also 
known as type B synoviocytes - to distinguish them from the type A 
macrophage-like synovial cells - have a clear fibroblast phenotype in term 
of expression of type IV and V collagen, vimentin and CD90 (Thy-1). 
Nevertheless, FLS have some unique characteristics compared to other 
fibroblast lineages, including the expression of Cadherin-11, an adhesion 
molecule important for homotypic aggregation [121].   
This delicate equilibrium is totally altered when a patient is affected with 
RA, whereby the synovial lining layer presents a marked increase in 
thickness and immune cells start to infiltrate the sublining, establishing 
cell-cell contact interactions with FLS. 
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It has long been debated whether synovial stromal cells are simple 
bystanders and inert actors during the development of RA or they rather 
play a critical role in initiating and propagating the disease (the so called 
“mesenchymal hypothesis” of RA, put forward by Firestein  [122]) . A 
series of studies in the last two decades have cast new light on the crucial 
importance of fibroblasts in the pathogenesis of RA, a concept which is 
currently well accepted [123]. One of the most important characteristics of 
these cells is that, upon proliferation, they become activated and ready to 
invade and destroy the cartilage tissue. For most of the studies performed 
worldwide, RA-FLS have been taken from patients undergoing joint 
replacement or synovial biopsies. However, it is imperative to highlight 
that long-term culture may affect both phenotypes and genotypes of these 
cells, as already been discussed by other authors [124]. 
Focusing on the role as immune cells, it has been showed that FLS express 
TLR1-7 but very low or basal transcript level of TLR8, -9 and -10 [118]. A 
summary on the role of each single TLR on RA-FLS has been collected by 
Ospelt in 2017 [125]. Briefly, while TLR-3 and -7 are sensors for double 
and single-stranded RNA respectively, TLR-2 (which use TLR-1 and -6 as 
heterodimers) and TLR-4 are sensors of bacterial activity, detecting the 
presence of lipoproteins such as LPS. As demonstrated in my lab by Kam 
and Bombardieri, upon stimulation of TLR-3, RA-FLS are able to produce 
high amount of B- cell activating factor (BAFF) and A proliferation-
inducing ligand (APRIL) [126]. In particular, several endogenous ligands, 
which are usually increased in an RA joint, have been identified in vitro for 
their ability to activate one or more TLR pathways. Specifically, cells 
undergoing necrosis can release self-molecules able to trigger TLR-3 
signalling [127], while fibrinogen can bind TLR-4, showing an even more 
potent activation in its citrullinated form. Similarly, free histones, which 
have been described to bind both TLR-2 and -4, were able to activate TLRs 
with higher efficiency in their citrullinated form or when presented as 
immunocomplexes. Furthermore, this result has been linked to the 
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subsequent presence of autoantibodies, especially ACPA, as described by 
Hatterer et al [128]. Only a few studies have focused on DNA sensors, 
such as TLR-9, since 24 hours stimulation of RA-FLS with unmethylated 
CpG rich DNA has not shown any increase in inflammatory cytokines such 
as IL-6 or IL-8 [129]. Only recently Carmona-Rivera et al have described 
the ability of RA-FLS to internalise (NETs)-derived citrullinated histones 
through a receptor for advanced glycation end products (RAGE) and TLR-
9 pathway [130]. Furthermore, they showed that FLS primed with NETs 
products are able, in a mouse model of RA, to promote ACPA production. 
Nevertheless, some of these results have been criticised and the presence of 
TLR-9 on RA-FLS is questionable. 
It is important to mention that TLRs are not the only innate immune 
pathogen recognition receptors (PRR) described in FLS. Also, retinoic 
acid-inducible gene I (RIG-I) and MDA5 (which bind nucleotides), NOD1 
(recognizing bacterial molecules containing D-glutamyl-meso-
diaminopimelic acid (iE-DAP) moiety) and NOD2 have been described in 
these cells [131-134].  
For what concern the interaction with other resident as well as infiltrating 
immune cells, synovial fibroblasts can orchestrate strong interaction with T 
cells, monocytes, macrophages, endothelial cells and osteoclasts [135-138]. 
Furthermore, RA-FLS likely have a role in the formation of ELS and B 
cells survival.  
As above mentioned, RA patients can be stratified - following histological 
analysis - in three different pathotypes: i) the pauci immune or “fibroid 
pathotype”, characterised by an increase of the fibrotic component and a 
lower number of immune infiltrates; ii) the diffuse myeloid pathotype, 
where monocytes and macrophages are the most abundant cells; iii) the 
lympho-myeloid pathotype, where B an T cells aggregates are predominant 
and can often organise themselves in [65, 139].  
Recent evidence is leading to the idea that RA-FLS might promote and 
orchestrate formation of ELS trough the production of receptor activator of 
NF-κB ligand (RANKL), CCL19 and CCL21 [75, 140]. Furthermore, the 
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high level of APRIL, BAFF - produced upon stimulation of the TLRs - and 
CXCL12, are able to create the perfect environment for the survival of B 
cells and plasma cells, including potentially ACPA producing-autoreactive 
clones.  
Beyond all the described indirect effects on other cell types, one of the 
characteristics which allow RA-FLS to actively contribute to the disease is 
the invasion and destruction of the cartilage. One of the prerequisites for 
the attachment of these cells to chondrocytes appears to be the loss of key 
molecular elements of the cartilage, such as proteoglycan, as shown in a 
TNF transgenic mouse model by Korb-Pap et al [141]. Taken together 
these results have raised the hypothesis that activated synovial fibroblasts 
might be able to migrate through the blood stream from an inflamed joint 
to a non-inflamed joint, with the subsequent establishment of a new 
destruction process. Among the adhesion molecules, integrins and 
syndecans have been implicated in the attachment of fibroblasts to the 
cartilage matrix, specifically α5β1 integrin which binds fibronectin, a 
protein markedly elevated in the RA joints [142]. Another peculiarity of 
RA-FLS is the production of destructive enzymes, which is often 
stimulated by TNF and IL-1. Among these the most important are matrix 
metalloproteinases (MMP 1,3 9, 13, 14 and 15), a disintegrin and 
metalloproteinase with thrombospondin motifs (ADAMTs) and cathepsins 
B, L, and K [143] . 
From a gene regulation point of view, it is important to mention that 
several studies are bringing novel evidence that the observed pro-
inflammatory stable phenotype of RA-FLS is due, at least in part, to 
epigenetic modifications (DNA methylation, histone deacetylation) and 
transcription repression by microRNASs [144-146].  
Another assumption which has been recently been challenged is the 
phenotypical stability of RA-FLS once activated. The introduction of 
fluorescence-activated cell sorting (FACS) for the characterization of FLS - 
a technique which has been underused with these cells due to intrinsic 
technical difficulties - together with immunostaining and genotypization, 
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have lately changed this belief. Indeed, FLS from different joints differ in 
term of function, interaction and, moreover, gene expression compared 
with other stromal or hematopoietic cells. This has been shown in 
particular for Hox genes, a group of genes that controls limb development 
from the embryonic state, and that are expressed as blueprints of their 
specific location. Frank-Bertonceli et al demonstrated that FLS from 
different limbs maintain this blueprint established during embryogenesis in 
adult life [147].  
Furthermore, the synovia itself displays heterogeneity in terms of stromal 
cell populations. The lining layer stroma have abundant VCAM1, Cadherin 
11 and podoplanin, while synoviocytes in the sublining express more 
CD90 and CD248 [121, 148].  
Regarding this aspect one of the most interesting recent studies has been 
published by Mizoguchi et al in 2018, where they identified in fresh human 
synovium different subsets of RA-FLS, most of them Podoplanin+ and 
Cadherin11+ but further distinguished for their expression of CD34 and 
CD90 [149]. CD34 is a transmembrane phosphoglycoprotein, first 
identified on hematopoietic stem and progenitor cells but now also known 
to be express on MSC and other stromal cells, including corneal 
keratinocytes and epithelial progenitor [150]. The role of CD90, instead, 
has not yet been fully elucidated but a role in cell-cell and cell-matrix 
interactions, with implications in inflammation and fibrosis has been 
suggested [151]. One subset in particular, CD34-CD90+ seems remarkably 
increased in the sublining area around blood vessels, and this expansion 
has been connected to disease activity, tissue invasion and infiltration of 
other immune cells. Also, gene expression profiling analysis of this subset 
has highlighted a high expression of RANKL and a low expression of 
osteprotegerin (OPG, a negative modulator of osteoclastogenesis) 
suggesting their role in bone loss. On the other side, CD34-CD90- 
fibroblasts- whose ability to promote osteoblastic bone formation trough 
the expression of BMP-6 has led to their identification as a “protective” 
subset - seems strongly reduced in the RA synovia. A third subset, CD34+, 
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appeared to be transcriptionally imprinted as a strong secretory rather than 
an invasive phenotype, due to the high expression levels of IL-6, C-C Motif 
Chemokine Ligand 2 (CCL2) and C-X-C motif chemokine 12 ( CXCL12), 
among others.  
In addition, Choi et al have identified the expression of supplementary FLS 
markers in early arthritis patients. These include the fibroblast activation 
protein (FAP) and the decay-accelerating factor (DAF) or CD55 [152]. 
FAP is a cell surface type II glycoprotein with ectoenzyme activity and, 
interestingly appears to be expressed on stromal fibroblasts of 90% of 
human carcinoma. It has been implicated in the control of fibroblasts 
growth during development and tissue repair. Conversely, DAF, which is a 
70 kDa membrane glycoprotein that attaches to the cell membrane via a 
glycophosphatidylinositol (GPI) anchor, is widely distributed among 
hematopoietic and non-hematopoietic cells. On FLS, DAF seems to 
mediate contacts with CD97 on other immune cells and may be of primary 
importance in maintaining and amplifying synovial inflammation. It has 
also been linked to interactions with complement proteins.  
This work on fibroblast subsets has been very recently pushed forward by 
Croft, Barone and Buckley who identified and described the biological 
behaviour of FLS responsible for mediating either inflammation or tissue 
damage in arthritis. In an elegant in vivo work, they have shown that 
deletion of fibroblast activation protein-α (FAPα)+ fibroblasts suppressed 
both inflammation and bone erosions of resolving arthritis. Specifically, 
using single-cell transcriptional analysis, they identified two main 
fibroblast subsets among the FAPα+ population: FAPα+THY1+, resident 
in the synovial sub-lining and with a role as immune effector; 
FAPα+THY1−, a more aggressive and invasive phenotype resident in the 
synovial lining layer. Furthermore, in vivo cell transfer experiments in 
murine joints have shown very different behaviour of these two subsets. 
When FAPα+THY1− fibroblasts were transferred, they acted as mediators 
of bone and cartilage destruction with small effect on inflammation; on the 
opposite the transfer of FAPα+ THY1+ fibroblasts resulted in an 
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orchestrated and persistent inflammatory arthritis, with fewer effect on 
bone and cartilage[77].  
 
From a metabolic point of view a very inclusive review on FLS has been 
written and published by Falconer in 2018, highlighting a sort of metabolic 
imprinting of synovial cells  - due probably to epigenetics changes - 
promoted by the inflammatory microenvironment, which is long lasting in 
in vitro cultures [153]. Several of these metabolic studies have focused on 
the mitochondrial metabolism and dynamics in order to obtain a complete 
and more adequate picture of the synovia, but further studies are needed to 
fully clarify the relationship between metabolic changes and the phenotypic 



















The Epstein-Barr Virus  
Discovery and History of EBV 
 
It has been more than 50 years since the EBV, the first tumour-inducing 
virus, was discovered in London. In 1964, a group of scientists published 
on the Lancet the paper “Virus Particles in Cultured Lymphoblast from 
Burkitt’s Lymphoma” which will radically change the cancer field, and 
among them, there are two young researchers Anthony Epstein and 
Yvonne Barr who will later name the virus.  
In order to the get the fascination of this discovery a step back in time and 
space is needed.  
Dr Denis Parson Burkitt was working in equatorial Africa - and 
specifically in Uganda - when, in 1958, he started to investigate a form of 
cancer which was very common in young kids in that area. It was 
characterised by painful face or neck swelling and was rapidly fatal if left 
untreated. He later discovered that the tumour was caused by an 
uncontrolled and aggressive proliferation of white blood cells. 
Unfortunately, he had no idea what was causing the tumour but, thanks to 
some epidemiological studies, he noticed the disease was following a 
similar pattern to malaria, since it was localized in areas with hot weather 
and heavy rainfall. This would have been the first hint the Burkitt’s 
lymphoma - later described after him – was probably transmitted by some 
sort of microorganism. 
A few years later, in 1961, Burkitt was presenting in London a lecture 
entitled ‘The commonest children’s cancer in tropical Africa: a hitherto 
unrecognized syndrome’, containing most of his studies and hypothesis 
and, luckily, Epstein was among the audience. It was thanks to his prior 
knowledge of both Rous Sarcoma Virus (RSV) – a transmissible agent 
causing tumour in chicken – and the further advantage of having learned a 
brand new technology for the time – electron microscopy - in the 
Rockefeller Institute laboratory of George Pallade, that Epstein was able to 
advance the idea that an oncogenic virus depending on some sort of vector 
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would be involved. This simple question would have started a long-
standing collaboration between the two scientists but, most importantly, it 
would set the dawn of human tumour virology.  
Unfortunately, for 3 long years, every kind of attempt of retrieving 
Burkitt’s sample from Africa and to culture the white blood cells from the 
tissues had miserably failed and Epstein and Barr – at the time working 
with Burt Achong – where left with nothing more than frustration. Quoting 
one of the most elegant review written on EBV by Young, Yap and 
Murray, “It is here that serendipity played a part: a delayed and rerouted 
flight from Kampala in December 1963 resulted in a BL biopsy reaching 
the London laboratory later than expected. The transit medium in which 
the BL biopsy was shipped was unusually cloudy but, rather than the 
suspected contamination with bacteria, microscopic examination revealed 
viable tumour cells floating free of the main lymphoma mass. These cells 
grew when suspended in fresh culture medium, requiring the culture to be 
split into new culture bottles. And so, the first cell line from a human 
lymphoma was established, and early in 1964, Epstein prepared these BL 
cells (now named the EB1 cell line after Epstein and Barr) for electron 
microscopy. He was exhilarated to observe unequivocal virus particles in a 
cultured BL cell and it was clear from the morphology of the virus 
particles that this was a herpesvirus. Unlike the three other human 
herpesviruses known at that time, this virus was inert as it did not induce 
the characteristic lytic infection usually associated with herpesvirus 
replication. These observations were published in a Lancet paper that 
became a citation classic in 1979”[154, 155]. For a timeline of the major 
milestone in EBV research check figure.1.5.  
Classification of EBV 
 
The EBV - also called human herpes virus 4 (HHV-4) - is classified within 
the gammaherpevirus subfamily and has to be considered as the prototype 
of the genus Lymphocryptovirus. In human two major EBV types have 
been detected, relatively EBV-1 and EBV-2. Formally they differ in the 
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EBNA expression sequence (EBNA-2, EBNA-3A, EBNA-3B, and EBNA-
3C) [156]. These two subtypes - also referred as type A and type B - differ 
in the way they are able to immortalize cells lines, with EBV-2 subtype 
having less immortalizing efficiency than EBV1, probably due to mutation 
in EBNA-2 [157, 158]. 
Nevertheless, in 2019 Zanella et al have published a newer and more 
specific classification based on phylogenomic and population analysis 
[159]. In their work, they criticised the old classification claiming that only 
small subsets of genes have been used to sort out strains and this have led 
to failure in identifying all the genomic variability and recombinant region 
present in EBV genome. In order to avoid misinterpretation and to 
minimize recombination signals - which appears to be 2.5-times stronger 
that the mutation events - they used a hierarchical bayesian analysis of 
population structure (hierBAPS), which resulted in the differentiation of 12 
EBV populations. These populations are mostly related among them due to 













Figure 1.5. From “Nature Perspectives, Young, Yap and Murray, 2016: Timeline showing the 
major milestones in EBV research. ACIF, anti‐complement immunofluorescence; BL, Burkitt 
lymphoma; EBER ISH, Epstein–Barr virus‐encoded RNA in situ hybridization; EBNA, 
Epstein–Barr nuclear antigen; EBV, Epstein–Barr virus; ENK, extranodal natural killer; 
HIV, human immunodeficiency virus; HL, Hodgkin lymphoma; HRS, Hodgkin–Reed–
Sternberg; IgA, immunoglobulin A; IM, infectious mononucleosis; LMP, latent membrane 
protein; NPC, nasopharyngeal carcinoma; PTLD, post‐transplant lymphoproliferative 
disease; Q‐PCR, quantitative PCR; TNFR, tumour necrosis factor receptor; VCA, viral 











EBV Pathologies and Epidemiology 
 
EBV is one of the most common viruses among the general population. 
Children in developing countries usually acquire the infection during the 
first five years of life, while in developed countries this event is usually 
delayed to adolescence. The presence of the virus inside the B cells is 
usually asymptomatic but, in some cases, can lead to an infectious 
mononucleosis which usually resolves in 2 weeks. The virus then survives 
in patients with an asymptomatic infection and sign of previous infection 
can be usually found in 90% of adults [160].   
The virus is strongly associated with several other diseases, in particular 
some types of cancer, such as Hodgkin’s lymphoma, Burkitt's 
lymphoma, gastric cancer and nasopharyngeal carcinoma (for a detailed list 
of EBV-associated diseases check table 1.6) [161]. However, in the last 30 
years the strong lymphotropic behaviour of EBV have gained interest in its 
ability to modulate immune responses with mounting evidence regarding 
the ability of EBV to induce the breach of self-immunological tolerance 
and the onset of autoimmunity [162, 163]. 
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Type of disease    Disease 
Nonmalignant disease 
   
• Infectious mononucleosis 
• Chronic active infection 
• Oral hairy leukoplakia 
Malignant disease Immunocompromised host B cell malignancies Acquired immunodeficiency • AIDS-associated B cell lymphomas 
• Post- transplantation lymphoproliferative disorder  
• Lymphomatoid granulomatosis 
• Methotrexate-associated B cell Lymphoma 
   
Congenital Immunodeficiency • Severe combined immunodeficiency-associated B cell lymphomas 
• Wiskott-Aldrich syndrome-associated B cell lymphomas  






Immunocompetent host B cell malignancies 
 
• Burkitt lymphoma 
    
• Classical Hodgkin lymphoma 
  
T cell malignancies 
 
• Extranodal NK/T cell lymphoma, nasal type  
• Virus-associated hemophagocytic syndrome T cell lymphomas   
Epithelial cell malignancies 
 
• Nonglandular nasopharyngeal carcinoma 
• Lymphoepithelioma-like carcinoma (salivary, thymus, lungs, stomach) 
• Breast carcinoma 
• Hepatocellular carcinoma   
Mesenchymal malignancies 
 
• Follicular dendritic cell sarcoma 
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Table1.6. Epstein Barr Virus-associated diseases. Readapted from “The Annual Review of Pathology: Mechanisms of Disease Spectrum of Epstein-Barr Virus-




EBV Structure and Genome 
 
EBV has a diameter of approximately 122-180 nm and its main structure is 
composed of i) a double helix of DNA containing 172'000 base pairs and 
around 85 genes [164]; ii) a protein nucleocapsid protecting the DNA; iii) a 
protein tegument surrounding the nucleocapsid which in turn is surrounded 
by a structure - called the envelope - containing both glycoproteins, 
essential for infection, and lipids [165] (fig. 1.6 and 1.7).
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Figure 1.6. Epstein Barr Virus Structure. From “The role of Epstein-Barr viruses in Burkitt’ Lymphoma, Mary Frazier Greene, 2014”. The structure of the 
EBV is characterised by the presence of an envelope covered in proteins, a viral tegument, and a viral capsid containing DNA.
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Figure 1.7. Epstein Barr Virus genome. EBV can have both a double-stranded 
DNA episome (A) or a linear form (B), with the origins of plasmid replication (oriP) 
and lytic replication (oriLyt) indicated. The Epstein-Barr nuclear antigen leader 
protein (EBNA-LP), crucial for the latent stage is transcribed from the BAMHI W, a 
region of variable repeated exon. From “Tao, Q., et al., Epstein-Barr virus (EBV) 
and its associated human cancers-genetics, epigenetics, pathobiology and 











EBV Cell entry  
 
One of the peculiarities of the virus is its lymphotropic tropism toward B 
cells. Nowadays it is  known that the virus has several cell entry 
mechanisms but the preferentially adopted one (and most studied) is the 
binding to CD21 - also known as CR2 complement receptor – or CD35 by 
the viral envelope protein gp350/220 [167]. EBV can also infect other cells 
types, such as mesenchymal cells, T cells and epithelial cells. The latter can 
be targeted mainly via gHgL which - together with gp42 and gB - forms a 
viral glycoprotein complex that plays a fundamental role in term of 
membrane fusion.  
 
Focusing on the fusion machinery that allows to entry into the cells, it is 
important to mention that - as other herpesvirus – EBV adopts three to six 
envelope proteins to perform all the operations needed, binding to the host 
receptor, activate the fusogen and the virus-driven fusion process [168]. 
After the binding of gp350/220 to the CD21, the virion enters the host cells 
by endocytosis, and this event greatly increases the efficiency of infection. 
Nevertheless, this step is not essential, and the virus is able to find 
alternative ways. Indeed, Nemerow and Cooper demonstrated in 1984 that 
B lymphoblastoid cell lines are infected by a direct fusion of gp42 (part of 







(From previous page) Figure 1.8. Cartoon showing the endocytosis entry pathway of EBV into B-Cell: From Advances in Virus research, Mohl, Chen and Longnecker, 
2019: After gp350/220 binds the CD21, gp42 can interact with the MHCII molecule. This leads to conformational changes in the gp42 that may activate gp42 itself or gH/gL 
allowing the final binding of gB. gB will then rearrange and finally fuse with the host cell membrane. For colour map check reference. From “Mohl, B.S., J. Chen, and R. 
Longnecker, Gammaherpesvirus entry and fusion: A tale how two human pathogenic viruses enter their host cells. Adv Virus Res, 2019. 104: p. 313-343” [168]..
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This peculiar alternative entry mechanism has been connected by Trier et al 
directly to the RA-shared epitope and thanks to their findings on the 
MHCII crystal structure they suggest that “EBV is able to induce the onset 
of RA in predisposed SE-positive individuals, by promoting entry of B-cells 
through direct contact between SE and gp42 in the entry complex” [170] 
(Fig. 1.9). 
Once the virus aggregates within the membranes it can be internalized 









Figure 1.9. Cartoon Showing the EBV fusion Model for gp42/MHCII: From International Journal of Molecular Sciences, Trier et al, 2018. Once gp42 is active it will 
interact with gh/gL and the entire complex interact with gB. Finally, the gp42 will interact with the β1 domain of the MHCII, allowing the membrane to fuse and the virus to 
enter the host. From “Trier, N., et al., Human MHC-II with Shared Epitope Motifs Are Optimal Epstein-Barr Virus Glycoprotein 42 Ligands-Relation to Rheumatoid 
Arthritis. Int J Mol Sci, 2018. 19(1)” [170]. 
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EBV Primary infection and persistence: from the germinal center to the 
memory compartment 
 
The mucosal tissue of the oropharynx is usually where the EBV primary 
infection takes place. However, the first cell to be targeted by the virus is 
still a matter of discussion, being either the epithelial cells or the B cells. 
Several theories have bene proposed in the last 40 years, with the epithelial 
model as the most accepted: viral particles - present in the saliva of 
infected individual – might access the oral cavity of the host, and 
specifically the lymphoid tissue. Lytic replication would take place inside 
the epithelial cells which then, in turn, would infect the B lymphocytes. 
Several observations are pointing in this direction: EBV replication has 
been observed in normal tongue epithelium, suggesting that the tongue is 
the source for EBV in saliva [172]; patients with IM usually presents EBV 
in desquamate epithelial cells but also viral DNA, mRNA and proteins 
[173, 174].  
Nevertheless, a discreet amount of data has shown that EBV can directly 
gain access and infect B cells trough crypt structures of the tonsillar 
lymphoepithelium [175]. 
Despite all these controversies it is quite obvious that the B cells are the 
main target of the virus since - during the maximum disease activity in IM 
- the number of EBV infected cells can account for almost 1% of the 
circulating B Lymphocytes [176]. After this stage EBV mostly survives in 
a silent form inside B cells (named latency phase) with occasional cycles of 
replication (named lytic phase) (fig.1.10). The infectious viruses are 
produced during this lytic phase, with approximately 80 viral proteins 
expressed, including viral capsid antigens, structural proteins and 
transcription factors. The switch between the latency and lytic stage is 
possible thanks to BZLF1 (also known as Zta, EB1, associated with its 
product gene ZEBRA) and BRLF1(associated with Rta).  
The alternative pathway for the virus consists in the already mentioned 
latent phase, a tool for EBV to become “stealth” inside the host’s blood and 
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survive for years. During the latency phase EBV infected B cells can show 
four different latent programs, each of them with a distinct EBV gene 
expression profile, including EBV EBNAs, latent membrane protein 1 
(LMP-1) and LMP2A [177]. Importantly, these two last proteins are 
involved in a mechanism, called transformation, that can actually 
immortalize B cells in vitro by mimicking two strong activation and 
survival signals: an activated B cell receptor (BCR), usually activated by 
the antigen, and a CD40 mediated one, respectively, usually mediated by a 
helper T cells (fig 1.11). The immortalized cells are often referred to 
lymphoblastoid cell lines or LCL. At this point the viral genome is not 
linear but is maintained as a circular episome, being distributed equally to 
daughter cells at each cell division [161]. Interestingly, this oncogenic 
virus has the ability to be found also as integrated copies in the host’s 
chromosomes. This is particular evident for a Burkitt’s Lymphoma cell 
line, named Namalwa, which mainly contain only integrated copies of 
EBV [178]. The study of integration copies is of great interest because this 
event can directly contribute to oncogenic mutations, having multiple 
integration sites distributed mainly on repeated regions (G-Band-Positive) 
but also functional genes areas (cell motility factor MACF1; cell 
differentiation/tumour suppressor BACH2, myeloid and B cell 
protooncogene REL and 
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Figure 1.10. Epstein Barr Virus Life Cycle. EBV can infect Naïve B cell, pushing them into an iper-proliferative status (lymphoblast) which resemble the GC CD38+ 
stage. At this point it can survive in a silent form, pushing the cell toward a Memory B cell differentiation (named latency phase) with occasional cycles of replication 
(named lytic phase). During the latency phase EBV infected B cells are characterised by a distinct EBV gene expression profile including EBV nuclear antigen (EBNA), 
latent membrane protein (LMP) and  Epstein–Barr virus-encoded small RNAs (EBER). Instead during the lytic phase the viral machinery switch to different molecules in 
order to reproduce the structural elements of the virus, such as BZLF or the Viral Capside Antigen (VCA). From “Tsurumi, T., M. Fujita, and A. Kudoh, Latent and lytic 
Epstein-Barr virus replication strategies. Rev Med Virol, 2005. 15(1): p. 3-15” [179].  
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Figure 1.11. Epstein Barr Virus Immortalizing Machinery.  LMP1 and LMP2A mimic CD40 and Ig receptors in B cells. LMP1 activation induce canonical and 
non canonical NF-κB signaling. On the other side LMP2A activates B cell by means of the Src family tyrosine kinase Lyn with a final results of a constant phosphorylation 
of LMP2A, which allows the recruitment of Syk (TNF receptor associated factors (TRAF); TNFR1-associated death domain (TRADD) receptor interacting protein (RIP)) 
From “Gordon, L.I. and R. Longnecker, Off-targeting oft-targeted CD20 in cHL. Blood, 2012. 119(18): p. 4095-6”. [180].
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b-cell lymphoma protein 11A (BCL11A) [181]. In order to distinguish 
between episomal and integrated copies, Reisinger et al have shown that 
fluorescence in situ hybridization (FISH) combined with dynamic 
molecular combing of the host cell DNA can facilitate this discrimination 
[182].  
Thanks to LCL, it has been possible to investigate in vitro the different four 
latent programs, which also depend on the differentiation state of the 
infected cells: i) Latency III (or growth program), probably the most 
described one, where naïve B cells in tonsil are targeted, all latent genes are 
expressed driving a great proliferation of the B cells (EBER1-2, EBNA 1-
LP, LMP1,2A,2B); ii) Latency II or default program, usually activated in 
the germinal center (EBER1-2, EBNA-1, LMP2A, LMP1); iii) Latency I or 
Latent program, characteristic of the memory cells in the blood stream 
(EBER 1-2 and EBNA-1); iv) Latency 0, EBER and LMP2A.  
Basically, once the naïve B cells in the lymphoid tissue of the Waldeyer’s 
ring become infected, the virus activates the cells to become proliferating 
blasts (Latency III). Then, switching between the different programmes, 
the cells will enter inside the follicle to initiate a GC reaction (Latency II). 
Here they will receive surrogate survival signals thanks to the 
LMP1/LMP2A axis, with the final aim of finally differentiate into a long-
lived memory B cells (Latency I/0), in orders to survive protected into the 
blood stream. This is called “The germinal centre model” (GCM) and is 
supported by several evidences [183] (Fig 1.12). Quoting Thorley-Lawson 
from the Epstein Barr Volume 1 (Münz, 2015) “the GCM provided a way 
to understand the complex biology of EBV. It has stood for 15 years and 
many tests of its reliability and predictive power. To date, it remains the 
only model that consistently provides a conceptual framework for 
understanding the complex and subtle behaviours of the virus”. It is 
important to mention that some authors have highlighted the possibility 
where also memory cells could become directly infected and that 
persistence could happen without transformation outside of the germinal 
center [184]. For instance, it has been shown by Babcock et al that the 
 80 
frequency of infected memory B cells expressing the latency 0 in 




Figure 1.12. The germinal Centre Model: This Diagram has been obtained from “EBV persistence-Introducing the virus Thorley-Lawson (From “Epstein 
Barr Volume I, Münz, 2015”). For details check text.
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EBV and latent antigens 
 
Apart from the one already described, other tools essential for the 
molecular viral machinery are EBNA-1, EBNA-3C and EBNA-2 [186]. In 
order to become effective all these elements are sequentially orchestrated 
in their expression by different promoters. EBNA-1 binds the EBV genome 
to chromosome mediating episomal persistence and maintenance. EBNA-2 
is a transactivator of both viral genes (LMP1 and LMP2A) but also cellular 
genes (such as CD21, c-FGR, c-MYC and specifically CD23). Indeed one 
of the basic feature of EBV is the presence of the 3-Kb BAMHI W repeat 
region (fig. 1.13), a  major internal repeat containing tandemly arranged 
copies of similar size sequence and exon content [187]. Essential for the 
transforming function, each BAMHI repeat contains Wp, the first promoter 







Figure 1.13. BamHI W Repeated region.   EBV latency III transcript showing location of EBV W repeat stable introns. From: “Moss, W.N., Analyses of non-coding 
RNAs generated from the Epstein-Barr virus W repeat region. Proceedings Iwbbio 2014: International Work-Conference on Bioinformatics and Biomedical Engineering, 
Vols 1 and 2, 2014: p. 238-252” [188] .
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for a 66-amino acid domain for EBNA-LP, the first EBV nuclear antigen 
expressed [189]. Together with EBNA-2, these antigens trigger the full 
latent gene expression activating Cp, another promoter whit a larger 
activation activity (which block Wp and produce EBNA1,2,3A,3B,3C) 
(fig. 1.7). At this point also the LMP promoters are activated, thus 
producing the mRNA for LMP1 and 2 [190]. It is important to add that the 
cytoplasmic portion of LMP1 contains carboxyl terminal activator regions 
(CTARs) that are similar to the human CD40, which are able to interact 
with the adaptor proteins tumour necrosis factor (TRAFF) and TNF 
receptor-1 associated death domain (TRADD) [191]. On the other hand, 
LMP2A has a N-terminal cytoplasmic portion with eight tyrosine residues, 
two of which form an immunoreceptor tyrosine-based activation motif 
(ITAM), the same as the one found in the α and β chains of the B cell 
receptor [192].  
EBER1 and 2, first discovered in 1981, are small non-polyadenylated 
RNAs that represent the most abundant RNA in cells during latency. They 
are short nucleotides in length, respectively 167 and 172 nt. Intriguingly, 
they are transcribed by the host’s RNA polymerase III during the latent 
infection. Many of the function of EBERs are still unclear but it is known 
that they can bind the ds-RNA-activate protein Kinase (PKR), which works 
in synergy with interferons, suggesting a mechanism in which the EBERs 
can enhance viral resistance [193]. The expression of EBER can induce 
cancer in severe combined immunodeficient mice (SCID) [194, 195]. 
Specifically, EBER1 can associates with human ribosomal protein L22, 
causing the latter to move from the nucleolus to the nucleoplasm [196]. 
Also, it has been shown by Kitagawa that this molecule can induce IL-10 





EBV and lytic antigens (reactivation):  
 
The complete infectious viruses are produced during the lytic phase, as 
usually been observed during acute infection and sporadically in persistent 
infection. As already mentioned, the process is kicked into gear by BZLF1 
and BRLF1, resulting in the expression of essential early DNA synthesis 
molecules (DNA polymerase) such as BMRF1, BHRF1, BFRF1 and 
BALF2. Different phenotypes and genetic polymorphism of these genes 
from isolated EBV specimen account for the enhanced lytic replication 
capacity that has been shown for the M81 isolated cells in a NPC patient, 
providing evidence that - despite EBV almost global infection - small 
differences in strains can strongly contribute to oncogenesis [198]. 
Late lytic genes are then expressed in order to produce the protein need for 
viral structure, like BLLF1and BALF4 (who encodes respectively for the 
envelope glycoproteins gp350, gp220, and gp110). 
At this point the real replication - a series of events that will also lead to the 
host cell death – will starts, with the synthesis of the viral DNA inside the 
nucleus. The DNA is then packaged insides the viral capsids and released 
into the cytoplasm, ready to fuse with the host plasma membrane in order 
to be spread from the host cells in an enveloped form.   
A complete list for both latent and lytic genes and proteins can be found 








nuclear antigen 1 
(EBNA-1)  
Binds EBV genome to chromosomes mediating episomal persistence and maintenance; may 
inhibit apoptosis in Burkitt lymphoma cells; Gly-Ala repeat inhibits processing of EBNA1 
through protesomes, precluding presentation of antigenic peptides with MHC-I at the cell 
surface, thus avoiding detection by CD8+ T cells  
Epstein-Barr virus 
nuclear antigen 2 
(EBNA-2)  
Transactivator of several viral genes (LMP1 and LMP2A) and cellular genes (CD21, c-FGR, 
c-MYC, CD23) essential for cellular transformation ; interacts with transcription factor RBP-
JK to promote conversion of resting B lymphocytes into lymphoblastoid B cells. 
Epstein-Barr virus 
nuclear antigen 3C 
(EBNA-3C)  
Essential for EBV-mediated transformation of primary B lymphocytes and interacts with 
RBP-JK ; EBNA-3C promotes LMP1 expression in the presence of EBNA-2.  
Epstein-Barr virus 
nuclear antigen leader 
protein (EBNA-LP)  
Key role in upregulating cell gene expression critical for lymphoblastoid B cell outgrowth 
and augments the ability of EBNA-2 to transactivate LMP1. 
Latent membrane 
protein 1 (LMP1 ) 
Mimics signaling through CD40, a B cell activation and differentiation receptor, and in turn 
activates NFκB pathways to promote cell survival; promotes B cell lymphoma formation in 
transgenic mice expressing the gene. 
Latent membrane 
protein 2A (LMP2A)  
Constitutive dominant negative modulator of 
B cell receptor signaling by sequestering tyrosine kinases through interactions with its 
immunoreceptor tyrosine-based activation motifs, preventing entry into the lytic cycle by 
antigenic stimulation; promotes B cell survival through activation of the same sequestered 
tyrosine kinases in an antigen- and B cell receptor-independent manner. 
Epstein-Barr virus–
encoded RNAs 1 and 2 
(EBER1 and 2)  
Small nonpolyadenylated RNAs that represent the most abundant RNAs in latently infected 
cells; role in EBV infection still unclear  
 
Table 1.7. EBV virus-encoded latent infection genes products.  Readapted from 
“Spectrum of Epstein-Barr Virus-Associated Disease, J.L. Kutok and F.Wang, 2006, 











BZLF1 / BRLF1  Key transactivators of lytic EBV gene expression, coordinately upregulating expression from 
early EBV promoters 
BHRF1  Colinear homology with BCL-2, prevents apoptotic cell death in lytic EBV infection; 
nonessential for growth transformation of B cells and for virus replication in culture  
BCRF1  Homology to human interleukin-10; may downregulate the host immune response during viral 
replication  
BALF5  Replication factor; core DNA polymerase 
BALF2  Replication factor; single-strand DNA binding protein 
BMRF1  Replication factor; processivity factors 
BSLF1 and  
BBLF4  
Replication factor; primase and helicase complex 
BBLF2/3  Replication factor; spliced primase helicase complex component 
BKRF3  Replication factor uracil DNA glycosylase 
BLLF1  
(gp350/220)  
Mediates adsorption between EBV and CD21 
 
Table 1.8. EBV virus-encoded lytic infection genes products. Readapted from 
“Spectrum of Epstein-Barr Virus-Associated Disease, J.L. Kutok and F.Wang, 2006, 




Control of EBV infection by the immune system 
 
The sporadic expansion of the virus – as shown in the GCM – is 
counterbalanced by the immune system where both humoral and cell 
mediated adaptive responses take place. Indeed, several antibodies against 
different viral elements can be found in the serum of EBV+ individuals, 
such as those against EBNA, VCA (viral capsid antigen), EA (early 
antigen). These antibodies are not just helping in containing the spreading 
of infection but are also a consistent and reliable diagnostic tool to 
discriminate between different EBV-related diseases or phase of infection 
(see table 1.9) [199].  
Regarding the cell mediated response the main guardians of EBV 
homeostasis are the cytotoxic CD8+ T cells, which are able recognise EBV 
infected cells upon lytic reactivation but can also contribute actively to 
patients’ symptoms. Things are more complicated during the various 
latency programs: the CD8+ specific T cells for latent antigen are present 
but to a smaller degree. The majority of them are targeting EBNA-3A, 3B 
and 3C [200]. Also, subsets targeting LMP2A and LMP1 are present [201]. 
It is important to report that a response to EBNA-1 protein has been 
described in IM patient carrying particular HLA alleles, specifically HLA-
B*3501, which are usually uncommon in the general population [202]. 
People with these alleles are characterised by a strong CD8+ T cell 
response against EBNA-1. However, CD8+ are mostly unable to recognise 
EBV infected cells during latency I (characterised by EBNA-1 expression). 
This account for the virus persistence a low level in infected individual 
(between 1-5 cells every 100’000-1’000’000 cells) [163]. Also NK cells 
can be involved in the EBV response through the type I INF axis, and this 
is quite evident in NK deficiencies, which are usually associated with 
increasing susceptibility to EBV infection [203]. 
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Table 1.9. EBV Diagnostic Test Profile. From “Virology, Epstein-Barr Virus, 
















Subpopulation of CD23/CD58 B cells that proliferates in vitro after 
infections 
  
It is quite clear at this point that, by these molecular means, B cells acquire 
a lymphoblastoid cell lines phenotype, which resemble a germinal center B 
cell for the  expression of CD38, CD10, CD77, BCL-6 and AID, plus the 
chemokine receptors CXCR4, CXCR5 (but not CCR7) [204]. These cells 
are actually capable of indefinite growth. Moreover, in vitro 
characterisation by Megyola et al of EBV+ B cells from healthy donors 
have shown that, after infection, these lymphoblast are mainly formed by 
two specific and unusual subsets: a CD58+/CD23low non proliferating IL-6 
producing subset and a CD58+/CD23hi proliferating one [205]. CD23, also 
known as Fragment crystallization (Fc) epsilon RII (FcεRII) is the "low-
affinity" receptor for IgE while CD58 or lymphocyte function-associated 
antigen 3 (LFA-3) is a cell adhesion molecule expressed on APC, 
particularly macrophages. There has not been any functional connection 
between EBV and the purpose for these receptors, nevertheless CD23 
seems to be highly expressed in EBV-related lymphomas. 
 
EBV in Autoimmunity: Focus on MS 
  
Due to the ability to infect preferentially B lymphocytes - one of the most 
important actors of the immune system – the EBV has nourished a wide 
field of speculation regarding a possible connection to autoimmunity. 
Several studies have been done in this direction but a clear a demonstration 
of causality, defined as state in which the reduction of the frequency of the 
virus results in a reduction of a specific autoimmune disease or condition, 
has bene difficult. In fact, this would require that prevention of the 
infection results in a reduction of the disease. As suggested by Ascherio, a 
strategy to understand this could be trough i) meta-analyses combining the 
data from several case–control studies ii) case-control studies of paediatric 
populations in which prevalence of EBV positivity is still low at ~75 % or 
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less. The two most studied diseases are SLE and MS and, so far, evidence 
has been found only for the latter. For this reason, the next chapter will 
focus only on MS. 
MS is a chronic inflammatory and neurodegenerative diseases that affect 
mainly the central nervous system and is caused by an immune-mediated 
demyelinating process. Several immune cells ( B, T, macrophages) are 
usually found in biopsies material [206]. Alteration at a systemic level have 
being described, such an altered cellular immunity against myelin antigens 
or impaired response of Treg [207-209]. The disease usually has a higher 
incidence in women more than man and manifest between 20 and 40 years 
of age. Geographically, the most affected areas are Europe, the USA, 
Canada and Australia. A combination of genetic factors (the risk-allele 
HLA-DR15) and environmental factors (vitamin D deficiency, cigarette 
smoking, IM and EBV infection) has been highlighted in MS [210, 211]. 
Regarding the epidemiological evidence, we now know that MS risk is 2.3-
fold-higher between individual with a clinical history of IM, as compared 
to individual which have never been affected by the disease. It has been 
speculated that high level of hygiene in childhood can reduce exposure to 
environmental agents and this can delay the age of primary EBV infection. 
Furthermore, individual which are EBV negative tend to not develop MS, 
although they have high seroconversion rates and high IM incidence when 
exposed to the virus [212].  
Regarding a potential mechanism relating EBV to MS, it has to be 
mentioned that: i) EBV viral load in patient with MS is only modestly 
increased; ii) MS has not been reported as a complication of 
immunosuppression in post-transplant lymphoproliferative diseases; iii) 
monoclonal antibodies that either prevent T central migration into the CNS 
(natalizumab) or deplete B cells ( rituximab) are both very effective against 
MS relapses [213]; iv) anti-EBNA-1 and EBNA-2 have a strong correlation 
with MS development in young adults [214]. These findings suggest that a 
hyperactive or uncontrolled immune response toward EBV operated by the 
immune system - rather than lytic viral replication or over proliferation of 
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infected cells - can cause MS. Several epidemiological and clinical 
evidence have shown that anti-EBNA-1 antibodies and CD4+ EBNA-1 
specific T cells can cross-react with myelin antigens and leading to the 
evident damage present in MS patients [215]. Also, Serafini and Aloisi just 
recently demonstrated that EBV specific CD8+ T cells can access the brain 
and selectively target infected cells, strongly contributing to MS 
pathogenesis [216]. It is also believed that B cells can take part in this 
process not only in antibody production but also with the presentation of 
cross-reactive antigens [217]. 
  




The rationale for the association between EBV in RA (and in general in 
other autoimmune disease) is that viral latent genes in vivo may potentially 
rescue an autoreactive B cell clone - which in a normal scenario would be 
induced either to apoptosis or to clonal anergy during a series of 
physiological tolerance checkpoints - allowing it to access the GC and, 
subsequently, enter the blood stream as part of the memory B cell 
compartment. This latently infected B cell is not able to produce antibodies 
by itself because, upon the intrinsic plasmacells final differentiation, it 
would start to produce viral particles and become a target for T CD8+ anti-
EBV specific cytotoxic cells. Nevertheless, an EBV-rescued B cell could 
theoretically escape depletion and present autoantigens to T cells favouring 
a breach of immunological tolerance. Interestingly, some evidence 
supporting this theory has been provided by Swanson-Mungerson and 
Longnecker in a mouse model of autoreactivity, where they have 
demonstrated that LMP2 can actually breach tolerance [123]. 
 
Unfortunately, epidemiological data linking EBV and RA are debatable 
since EBV viral infection is by definition not more frequents in patients 
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with RA than in control patient [218] given that 95% of the population is 
infected. Experimentally, one of the most important studies about this topic 
has been done produced by Tracy et al, where they profiled the self and 
polyreactive properties of BCRs expressed by EBV infected memory B 
cells present during the acute phase of infection with the final aim of 
understanding the role of the virus in this process. In their elegant work, 
they have discovered that EBV can be found in self-reactive memory cells 
during IM, but it does not preferentially survive in these cells. Of more 
importance, apparently EBV is able to persist in B cells producing low 
affinity self-reactive and polyreactive antibodies, and this might be 
connected to a mechanism in which the virus ensure its survival by 
reducing the chances of being seen as a threat by the immune system [219]. 
 
However, in my laboratory Croia and Bombardieri have generated an 
impressive amount of data connecting EBV with RA and SS and linking it 
to a possible autoimmune mechanism in ectopic GCs. Also new evidences 
are emerging every year about this issue or, in general , about the role of 
EBV other  autoimmune disease, such as the above mentioned work 
published by Serafini and Aloisi in multiple sclerosis in 2019 [216]. It is 
important to mention that one of the most comprehensive review has been 
published by Balandraud and Roudier in 2017, and some of the most 
important point highlighted in it will be discussed here [64]. 
 
Molecular mimicry mechanism between EBV and self-proteins 
 
As already stated in this introduction, there are several points of connection 
between EBV epitopes and autoantigens. This molecular mimicry could 
potentially break tolerance and lead to the development of RA. The most 
likely candidate is the shared epitope, since  part of the QKRAA sequence 
is present in the gp110, a glycoprotein expressed during replication of the 
virus on the envelope [220]. Indeed, EBV seropositive healthy individual 
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have T cells who recognise QKRAA and their antibodies are able to bind 
gp110. 
Regarding the HLAs complex, the similarities are not limited to HLA-
DRB1 since Fox et al in have later showed that in SS, the protein expressed 
by the allele HLA-DQ*0302  can actually overlap EBNA-6 aminoacidic 
sequence. Also, authors have showed that deiminated EBNA-1 can be a 
target of ACPA and can cross react with form of human citrullinated fibrin 
[221, 222]. It is interesting to mention that recently Harley et have shown 
by computational method that several autoimmune diseases risk loci are 
occupied by EBNA-2 [223]. 
 
Humoral response to EBV antigens in rheumatoid arthritis 
 
It is fascinating that one of the most important antibodies against EBV, the 
anti-EBNA-1, was discovered in RA an initially named rheumatoid-
arthritis-associated nuclear antigen (RANA) [224]. These antibodies were 
targeting nuclei antigens in B cells and, most importantly, RA patient 
showed a higher reactivity (67%) compared to healthy control (8%)[225, 
226]. Was later discovered that this mysterious antigen was, in fact, 
EBNA-1 [227]. Another strong connection was made by Alspaugh, who 
demonstrated that not just anti EBNA-1, but also other antibodies targeting 
VCA and EA, were significantly increased in serum and synovial fluid 
from RA patient[225]. 
It has been already mentioned that viral antigens can be citrullinated and 
become an ACPA target and Merlini et al identified a small region of 23 aa 
(between aa 35 and 58) on the EBNA-1 that is highly reactive with serum 
from RA patient [228]. Pratesi and Migliorini later confirmed - using 
synthesized peptides modified or unmodified for citrullination - that this 
region was indeed target by ACPA [221]. Furthermore it has been 
demonstrated that citrullinated fibrinogen peptides can be targeted by anti 
EBNA-1, casting further evidence on how the virus can break tolerance 
trough antigens-cross reactivity [222]. More recently Trier et al have 
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showed that citrullinated EBNA-2 peptides from three different strains of 
EBV (B95-8, AG786 and GD1) are targeted very differently by RA sera. 
For each strain several peptides have been produced and then tested with 
sera from RA patients and healthy donors (Fig.1.14). Specifically, one 
strain, the AG786, react more than the others, pointing at the hypothesis 









Figure 1.14. Overlapping antibody reactivities to Cit-Gly-containing peptides 
among the three Epstein-Barr virus strains B95-8, GD1 and AG876.  From 
“Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses 
rheumatoid arthritis, Trier et al, 2018, Scientific Reports: “The coloured fields 
represent the number of peptides recognised for the individual sera, and hence the 
degree of overlapping reactivities in a serum pool”[229].
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Cell-mediated immune response to EBV in rheumatoid arthritis 
 
Almost 40 years ago Tosato studies demonstrated that T cells from RA 
patients are defective in controlling the virus as they do in healthy donor. 
Indeed they showed that LCLs - the cells line naturally harbouring the 
virus - arise more often from RA blood than from controls, underlying an 
impairment from the CD8+ T cells in taking care of the infection [230]. 
Of interest, RA patients have less circulating anti-gp110 T cells, and this 
lower frequency has been connected to HLA-DRB1*04:04, one of the 
shared epitopes alleles, which has shown less efficiency in controlling the 
gp110 epitope [231]. Toussirot et al have later showed that this impairment 
it is also connected to an increased disease activity [232]. Other studies 
have highlighted in RA the clonal expansion of dysfunctional T CD8+ anti-
EBV in responding to lytic EBV peptides [233]. 
 
EBV load in patients with RA: 
 
RA patients are characterised by high systemic EBV load, directly 
connected to the above-mentioned T cells impairment.  Also, EBV DNA 
can be detected more frequently in PBMCs saliva and synovial fluid from 
RA. Several techniques have been used during the last 40 years in order to 
quantify EBV DNA (ISH, PCR, ecce cc) but the actual state of the art is 
real time PCR for BamHI W repeated region. Using this technique 
Balandraud and his group have managed to demonstrate that EBV load was 
10-fold higher in RA patient than in healthy controls. Specifically they 
observed that the EBV DNA load was significantly increase PBMC from 
RA patients(n = 84, mean 15.6 copies/500 ng DNA) than in non-RA 
inflammatory diseases (n = 34, mean 5.7 copies/500ng DNA) and normal 
controls (n=69, mean 1.9 copies/500 ng DNA)[234]. 
RA patients usually undergo long-term treatments, and some of these drugs 
have shown to have an effect on EBV load. Some speculations have been 
made that long-term use of methotrexate might lead to induction EBV 
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associated lymphomas, but further studies are needed[235]. The majority 
of TNF blockers – such as Infliximab or Etanercepet – shows that patient 
load is stable over time[236]. Nevertheless, new biological treatment such 
as abatacept ( CTLA4 Ig) and the anti-IL-6 Tocilizumab are under study. 
Regarding abatacept, the fact that this drug inhibit T cells activation might 
lead to increase EBV replication, as found by Bassil in patients undergoing 
kidney transplant [237].  
On the other hand, Erre et al found by PCR that EBV load was increases in 
RA patient compared to control, but surprisingly lower in RA patient 
undergoing treatment with tocilizumab[238]. This might be connected to 
the evidences highlighted by Megyola that different subsets of EBV 
infected cells might sustain each other through an IL-6 mechanism, leading 
to higher levels of circulating infected B cells. 
 
EBV in the ectopic GC of synovial membrane of RA patients  
 
Regarding the possibility that EBV might survive in ectopic GC inside the 
synovia of RA patient, several evidences have been provided by Croia et al 
in my lab. The authors investigated – through RT-PCR, 
immunohistochemistry and in situ hybridisation - latent and lytic infection 
in 43 synovial tissue characterised by presence or absence of ectopic GCs 
and compared them to 11 control osteoarthritis.  This broad screening has 
analysed LMP2A and EBER transcript, EBER+ cells, and 
immunoreactivity for EBV latent (LMP1 and LMP2A) and lytic (BFRF1) 
antigens. Intriguingly, they highlighted a strong EBV dysregulation in RA 
patient positive for ectopic GC, which was not identified in osteoarthritis 
controls. The most important result is that EBV infection was colocalizing 
in synovia with autoreactive ACPA+ B cells and plasmacells (Fig.1.15).  
Further in vivo evidences have been provided by transplantation of RA 
synovial tissue positive for ectopic GC) into SCID mice, which resulted in 
a strong production of ACPA and anti-viral citrullinated peptides 1 and 2 
(VCP1 &VCP2). Also, analysis of T cells (both CD4+ and CD8+) 
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suggested that EBV persistence in the ectopic GC may be possible by the 
exclusion of T cells from the B cells follicles. A similar work has been 
repeated by Croia et al in SS, confirming that EBV dysregulation was 
present only in ectopic GC positive salivary gland and was colocalizing 




pathological tissues has been associated with lymphoid neogen-
esis,16 17 suggesting that EBV colonisation of ELS might be con-
sidered a signature of organ-specific autoimmunity. ELS may
enable an active EBV infection to be established outside second-
ary lymphoid tissues where circulating EBV-infected B cells
preferentially home, and much of the viral life cycle normally
occurs.10 This scenario raises the question of whether EBV is
primarily involved in ELS formation through its unique ability
to infect and activate B cells,10 11 or if ELS-associated EBV dys-
regulation is secondary to B-cell activation that characterises
autoimmune diseases. In either case, the outcome would be the
establishment of extralymphatic niches of EBV infection with a
direct impact on B-cell function and EBV immune surveillance.
EBV infection in the RA synovium was characterised by
expression of both latency and lytic gene expression pro-
grammes. The latent EBV transcripts EBERs and LMP2A were
detected in all ELS+ RA synovia using real-time RT-PCR, and
high numbers of EBER+, LMP1+ and LMP2A+ B cells were
found associated with ectopic GC. According to the GC model
of EBV persistence, EBV employs four sequentially expressed,
virally encoded latency transcription programmes which drive
infected naive B cells to become proliferating blasts and partici-
pate in GC reactions (where both LMP1 and LMP2A are
expressed) in secondary lymphoid tissues, and finally enter the
memory B-cell compartment where the virus establishes per-
sistent infection.11 LMP1 and LMP2A possess the signalling
properties of CD40 and the B-cell receptor, respectively, and
have the capacity to promote the development of infected B
cells in the absence of cognate antigen.48 Consistent with the
GC model, we show here that both LMP1 and LMP2A are
expressed in EBV-infected B cells transiting ectopic GC in the
RA synovium, suggesting that these viral proteins may be
involved in the abnormal expansion and survival of
EBV-infected B cells observed in the pathological tissue. The
demonstration that BFRF1, an antigen associated with the
early lytic cycle of EBV infection,36 is expressed in a substantial
proportion of plasma cells at the edge of synovial GC, and indi-
cates that viral reactivation is initiated as a consequence of dif-
ferentiation of EBV-infected B cells in these structures. By
contrast, EBV structural proteins, like p160 and gp350/220,
were rarely detected in synovial ELS suggesting abortive viral
replication or very efficient elimination of cells expressing EBV
late-lytic antigens.
Because LMP2A has been shown to break tolerance mechan-
isms and induce autoreactive B-cell activation when constitu-
tively expressed in transgenic mice,12 13 EBV infection has been
discussed as a biologically plausible mechanism allowing poten-
tially pathogenic autoreactive B-cell clones to escape deletion
and cause autoimmunity.49 The RA synovium represents an
ideal experimental setting to test this hypothesis, since synovial
GC supports the in situ differentiation of ACPA-producing
plasma cells.27 28 Here, we show for the first time that a
Figure 4 Detection of the Epstein–Barr virus early lytic protein BFRF1 in anticitrullinated protein/peptide antibodies-producing plasma cells in
ectopic lymphoid structures+ rheumatoid arthritis (RA) synovia. Double immunofluorescence staining for CD20 (red) and CD138 (green) shows a
representative B-cell follicle surrounded by plasma cells (A). At the border of the same B-cell follicle (marked with an asterisk in A,B,D,F) many of
the CD138 plasma cells (green in B–D) react with citrullinated fibrinogen (cFb; red in B,C), indicating that they produce APCA. No binding of
non-citrullinated Fb is detected (D). In the same perifollicular area, a substantial fraction of CD138+ plasma cells (green) coexpresses BFRF1 (red)
(F) the area marked with a frame in (F) is shown at higher magnification in (G) while most BFRF1+ cells (red) are cFb-reactive (green), and vice
versa (H–J). The insets in (H,I) highlight the colocalisation of cFb and BFRF1 in the cell cytoplasm. Panels (K–N) show double immunostainings for
CD138/cFb (K), CD138/BFRF1 (L), and cFb/BFRF1 (M,N) the area marked with a frame in (M) is shown at higher magnification in (N) in consecutive
sections of a different RA synovial sample. The column bar graph in (E) shows the results of cell counts performed in six synovial RA samples.
Values are means±SEM of the percentages of double positive CD138+/cFb+ and CD138+/BFRF1+ cells on total CD138+ plasma cells, and of
double positive cFb+/BFRF1+ cells on total BFRF1+ and cFb+ cells. Bars: 100 mm in A; 50 mm in (B,D,F,K–M); 20 mm in (C,G,H–J,N) 10 mm in
the insets in (K,L) 5 mm in the insets in (H,I,N).
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Figure 1.15. Detection of the Epstein–Barr virus early lytic protein BFRF1 in anticitrullinated protein/peptide antibodies-producing plasma cells in 
ectopic lymphoid structures+ rheumatoid arthritis (RA) synovia (previous page):  From Epstein–Barr virus persistence and infection of autoreactive 
plasma cells in synovial lymphoid structures in rheumatoid arthritis, Croia et al, 2013, Basic and Translational Research. “Double immunofluorescence 
staining for CD20 (red) and CD138 (green) shows a representative B-cell follicle surrounded by plasma cells (A). At the border of the same B-cell follicle 
(marked with an asterisk in A,B,D,F) many of the CD138 plasma cells (green in B–D) react with citrullinated fibrinogen (cFb; red in B,C), indicating that 
they produce APCA. No binding of non-citrullinated Fb is detected (D). In the same perifollicular area, a substantial fraction of CD138+ plasma cells 
(green) coexpresses BFRF1 (red) (F) the area marked with a frame in (F) is shown at higher magnification in (G) while most BFRF1+ cells (red) are cFb-
reactive (green), and vice versa (H–J). The insets in (H,I) highlight the colocalisation of cFb and BFRF1 in the cell cytoplasm. Panels (K–N) show double 
immunostainings for CD138/cFb (K), CD138/BFRF1 (L), and cFb/BFRF1 (M,N) the area marked with a frame in (M) is shown at higher magnification in 
(N) in consecutive sections of a different RA synovial sample. The column bar graph in (E) shows the results of cell counts performed in six synovial RA 
samples. Values are means±SEM of the percentages of double positive CD138+/cFb+ and CD138+/BFRF1+ cells on total CD138+ plasma cells, and of 
double positive cFb+/BFRF1+ cells on total BFRF1+ and cFb+ cells. Bars: 100 mm in A; 50 mm in (B,D,F,K–M); 20 mm in (C,G,H–J,N) 10 mm in the 

































CHAPTER 2 RATIONALE OF THE THESIS AND AIMS 
 
The main aim of my PhD project is to clarify the intimate relationship 
between EBV, autoreactive B cells activation and the maintenance of 
autoimmunity against citrullinated antigens in the joints. Given the strong 
connection between EBV and RA I hypothesized that recreating in vitro the 
synovial environment using a RA-FLS feeding layer could enhance the 
proliferation of B cells, due to the production of survival factors. I also 
hypothesized that EBV-infected B cells might have a proliferative 
advantage compared to their uninfected counterpart and that this might lead 
more easily to the escape of an autoreactive B cells, which could resemble 
a possible mechanism that triggers autoimmunity in vivo. In this sense the 
RA-FLS could create a unique niche for EBV-infected cells, increasing the 
chances of developing autoreactivity, due to lack of control. 
 
In particular, I shall study if and how synovial fluid and synovial tissue 
RA-FLS enhance selectively the long-term survival of naturally occurring 
EBV infected B cells obtained from circulating B cells of RA patients and 
healthy donor. Also, I shall investigate if in turn EBV B cells are able to 
enhance RA-FLS inflammatory response. Finally understand if these cells 
are autoreactive. 
 
Aim & Objectives  
 
My PhD project aims to establish the relevance of EBV in sustaining 
autoreactive B cells activation in the RA joints. In order to do this, I need 
to: 
i) Verify whether B cells forming long-term clusters in co-culture with RA-
FLS display a preferential selection of clones harbouring EBV.  
ii) Verify whether B cells harbouring EBV have an autoreactive phenotype 





CHAPTER 3 RESEARCH METHODOLOGIES.  
 
Patient recruitment, sample process procedure and cell culture 
 
FLS have been obtained from different sources: joint replacement 
surgeries, synovioctemy surgeries, synovial biopsies or synovial fluid of 
psoriatic arthritis (PsA), osteoarthritis (OA) and ACPA+ RA patients. B 
cell have been obtained from peripheral blood of the ACPA+ RA patients 
and healthy donor. All RA patients in the study fulfilled the 2015 
ACR/EULAR classification criteria for RA. Patients enrolled in this study 
are part of the Experimental Medicine and Rheumatology Research Tissue 
bank (EMR-RTB, previously Qmul-Rbb). Patients sample have been 
collected at the Rheumatology department of the Mile End Hospital of 
London, part of the Experimental Medicine and Rheumatology (EMR) 
department of the Queen Mary University of London (QMUL). Healthy 
donor blood has been collected at the EMR department of QMUL. 
Prior to sample collection a written informed consent was obtained from 
both patients and healthy donors. All tissue was obtained immediately after 
surgeries or collection. Table 4.1 is showing all sample collected. Table 4.2 
is showing samples according to the relative experiment. Sample have not 
been tested for EBV seropositivity. 
 
a) Isolation and Culture of FLS 
 
Synovial fluid was collected in heparinised syringe, diluted upon arrival on 
phosphate buffered saline (PBS) and centrifuged 10' at 1500 rpm RT. The 
resulting pellet was resuspended in 10 ml of filtered complete growth 
medium (CM) [ Dulbecco's Modified Eagle Medium: Nutrient Mixture F-
12 (DMEM/F12) with 10% heat inactivated fetal bovine serum (FBS), 1% 
Antibiotic-Antimycotic (Streptomycin, Amphotericin B, Penicillin) 
(Gibco/Thermo Fisher Scientific) ] and plated in a T25 tissue culture flask. 
Cultures were incubated at 37°C with 5% CO2 for 48 h, after which 
medium was aspirated and cultures were washed with (PBS) to remove 
 106 
unattached cells. Every 10 to 14 days adherent confluents cells were 
removed from flasks by trypsinization, and splitted at 1:3 ratio in fresh 
growth medium. Complete growth medium was replaced every 3 to 4 days. 
After passage 4 cells were used for experiments in order to avoid any 
contamination from synovial macrophages, which are known to resist in 
culture during the first passages. After passage 4 FLS are the dominant 
cells resulting in a relatively homogenous population [240]. 
 
Synovial tissue was minced, washed with DMEM - F12 and plated in a 10 
mm petri dishes with complete fresh medium. After 48 hours tissue was 
removed, mashed under a 70 μm nylon mesh cell strainer (Becton 
Dickinson, Oxford, UK) and digested overnight at 37°C with 1.5 mg/ml 
Dispase II in DMEM supplemented with 10% FCS, 50 IU/ml penicillin-
streptomycin and 10 mM HEPES buffer (Gibco/Invitrogen, Paisley, UK). 
Suspension was then passed through cell strainer, centrifuged and the cell 
pellet resuspended in 10 ml of complete growth medium and plated in a 
T25 flask. Culture were maintained at 37°C with 5% CO2 and splitted at 
1:3 ratio when they reached confluence. Passages 4 and 5 were used for 
experiments.  
 
To have an estimation of the number of cells in culture, all FLS have been 
cultured and managed using seeding density rules found in literature (1.0-
1.4 x 104 cells/cm2, Table 3.1 ). Seeding density appears to work better 
than standard counting cells protocol (like trypan blue) since the FLS – 
after being detached with trypsin - tend to form aggregates making it hard 




b) Peripheral blood mononuclear cells isolation and CD19+ 
purification. 
  
Peripheral blood mononuclear cells (PBMC) were obtained from 20 ml 
blood sample collected from patients and healthy donors in heparinised 
tubes. PBMC were isolated using Hystopaque 1077 density centrifugation. 
CD19+ B cells have been purified from isolated PBMC by means of 
magnetic selection with CD19+ microbeads (Miltenyi Biotech, Germany) 
with a final yield between 1,8x105 -8x105 number of purified cells. Cells 
were maintained in a suitable medium for B cell (CM-B: Roswell Park 
Memorial Institute-1640 (RPMI 1640) low glucose with 10% heat 
inactivated FBS, 1% L-Glutamine, 1% Antibiotic-Antimycotic). The purity 
of CD19+ B cells isolation was checked by fluorescence-activated cells 
sorting (FACS, BD Fortessa). Cells have also been characterized for 
immunoglobulin production. 2x105 cells have been used for purity and 
characterization respectively. 
 
Both fresh and frozen sample have been used in these experiments. It is 
important to state that for the co-culture system only frozen sample have 
been used. A comparison between fresh and frozen B cells samples to 




In the first protocol FLS were plated in a 96 well plate (2’500 cells p/w) 
and cultured in FLS-CM for one/two weeks until sub-confluence (70-90%) 
was reached. For all these experiments FLS after passage 4 have been used.  
Before adding the PBMCs, FLS-CM has been completely aspirated. The 
ratio between cells has been modified based on the lowest number of 
mononuclear cells obtained during the purification (150'000 PBMC p/w).   
Different stimuli have been added to the co-culture 
i) IL-2 (1000 U/ml, Sigma) to enhance cellular survival. 
 108 
ii) CpG (2.5 µg/ml, ODN2006, Invivogen) which is used to stimulate Toll 
Like receptor 9 in order to differentiate  B cells toward antibody producing 
plasma-cells [241, 242].  
Cells have been cultured in a total volume of 250 µl. 
 
 
In the subsequent protocol optimization, I used a 48-well plate (7'500 cells 
p/w, 8 wells/condition) and cultured in FLS-CM for one/two weeks until 
sub-confluence (70-90%) was reached. For all this experiment FLS after 
passage 4 have been used.  
Before adding the purified CD19+, FLS-CM has been completely 
aspirated. The ratio between cells has been modified based on the lowest 
number of mononuclear cells obtained during the purification (i.e., 7'500 
FLS; 25'000 CD19+ p/w).  250’000 purified B cells have been stored again 
to be used as time 0 control in sorting analysis. 
Same different stimuli have been added to the co-culture 
i) IL-2 (1000 U/ml, Sigma) to enhance cellular survival; 
ii) CpG (2.5 µg/ml, ODN2006, Invivogen)  
 
At the beginning of the co-culture, cells and stimuli have been plated in a 
total volume of 700 µl (CM-B-cells). 150 µl have then been collected after 
two days and replaced with 650 µl in order to reach the final volume of 
1200 µl. This difference at day 0 and day 2 was important to let the CD19+ 
cells seed to the bottom of the well and attach to the FLS during the first 48 
hours (which are critical), but also to use a lower quantity of the two 
stimuli which, at the operational concentration, will not be consumed in the 
firsts days. 150 µl of SN has been then collected every 15 days (15, 30, 45, 
60, 75, 90, 105 day) and replaced with 200 µl in order to compensate 
evaporation. SN were pooled between wells containing the same stimulus, 
centrifuged for 10' at 1800 rpm to obtain cell free suspension and frozen at 
-20C. As control, FLS alone (with or without stimuli) and CD19+ B cells 
alone have been used.  
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A maximum of 123 days has been reached but best conditions for this 
experiment has been assessed at 60-75 days. Matched sample (FLS and 
CD19+ cells from the same patient) was possible only in one case (co-
culture of RA-FLS Qmul-Rbb 2018/003 and RACD19+ EMRRTB 0160). 
 
In an optimization procedure for the co-culture system, different protocols 
and ratio between FLS and B cells have been tested in order to increase the 
likelihood of survival and growth of EBV-infected B cells. This has led to 
a new protocol of the co-culture in which 2 wells from a 12well plate are 
used as biological replicates with 30’000FLS and 360’000 B cells p/w 
respectively (2ml each of CM-B cells have been added). This increased the 
ratio between FLS and B cells from 1/1.6 to 1/12. Also, given the average 
distribution of infected EBV cell in normal population (1-5 cells every 
1*106 cells), the probability in the previous assay of obtaining an EBV 
infected cell was 0.50 while in the new one is 3.60. Furthermore, 
proliferation was observed earlier (14 days) and all experiment have been 
reduced to 28 days.  
 
At least in one case (Experiment 0051), after sorting, EBV+ B cells have 
been plated again in a second co-culture and maintained for 36 more days, 
for a total time in co-culture of 64 days (fig 3.1). After this second co-
culture, Experiment 0051 cells were clearly showing  behaviour of LCL    





Figure 3.1. Experiment 0051: 1st and 2nd co-culture. Here is shown the protocol of experiment 0051. 4 condition from normal protocol are shown as previously 
described. After sorting not all of B cells have been used for BAMHIW qPCR. Instead 30’000 cells have been divided and plated again with or without fibroblast and kept in 
culture again for other 36 days for a total time in co-culture of 64 days. 
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Purity, Characterisation and Lymphoblast presence in Purified CD19+ 
B cells 
All the panel have been designed using the Fluorofinder online platform, 
which allows to visualise the spectra in order to detect spectral overlap. An 
aliquot of the purified CD19+ B cells (2x105) have been screened for 
purity, characterized for immunoglobulin production and checked for the 
presence of CD58+/CD23hi Lymphoblast with three different panels (table 
3.2) The aim of purity panel 1 is to check for presence of contaminants like 
monocyte, NK or, more important, T-Cells. Panel 1 markers are: CD3 
BV785, CD20 AF488, CD38 BV711, IgD BV421, CD56 APC Cy7 
(Biolegend); CD19 PerCP.Cy5.5, CD 27 APC (ebioscience); CD14 PE 
(BD).  
 
The aim of panel 2 is to characterize the CD19+ B cells for their stage 
(mostly for the presence of lymphoblast CD38+ cells) and their production 
of immunoglobulins. Panel 2 markers are: CD3 PE Cy5 (Beckman coulter), 
CD19 PerCP.Cy5.5, CD 27 APC (ebioscience); CD20 AF488, CD38 
BV711, IgM BV421, CD24 PE/Dazzle 594 (Biolegend); IgD PE, IgG APC 
H7 (BD Pharmigen™). 
The aim of panel 3 is to check the cells for the presence of CD58+/CD23+ 
Lymphoblast. Panel 3 markers are CD19 PerCP.Cy5.5, CD 27 APC 
(ebioscience); CD20 AF488, CD38 BV711, CD23 BV421, CD58/LFA3 
PECy5, CD14 BV510, CD56 BV510 (Biolegend), IgD PE (BD 
Pharmigen™), CD3 V500 (BD Horizon),  
All cells have been checked for viability by means of Zombie-Acqua live 
staining (Biolegend) and fixed in IC fixation buffer (eBioscience). 
  
Cell Sorting of B cells and FLS 
At the end of the co-culture (initially between day 90 or 105; for later 
experiment 28 days has been chosen as the endpoint) cells were ready for 
FACS analysis. Last aliquot of total SN was collected from each well and 
stored as previously described. Versene (1:5000 EDTA (1x) Gibco) has 
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been chosen compared to trypsin in order to preserve surface markers. 150 
µl p/w of versene have been added for 5 minutes at 37 degrees. This mild 
procedure usually results in the initial detachment of only B cells. After B-
cell were collected in a 2 ml eppendorf tube, centrifuged for 10' at 1800 
rpm, resuspended in cold PBS and kept in ice before staining procedure. 
Meanwhile other 150 µl of versene (this time cold) have been added for 20 
min at room temperature in order to detach the FLS, which are more 
susceptible to apoptosis during detachment. After this step cells have been 
collected with the same procedure of the B cells.  
 
 
a) B cell sorting:  
B-cells have been stained using Panel 1 for characterization and sorted on 
CD19/CD20. Cells have been collected in a 1.5 ml eppendorf tube 
containing 1 ml of CM-B used immediately for DNA extraction. When 
number of cells was higher than expected, surplus cells have been frozen in 
freezing medium (90% CM-B, 10% DMSO). 
 
b) FLS sorting:  
FLS have been stained for GYPA, CD45, CD34,CD90 BV650 (BD 
Optibuild); CAD-11 PE, Podoplanin AF-647 (Biolegend). Cells have been 
sorted based on physical parameters and expression of CD90+. Then 
collected in a 1.5 ml eppendorf tube containing 1 ml of CM-FLS and 
finally stored at -80 or used immediately for RNA extraction. 
Viability was assessed by means of Zombie NIR (Biolegend). Cells were 
not been fixed in order to perform molecular analysis.  
 
FACS data analysis 
 




gDNA isolation and PCR for the BamH1 W repeat region of EBV (W-
PCR) and calculation of frequency/level of EBV infected cells 
(Thorley-Lawson Laboratory): 
For calculation of frequency of EBV infected cells a qDNA-qPCR with 
serial dilution has been developed in my lab following original Torgbor 
and Thorley Lawson Protocol [243]. As a positive control and a standard 
for the dilutions EBV+ Namalwa cells (ATCC CRL-1432) have been used. 
Compared to other cell lines, such as Nc-Nc - which at a single cell level 
contain a very variable number of genome copies (anywhere from 2-30) -  
Namalwa copies are integrated (2) and extremely more stable. Thanks to 
this feature, these cells proved to be a high-quality tool to interpolate the 
exact number of EBV-infected cells. EBV-Ramos (ECACC) cells have 
been used as a negative control.  
 
a) Serial Dilutions and DNA extraction: 
Dilutions were made as follows: 5x104, 18’697 , 6’992, 2’614, 977, 365, 
136, 51, 19, 7, 2, 1 (4 biological replicates for standard; 4 biological 
replicates for sample). Controls (B cell Time 0 and  B- cell without 
fibroblasts) and sample have been placed in a 96 V bottom plate for 
subsequent PCR, spun at 1,200 rpm for 10 minutes at 4°C and the 
supernatant aspirated. To each well was then added 20 µl of digestion mix 
(prepared as follow:10X PCR buffer, 100 µl; Igepal (NP-40) 100 µl; 
Tween-20 100 µl; Proteinase K 50 µl of 20 mg/ ml stock and 650 µl of 
water). Plate was then sealed air-tight and incubated at 55°C overnight in 
an incubator. Then proteinase K deactivation was performed keeping the 
plate at 95°C for 10 minutes. Ten microliters (10 µl) of water were then 
added to all the sample and controls wells. b) W-repeat EBV gDNA-qPCR 
For each reaction a master mix was prepared containing: 5 µl of Taqman 
Gene Expression Mastermix, 0.5 µl of 900 nM primers+250 nM 
fluorogenic probe, 2.5 µl of DEPcTreated Water and 2 µl of sample. Final 
reaction volume was 10 µl (See Table 3.4 for primer and probe sequences). 
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qPCR reactions were performed following Taqman recommendation for 
mastermix on an ABI 7900HT Fast Real-Time PCR System and a 
QuantStudio 5 Real-time PCR System: Step 1 (1 cycle): 2 min at 50°C; 
Step 2 (1 cycle) 10 min a 95°C; Step 3 (50 cycles): 15sec at 95°C, 1min at 
60°C. Data were obtained with SDS and analysed using Prism. After W-
repeat EBV gDNA qPCR plate has been collected and stored at -20 for 
electrophoresis and sequencing 
 
Electrophoresis gel and Sanger Sequencing for EBV 
a) Electrophoresis gel: 
DNA concentration obtained from qPCR have been calculated using 
Quant-iT™ PicoGreen™ dsDNA Assay Kit and products have then used 
for electrophoresis analysis. Gel has been prepared using 4.5g of Agarose 
(Sigma Aldrich) diluted in 250 UltraPure TBE buffer 1X (ThermoFisher 
Scientific) to reach a percentage of 2, suitable to separate products between 
200 base pairs (bp) and 2000 bp. 5 µl of products have been mixed with 1 
µl of purple gel loading dye 6X (NewEngland Biolabs), loaded into the gel 
and run was performed in TBE buffer for 2 hours at 150 Volt. Gel results 
have been acquire using a Imaging System UV Transilluminator (UVP 
w/Sentech Stc-tb33usb). Gel products have been isolated and purified 
using a QIAquick Gel Extraction Kit (Quiagen) following Quiagen 
recommendation and prepared for sequencing.  
 
b) Sanger Sequencing: 
Gel products have been isolated and purified using a QIAquick Gel 
Extraction Kit (Quiagen) following Quiagen recommendation and 
concentration has been calculated using Nanodrop System (Thermofisher). 
To test integrity of products a 2nd round of PCR has been performed using 
"dummy" primers (unlabelled and not containing any probes). Best 
products have then been chosen and 5 µl have been sent for Sanger 
Sequencing using GATC biotech Service. Results have been visualized 
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using 4Peaks™ software and sequence alignment checked using 
Nucleotide Blast. 
 
RNA purification, RT-PCR and cDNA qPCR for FLS: 
 
RNA has been extracted from sorted FLS using Arcturus PicoPure™ RNA 
Isolation Kit (KIT0204). Elution has been performed with 12µl (3µl dead 
volume) resulting in a final volume of 9 µl. Such volume has been 
immediately retrotranscribed in a single reaction using a Superscript II 
Reverse trascriptase kit (Invitrogen). 23 µl of the sample volume obtained 
have been used in a pre-amplification step using Taqman PreAmp Master 
mix kit (final volume 50 µl) following Taqman recommendation for 
mastermix: Step 1 (1 cycle): 10 min a 95°C ; Step 2 (14 cycles): 15 sec at 
95°C, 4 min at 60°C. At the same time other 5 µl of sample have been used 
to perform quantification using a Quant-iT™ PicoGreen™ dsDNA Assay 
Kit (Thermofisher). Final qPCR step has been performed in technical 
triplicates 10 microliters final volume: 5 µl of Taqman Gene Expression 
Mastermix, 0.5 µl of 900 nM primers+250 nM fluorogenic probe, 0.5 µl of 
DEPcTreated Water and 4 µl of sample. Primers used were: GAPDH 
(housekeeping), IL-6, IL-8 and TNF-a. Reactions were performed 
following Taqman recommendation for mastermix on an ABI 7900HT Fast 
Real-Time PCR System: Step 1 (1 cycle): 2 min at 50°C; Step 2 (1 cycle) 
10 min a 95°C ; Step 3 (50 cycles): 15 sec at 95°C, 1min at 60°C. Data 




In order to identify EBV infection (CD19, EBNA-1, EBNA-2, LMP1, 
LMP2, EBER Table 3.5) PCR have been performed. RNA has been 
extracted and retrotranscribed has previously described. Reactions mix has 
been prepared as follow: 0.5µl of Q5® High-Fidelity DNA Polymerase, 
2000U/ml (NEB), 30.5 µl of DEPc treated water, 10 µl of Q5  5X reaction 
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buffer, 0.5 µl of 10 µM Primer (F/R) 1 µl of 10 µM dNTPs and 5 µl of 
sample lysate or 500ng).: Step 1 (1 cycle): 2 min at 50°C; Step 2 (1 cycle) 
10 min a 95°C ; Step 3 (40 cycles): 15 sec at 95°C, 1min at 60°C. Data 
were obtained with SDS. For this experiment Biorad CFX96 Real-Time 
PCR System have been used. 
 
 
EBV Nested PCR: 
 
In order to identify EBV infection (EBNA-2) 2 rounds of NESTED PCR 
have been performed. Nested PCR involves the use of two primer sets and 
two successive PCR reactions. RNA has been extracted and 
retrotranscribed has previously described. The first set of primers (Table 
3.5) are designed to anneal to sequences upstream from the second set of 
primers and are used in an initial PCR reaction. For first round reaction 
mix has been prepared as follow: 0.5µl of Q5® High-Fidelity DNA 
Polymerase, 2000U/ml (NEB), 30.5 µl of DEPc treated water, 10 µl of Q5  
5X reaction buffer, 1.5 µl of 10 µM Primer 1 EBNA 2F (sense), 1.5 µl of 
10 µM Primer 1 EBNA 2I (antisense), 1 µl of 10 µM dNTPs and 5 µl of 
sample lysate or 500ng). For second round reaction mix has been prepared 
in the same way, with the exception of the primers: Primer 1 EBNA 2C 
(sense); Primer 2EBNA 2G/B (antisense). Cycling conditions for a total 
volume of 50 µL are the one suggested by NEB for Q5® (both 1st round 
and 2nd round). For this experiment Biorad CFX96 Real-Time PCR System 
have been used. 
 
EBV Gradient PCR: 
 
In order to identify EBV infection (EBER and LMP2A, Table 3.5) gradient 
PCR have been performed. Gradient PCR is a technique that allows the 
empirical determination of an optimal annealing temperature. RNA has 
been extracted and retrotranscribed has previously described. Reaction mix 
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has been prepared in a total volume of 10 µl as follow: 0.5 µl of 10 µM of 
both forward and reverse primers (LMP2A/EBER), final concentration 
500nM/L, 3 µL of DEPc water, 5 µM of SYBR green blue mix (qPCRBIO) 
and 1 µl of templated (5ng/ µL). Cycling condition: Step 1 (1 cycle): 2 min 
at 50°C; Step 2 (1 cycle) 15 min a 95°C ; Step 3 (50 cycles): 15 sec at 
95°C, 1min at 70°,69.5°,68.4°,66.4°,64.0°,62.0°,60.7°,60°C. Data were 
obtained with SDS and analysed using Prism 50. For this experiment 
Biorad CFX96 Real-Time PCR System have been used. 
 
 
Enzyme-linked immunosorbent assays (ELISA) and Custom 
LEGENDplexTM Assay Panel test on supernatant from co-culture: 
 
All supernatants collected every 14 days from each well of the co-culture 
system have then been tested on several different ELISA and multiplex 
assay from biolegend in order to asses any variation in term of 
immunomodulation. Test have been performed for: total IgG, IgM and IgA 
(Bethyl Laboratories); IgG, IgM and IgA ACPA (Axis-Shield); Viral 
protein IgG-EBNA, IgG-VCA (Virion/Serion); IL-6, IL8 (ELISA MAX, 
Biolegend); April (ebioscience); BAFF/TNSF13B (R&D). 
LEGENDplexTM have been performed following company instructions. 
Analytes tested are APRIL, BAFF, CCL2 (MCP-1), CCL3 (MIP-1α), 
CXCL10 (IP-10), IL-6, IL-12p70, IL-22, IL-27, RANKL, TNF-α, TSLP, 
Rantes. 
 
Single cell sorting, digestion, RT-PCR and BamHIqPCR for EBNA-LP 
transcript: 
 
Single cell sorting, digestion and RT-PCR has been performed as 
previously described by Corsiero [244]. qPCR reactions were performed 
following Taqman recommendation for mastermix on a QuantStudio 5 
Real-time PCR System: Step 1 (1 cycle): 2 min at 50°C; Step 2 (1 cycle) 
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10 min a 95°C; Step 3 (50 cycles): 15sec at 95°C, 1min at 60°C. Data were 
obtained with SDS and analysed using Prism. Data have bene normalized 
on housekeeping gene GAPDH. 
 
Co-culture and Singles cells 10X genomics chromium sequencing: 
 
Sorted EBV+ RA-CD19+ cells at end of a normal co-culture assay have 
been plated again on RA-FLS, without stimuli. For each condition 1 wells 
from a 12well plate with 30’000 FLS and 93’000 B cells (Number has 
given by the Time 0 Control “leftover”; these cells were later dead and 
have not been use for this experiment). Cells have been cultured in 2ml of 
CM-B cells for 14 days. Medium has been changed and collected every 7 
days. 
At the endpoint, all medium has been collected gently to not disturb the 
RACD19+cell/RA-FLS interaction. Cells have been detached with 5 min 
trypsin at 37°C, collected in a 5ml eppendorf tube, spin down at 1500rpm 
for 5 minutes, resuspended in 100µl and kept on ice during transfer to the 
Genome Center of Queen Mary University (QMUL). Upon arrival, 
viability and number of cells was assessed using a Countess II automated 
cell counter; concentration trough centrifuge was operated when necessary. 
Preparation of sample and next steps have been performed following 10X 
suggestion:1000 cells have been loaded on the 10XChromium Controller 
instrument with 10x genomic reagents for VDJ and 5’transcriptomic 
analysis in order generate the libraries. Sequencing have been obtained 
with Illumina sequencing system.  
(Loading on Chromium Controller instrument and Illumina Sequencing 
have been performed by Genome Centre QMUL personnel). Output data 
obtained by Illumina have been analysed using free 10X software LOUPE 
and VLOUPE.  
Alternative analysis of Carejavi and comparison with other EBV infected 
cell line have been performed using R studio for Mac (Version 1.3.1093) 
and Seurat 3.0 from SatijLab [245] [246]. Codes used for quality control 
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(QC) and analysis have been obtained from SatijLab webpage ( 
https://satijalab.org/seurat/). Cell line used in comparison (GM12878 and 
GM18502) have been obtained from Osorio et al [247], are deposited in the 
NCBI Sequence Read Archive (SRA) and can be accessed along with 
processed data from the NCBI Gene Expression Omnibus (GEO, Series 
Accession: GSM484896 (for GM12878) and GSM2392689 (for 
GM18502)). In QC, cells having i) a number of features between 200 and 
6000, ii) a value less than 10% in mitochondrial genes, have been subset 
for analysis. 
 
Search Tool for the Retrieval of Interacting Genes/protein (STRING) 
Analysis: 
 
STRING is a biological database of known predicate protein/protein 
interaction. This database contains numerous information about these kinds 
of interaction, like experimental data, computational prediction methods 





Differences in quantitative variables were analysed by Mann Whitney U-
test or Kruskal-Wallis with Dunn’s post-test when comparing two or 
multiple groups, respectively. To test if the values were coming from a 
Gaussian distribution the Shapiro-Wilk normality test has been ran. 
For 10X, Cell ranger build-in software has run Principal component 
analysis (PCA), t-distributed Stochastic Neighbor Embedding (t-SNE) , 
clustering and differential expression: from 10X genomic: For each feature  
three values per cluster are computed: 1)The mean Unique molecular 
identifiers (UMI) counts per cell of this feature in cluster 2)The log2 fold-
change of this feature's expression in cluster i relative to all other clusters 
3)The p-value denoting significance of this feature's expression in cluster i 
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relative to other clusters, adjusted to account for the number of hypotheses 
(i.e. number of features) being tested. 
All statistical analyses were performed using GraphPad Prism version 6, 
(GraphPad Software, San Diego Ca, USA); Cell Ranger, LOUPE, 
VLOUPE (10Xgenomics); STRING. A p value <0.05 was considered 
statistically significant.  
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CHAPTER 4 TECHNICAL RESULTS   
 
In order to obtain long-standing EBV-infected B cells, I had to setup an in 
vitro co-culture system (Fig.4.1) whereby RA-FLS obtained from synovial 
fluid and synovial tissue of ACPA+ patients could have been cultured with 
B cells obtained from ACPA+ RA or healthy donor, with the final aim of 
understanding the long-term interactions between these two cells. 
 
Preliminary experiments and arrangement of co-culture system. 
 
Creating a biobank 
 
First, I needed to collect enough samples to obtain preliminary data. 
Thanks to the availability in my department, during the first months of my 
PhD has been possible to collect samples of different kind (synovial fluid, 
synovial tissue and peripheral blood) from patients (RA, osteoarthritis 
(OA), psoriatic arthritis (PsA)) and healthy donor. Thus, during these four 
years I have been able to create a small biobank of FLS, PBMCs and B 
cells that has allowed me not just to carry over my PhD but also to 
collaborate in my lab to several projects not directly related to EBV [249].  
Also, thanks to my supervisor Prof. Michele Bombardieri, I managed to 
obtain an official phlebotomist training from the National Health Service 
(NHS), in order to draw blood. This has not just allowed me to work 
independently when it comes to blood collection but also has gave me an 
incredible opportunity to directly interact with the patients.  
 





Successful culture of FLS from synovial tissue and synovial fluid 
 
During isolation, FLSs started to emerge from both synovial fluid and 
synovial tissue samples. The emerging cells showed an undoubtable 
fibroblast shape, were clearly alive when stained for trypan blue and have 
been dividing and proliferating at different rates. Most importantly, FLS 
from synovial fluid did not show any strong macroscopic differences when 
compared to their tissue counterpart. 
FLS were isolated and cultured successfully and have been frozen after 
passage 3 and beyond. All the experiments have been performed on frozen 
FLS for convenience: long time to reach passages 4 or 5, and timing of 
blood samples. Figure 4.1 is showing the 040/2016 RA-FLS, one of the 
most used sample, prior to the first co-culture experiment with total 
PBMCs: cells were alive and at a confluence of 80%.  
 
First co-cultures arrangement: several negative results 
 
The set-up of the co-culture system has required numerous attempts before 
demonstrating to be reliable. In this section I will quickly go through some 
of these attempts, but I will not discuss the data. In my first co-culture 
arrangement I decided to use total PBMCs obtained both from RA and HD 
patient. I choose a 96w/ell plate using 1,5 x 105 PBMCs por well. Once 
combined with the RA-FLS, the cells where cultured in (CM-B Cells) in 
250 µl (CM-B Cells) with stimuli. As control I used FLS and PBMCs 
alone, with or without stimuli. At the time I had two endpoints for the 
experiment, 14 and 28 days, and mostly I wanted to see any sort of 
interaction between the cells, the production of EBV related antibodies 
(EBNA IgG) and evidences of the presence of the virus. The final 
operation would have been extracting the RNA directly from the mix of 
cells, retrotranscribe it to cDNA, in order to perform sybr green qPCR 
using a group of primers available in my lab and designed by Dr. Croia. 
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(table 3.5). These primers were supposed to target specific B cells genes 
(such as CD19) or viral sequences (such as EBER or EBNA-1).  
After plating the cells, the co-culture was not checked day by day under the 
microscope to track the evolution of the experiment and I just decided to 
extract the total RNA after 14 and 28 days. At these two endpoints I also 
collected the SN in order to test it for the EBNA IgG. Unfortunately, after 
4 attempts the RNA yield tested at the Nanodrop was almost null. A 
preamplification step was used after the RT-PCR in order to increase the 
chances for a signal, but no amplification was obtained (data not shown). 




Figure 4.1. RA-FLS 040/2016 prior to co - culture (2016). Photo acquired with 
Olympus Microscope (brightfield). 
 
Furthermore, all the SN tested on ELISA for EBNA IgG resulted negative 
or very close to the negative control (data not shown) 
From these first results it looked almost like no cells were present in the 
co-culture, neither after 14 days nor 28 days. I decided then to repeat the 
experiment and to check the co-culture of PBMCs and FLS under the 
microscope in order to track the evolution and to identify any issue.  
After performing this simple operation, the problem was quite clear:  the 
PBMCs where showing a strong immune response toward the FLS in 
culture due to MHC mismatch (probably due the fraction in 
monocytes/macrophages or T CD8+ killer cells). At different degrees of 
level between the patients, the immune cells were responding to the FLS as 
foreign elements and this was due to heterologous nature of the assay. 
Indeed, obtaining FLS and PBMCs from the same patient has so far 
resulted quite difficult and was possible only in one case, as previously 
stated. From several picture obtained was evident that the PBMCs started 
to target the FLS already in the first hours during the experiments. After 14 
days most of the FLS were gone or showed ongoing apoptotic process 
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while after 28 days most of PBMCs left were strongly positive for trypan 
blue (data not shown). 
 
Get a clearer shot: 2
nd
 co-culture optimization 
 
CD19+ positive beads purification instead of total PBMCs 
 
For the purpose of reducing the variability – thus the kind of cells - inside 
the experiment, I decided to design a more controlled system. The first 
main change applied to the co-culture has been to perform a CD19+ 
positive selection, in order to get rid of any possible “contamination” from 
T cells or macrophages. Apart from the main concern above mentioned 
(the immune response toward FLS), the other issue I wanted to solve was 
to eliminate the T cells or the APC from the co-culture. Indeed, I wanted to 
confirm previous data produced from Kam and Bombardieri in my lab, 
showing that the FLS are able to some extent to trigger SHM and 
CSR[126]. 
This has resulted in a clearer arrangement for my purposes, as can be seen 
by microscope by figure 4.3 and figure 4.4. 
 
Increased amount of medium 
 
Due to the long-lasting nature of the experiment, the viability of the cells 
can be easily affected. One solution would have been to change the media, 
but unfortunately, with the 96 well plate assay this was resulting in either 
detaching the B cells from the FLS or losing all the floating cells. In order 
to solve this issue, I decide to switch for a 48 well plate, increase the 
amount of medium to 1.2 ml in each well (from previous 250 µl) and to 
collect and change the medium only every 14-15 days. This  have made 






Figure 4.2. Summary of the co-culture 2nd setup. Synovial fluid RA-FLS are co-cultured with CD19+ cells in a 48 well plate. CpG and Il-2 are added as stimuli.
Establishment of long-term co-culture of CD19+ + RAFLS 






Ring of PBMC  
12.500 CD19+/well in complete RPMI
(+ CpG 2,5 μg/ml; IL-2 10 u/ml)
7.500 SF p/w in complete DMEM




Co-culture system allows both FLS and CD19+ to survive up to 90 
days 
 
The 2nd set-up of the co-culture system has shown through microscopy 
what would be later confirmed by FACs analysis (see next chapter): a high 
percentage of both FLS and CD19+ cells were still alive at the end of the 
experiments compared to control (Fig 4.4) 
This has been indirectly confirmed also by ELISA in terms of 
immunoglobulins and cytokines production. Furthermore 3 out of 9 of the 
preliminary co-cultures during the set-up phase showed live cells still at 
105 days. This means that these cells have been able to survive in vitro for 
more than 3 months and this is a remarkable survival rate for B cells which 
are known to be usually short lived in the absence of strong survival 
signals. It is important to mention that the co-culture experiments were not 
run in parallel in order to allow a thorough examination at the endpoint.  At 
the time a reliable system to detect and quantify EBV was not in place, so 
these cultures have not been screened for the virus. 
 
RA-FLS induce class switched antibodies production from RACD19+ 
cells 
 
Preliminary data have shown that production of total IgM, IgG, and IgA 
from the CD19+ B cells co-cultured with RA-FLS under IL-2 and CpG 
stimulation is greatly increased compared to controls (Fig 4.5 & 4.6). Also, 
the ratio between IgM and IgG seems to vary along the time, as another 
confirmation of class switching. This has been shown in all my 
experiments with a slight variation between isotypes among different co-
culture. It is important to highlight that this is a highly specific 
characteristic of RA-FLS since dermal fibroblasts obtained from the same 
donor failed to induce Ig release[126]. However, I was not able to detect 
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antibodies against EBNA-1-IgG, VCA and CCP antigens (including 
ACPA-IgG, ACPA-IgM, ACPA-IgA HCP1 and 2, VCP1 and 2 in any of 




Figure 4.3. RA-FLS and isolated cells in co-culture on day 28. Isolated cells are presumed to be CD19+ obtained after purification. Photo acquired with 
Olympus Microscope (bright field).
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Figure 4.4. RA-FLS and isolated cells in co-culture on day 90. Isolated cells are presumed to be CD19+ obtained after purification. Photo acquired with 


































































































































































Figure 4.5. ELISA results for total IgM, IgG and IgA concentration (starting from previous page). IgM, IgG and IgA (B) concentration from 2 different co-
































































































































RAFLS + RACD19+ + IL-2
RAFLS+ RACD19+ + IL-2 + CpG
RAFLS + IL-2 + CpG
RACD19+ + IL-2 
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Figure 4.6. IgG, IgM, IGA production at day 2-60. Ration between IgG and IgM between day 2 and day 60 (starting from previous page).  IgG, IgM 
and IgA production from day 2 to day 60  from CD19+ co-cultured with RA-FLS plus stimuli (CpG + Il-2) is higher than control. Same results are merged to be expressed in 






































RAFLS + RACD19++ IL-2 + CpG
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It is possible that if ACPA+ EBV-infected B cells were present and 
proliferating in the co-culture, the level of anti-citrullinated antibodies 
might be below the level of detectability of the ELISA test used. Attempts 
to concentrate IgG in supernatant have been performed but failed. 
Alternative approaches (WB, ELISA for specific citrullinated antigens etc) 










The introduction of flowcytometry and cell-sorting to assess purity and 
characterize the sample before and after co-culture 
 
First panel design and sorting for co-culture RA-FLS and RACD19+: T 
cell contamination issue 
 
In order to analyse the evolution of the different subsets of B cells inside of 
the co-culture and to obtain a higher level of purity during molecular 
biology screening, I decided to adopt flowcytometry and single cells 
sorting analysis.  
The first small panel I designed contained only a few marker (DAPI, 
CD19, CD20, CD3, CD27 and CD38, see table 4.3 and methodologies) and 
was tested on the co-culture of sample RA-FLS 034/2016 and 
RACD19+099/2016, both ACPA+, at the end of the test. In order to 
increase cell purity, during the acquisition of the panel I decided to set up 
two fluorescence minus one staining, or FMO (CD20 and CD3). 
Unfortunately, this panel was designed with several bias – probably due to 
 136 
lack of experience – since instead of aiming for a double positive 
population of CD19 and CD20 I only targeted the CD19 cells. Also, CD20 
and CD3 – a common T cell human marker - were occupying the same 
fluorochrome (FITC). Nevertheless, this panel have revealed that - despite 
the CD19+ purification - the amount of T cells in the co-culture was still 






Figure 4.7. First FACS analysis and T cells contamination issue (previous page): First panel design and acquisition of co-culture RA-FLS 034/2016 and 
RACD19+099/2016. T cell contamination in the co-culture after 28 days can be identified through the CD20 FMO. Cells have been gated on physical parameters, then 




Purification yield increased after 2nd passage on column and masked 
antigen issue solved 
 
In order to increase purity, I decided - during the purification steps - to pass 
the CD19+ enriched fraction a 2nd time on a 2nd column and test cells with 
a  second panel: Zombie Aqua (instead of DAPI) CD3, CD14 (for 
monocytes) and then typical B cells markers such as CD19, IgD and CD27 
(but not CD20) (see table 4.3). In this case, I used blood collected from a 
healthy donor. While the T cells issue appeared to be solved (T cells 
fraction dropped from 72.9% in total PBMCS to 5.67 % in the 2nd B cell 
separation), the majority of cell in the CD3/CD19 appeared as double 
negative (DN, Figure 4.8). Nevertheless, this DN population showed the 
same pattern for IgD and CD27 when compared to the CD19+ cells. This 
made me speculate that the CD19+ purification antibody might have 
targeted the same antigen as the FACs one, thus masking the epitope. A 
3rd panel to address this has been created, adding this time CD20 and 
testing it again on a healthy donor sample before and after separation. I 
also added CD56 as a further marker for NK cells identification. This 
experiment resulted in obtaining CD20+ cells (81% after 2nd separation) 
and a small CD19+CD20+ fraction (18.8%) compared to the 
CD19+CD20+ population present in the PBMCs (28.3%) (Fig 4.9). 
Also, T cells exclusion worked more efficiently resulting in a drop from 
68.0% (PBMCs) to a 4.62% (1st separation) and to 0.27% (2nd separation).  
It is important to mention that B cells negative selection has been taken 
into account, but T contamination percentage was higher than in the 1st 






Comparison between PBMCs ( from CD 19+gate) 





















Figure 4.8. 2nd FACS Panel, T cells contamination solved and double negative issue (previous pages,  first figure is showing total PBMCs while second figure is 
showing 1st separation and 2nd separation) .With the 2nd FACs panel I managed to solve the T cells contamination problem. Nevertheless, in CD3/CD20 graph most of the 
cells resulted double negative. This double negative population appeared almost identical in term of IgD and CD27 expression when compared to the CD19+ cells. Cells have 






















































Figure 4.9. 3nd FACS Panel, double negative population issue solved (previous pages, first page PBMCs extraction, second page 1st separation, third page 2nd 
separation)): The inclusion of CD20 in my 3rd FACs panel have allowed me to discriminate the CD19+ before and after the purification, once the CD19+ epitope was 








Final panels: Purification, Characterization and Lymphoblast panel 
 
At this point, in order to standardise my co-culture system, I decided to 
setup 3 final panels that would have help to assess purity, but also to 
characterize my B cells subsets at the beginning and the end of the co-
culture. 
These 3 panels are: i) Purity Panel (basically the same of my 3rd panel); ii) 
Characterization panel (this panel is the most important, containing not just 
CD38, IgD and CD27, but also IgG , IgM and CD24); iii) Lymphoblast 
panel (this panel contain normal B cells marker plus the addiction of CD23 
and CD58, specific for EBV relates subsets as already mentioned in the 
introduction (page 91), whose outcome will be discussed in chapter 6. All 
the 3 panels can be visualized in appendix in table 3.2. 
 
Optimization of FACS on FLS  
 
Increased number of FLS and surface marker preservation for FACS 
 
I decided to focus also on the FLS and to setup a working FACS panel with 
the aim of exploring the effect induced by the B cells to the FLS during the 
time in culture. In order to optimize this procedure, I used fibroblast from 
different sources (RA, OA, PsA). The markers selected for this panel are 
both the more typical FLS markers (CD90, Cadherin 11), plus some of the 
ones that have gained interest recently (Podoplanin, DAF/CD55 and FAP). 
I also included Glycophorin (GYPA), CD45, PECAM1 and CD146 in the 
dump channel. 
After performing numerous attempts of optimization, the first obstacle has 
resulted in obtaining enough cells for a correct analysis. Indeed, when 
starting from a number of FLS comparable to PBMCs, the former had 
always resulted in a much lower yield. Luckily, according to Kaur and 
Esau report, I discover that almost 80% of stromal cells are lost during a 
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normal staining procedure, due to centrifugation [250]. Following the 
guidelines from this paper, I reduced the number of washes and 
centrifugation, and this had led to a strong increase in the fibroblast yield 
(Fig 4.10).  
In the same context I had to solve another issue. Compared to PBMCs, 
FLS are adherent cells and thus require being detached from the plate. 
Unfortunately, the use of trypsin has resulted in an almost total loss of 
some important surface marker, such as CD90. In order to solve this 
problem, I tested several detaching agents (both enzymatic and non-
enzymatic) such as accutase or versene, with the latter showing the better 
results in term of signal preservation for all the markers (Fig 4.11). It is 
important to mention that - compared to trypsine and accutase - versene 
require longer incubation times and this might lead to and increase number 
of dead cells, due to toxicity. Reduction of these incubation times and 
adding PBS 1:1 to the cell-versene suspension has increased viability. 
Interestingly, the fact that versene is a gentler detaching agent has resulted 
of great help for my co-culture system, in which I wanted to analyse the B 
cells and the FLS separately.  Since B cells after long time and culture tend 
to be attached to the stromal cells it would have been difficult to sort them 
using trypsin. The use of versene and the longer incubation time has 
allowed me to extract from the co-culture first an enriched B cells fraction 





Figure 4.10. Increased number of cells with New FLS Protocol: After reducing the number of centrifugation steps in the original protocol I managed to obtain a correct 























Figure 4.11. FLS detaching protocol: comparison of different detaching agents (previous pages; first page: versene separation, second page: accutase separation; 
third pages: trypsin separation) a): the same RA-FLS sample have been detached with versene (V), accutase (A) and trypsine (T). 10’000 events have been analysed. Cells 




Long-term culture of FLS cause small phenotype variations and 
difficult reproducibility of FACS data 
 
Once the right protocol was set-up, I decided to test both the co-culture 
system FLS, and to compare FLS from a different autoimmune disease to 
investigate any variability in my set of markers. In my first experiment I 
compared FLS from PsA and RA and the first result has been encouraging 
(Fig 4.12). Despite being identical for almost all the other markers 
(Cadherin11, Podoplanin, CD34 and CD90, the RA-FLS showed a clear 
double positive population for DAF/CD55 and FAP when compared to 
PsA-FLS. I decided to do the same for OA-FLS and also to test if the same 
samples can be stable or show differences trough passages. Unfortunately, 
this has not been the case: Figure 4.13 is showing that the same sample of 
RA-FLS  or OA-FLS behave quite randomly regarding the expression of 
this surface markers, with small differences between the two disease. 
Also, most of the small differences obtained - both when comparing cells 
from different diseases and passages or in my co-culture- have been 
extremely difficult to reproduce and are mostly more related to the time in 
culture and to experiment-induced effects. 
 
The co-culture results concerning the sorted RA-FLS at the end of each 





Figure 4.12. FACS Comparison between RA-FLS and PsA-FLS, passage 5 (previous page): RA-FLS and PsA-FLS have been compared trough FACS. The two samples 
appear quite similar regarding the expression of surface markers CD34. CD90, Podoplanin and Cadherin 11. Nevertheless RA-FLS show a double population of DAF/FAP 






























Figure 4.13. FACS Comparison between RA-FLS and OA-FLS at different passages (previous pages; first page: RA-FLS; second page: OAFLS): RA-FLS 057/11 
and OA-FLS 109/17 and 099/17 have been compared trough FACS at different passages. The small differences observed - regarding the expression of surface markers 
CD34, CD90, Podoplanin and Cadherin 11 - between the two batches of sample appear to be random and mostly more related to the time in culture and to experiment-
induced effects. Cells have been gated on physical parameters, Zombie Nir/dump channel, CD34-, Cadherin11/CD90, Podoplanin/CD90, DAF/FAP.
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FLS screening to address B cell-targeting stimuli induced effect in the 
co-culture  
 
CpG and IL-2 do not influence neither expression nor inflammatory 
cytokines production in RA-FLS 
 
During preliminary experiments for the co-culture system, a small 
difference has been observed in term of IL-6 response between un-
stimulated and stimulated RA-FLS with CpG and Il-2. This result was 
puzzling since FLS are usually thought to lack both IL-2 receptor and 
TLR9 [118]. In order to address this, a test has been run: RA-FLS have 
been cultured for 28 days in the same exact conditions obtained during co-
culture, with or without the stimuli. SN was collected every 7 days and - at 
the end of experiment - cells have been digested to obtain RNA. The SN 
has been tested at the different time points for the expression of IL-6 or IL-
8. The cDNA has been tested on qPCR for expression of IL-6 and IL-8, but 
also for TLR-9, BAFF, APRIL and IL2 receptor subunits (IL-2Rβ and 
ILR-2γ).  
 
The results showed - both by ELISA and by qPCR – that the stimuli do not 
induce IL-6 or IL-8, so the small difference observed was probably a 
random effect (Fig.4.14 & 4.15).  Also, RA-FLS seemed to have very basal 





























































































Figure 4.15. Relative Expression of co-culture related genes after 28 days stimulation 
with IL-2 and CpG on RA-FLS: Results relative expression on TLR9, IL-2Rb, Il2-Rg, 







































































































































































































Relative Expression - 
RAFLS 057/11
28 Days Stimulation
with IL-2 and CpG
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First proliferation events obtained in co-culture system 
 
Proliferation of RACD19+ B-cells is obtained in the presence of RA-FLS  
 
After 40 days of culture, in two experiments out of six, a sudden increased 
in the number of B cells was observed. This particular behaviour was 
observed only in 1 and 3 of the 8 biological replicates (Patient 1 3/8; 
Patient 6 1/8)  (Fig 4.16)  
The confirmation that the phenomenon observed was actually proliferation 
- and not only activation - has been given from the number of events 
obtained during FACS analysis and single cells sorting at the end of the 
experiment: considering a starting number of 12'500 RACD19+ cells (p/w), 
at least in one well analysed 65'192 events were reached, giving a 5.21 
ratio (the latter is not actually taking into account any death ratio, which 
are obviously believed to take place during this long experiment). 
Another important improvement at this point has been the introduction of 
the “Time 0” control: at the beginning of every co-culture, a small aliquot 
of isolate CD19+ B cells has been frozen to be tested as a control both for 
B cells subsets variation and for the presence of EBV. Unfortunately, at the 
time, none of my assays was working properly to identify and quantify the 
virus. This was later resolved and data comparing baseline and post-co-
culture EBV content are presented in Chapter 5. 
Nevertheless, results have shown that the majority of proliferating B-cells 
where alive and CD38+, when compared to the Time 0 Ctrl cells (Fig 4.17) 
This marker is usually expressed by proliferating lymphoblast in the GC 
but is also highly express by lymphoblastoid cell line which are established 
in vitro from the survival and proliferation of B cell naturally  harbouring 










Sorting of Lymphoblastoid CD38+ from coculture: 
day 105 (Time 0 and Time 105)
•Presence of live cells
•CD19+ /CD20+
• Increase in CD38+ Lymphoblastoid
Cells
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Figure 4.17. Sorting of Lymphoblastoid CD38+ from co-culture (previous page): Summary slide of final sorting on CD19+ B cells obtained at the end of the 
co-culture (day 105) compared to the CD19+ B cells purified at time 0. Cells are alive and the EBV-driven proliferation has resulted in a lymphoblast/GC CD38high alike 
cells. Gating strategy: cells have been gated on aqua for viability; on side scatter (SSC-A) and forward scatter (FSC-A) for physical parameter. Then CD3-CD20+ to exclude 
T cell contamination. Finally, on CD19+CD20+ and on CD38+CD27- for lymphoblast/GC CD38high alike cells. Interestingly at time 0 cells are CD19-CD20+ and this is 





CHAPTER 5: RA-FLS support proliferation, activation and 
differentiation of naturally occurring EBV+B cells 
 
In order to identify and quantify EBV in my co-culture system, several 
attempts have been performed with different molecular biology protocol. 
Unfortunately, most of them have been unsuccessful until finding the most 
suitable one. In these attempts I have i) tested the “old” batch of primer 
mentioned in chapter 4; ii) create a protocol for a gradient PCR; iii) create 
a protocol for a Nested PCR. None of these tests have worked due to lack 
of signal or specifity (data not shown). 
 
A reliable method for EBV quantification: BAMHI w repeated region 
sequence gDNA qPCR  
 
Successful Preliminary test for BAMHI w repeated sequence gDNA qPCR 
and sequencing results 
 
Thanks to the kindness of Dr Thorley Lawson, who has helped me in 
solving this issue, I later found out that the actual state of the art for EBV 
analysis and quantification it is a specific genomic DNA qPCR targeting 
the BAMHI W repeated region and based on limiting dilutions technique 
[243].  
 
Once obtained the probe and the cells to be used as control (new batches of  
Namalwa cells and Ramos), I decided to test the co-culture in which I 
observed proliferation. Several aliquots of frozen cells from these 
experiments have been thawed and then compared to a standard curve 
obtained from limiting dilutions of Namalwa cells. Indeed, this further 
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molecular analysis demonstrated that all sorted proliferating cells were 
positive for EBV (Fig 5.1).  
 
Unfortunately - since these cells were bulk sorted - a precise interpolation 
of the number of infected cells at a single cells level was not possible. 
Nevertheless, the qPCR template has then been used to perform 
electrophoresis analysis, which allowed the identification of a clear 191 bp 
product, absent in the negative control (Fig.5.2). This band was then 
sequenced, giving the final confirmation, by an alignment of 100 %, that 







Figure 5.1. PCR for the BamH1 W repeat region of EBV (W-PCR) and 
calculation of frequency/level of EBV copies in bulk gDNA (Thorley-Lawson 
Laboratory).  Cells sorted from proliferative wells resulted to be all positive for EBV. Also, 
number of infected cells was higher when compared to internal control. Namalwa cells and 
Ramos cell were used as a positive and negative control for EBV. Limitations of this assay is 





















































































































Figure 5.2. Agarose gel on W-PCR products: In positive control the product of the qPCR clearly appears at 191bp. This was absent in the negative control but present 
in 2 patients samples. The fact that this procedure is genomic a DNAqPCR explain the high presence of background. Occasionally the qPCR probe can appear as a second 
product between 50bp and 20bp. 















Figure 5.3. Sequencing on W-PCR products: Slide summary for sequencing results on W-PCR products. The 191bp product has been used to perform sequencing 
analysis giving an alignment of 100% with Human Herpesvirus 4 complete wild type genome.
Sequencing Results:EBV alignment 100%
 170 
 
Optimization test on Namalwa cells to improve EBV BamHI gDNA-
qPCR at single cell level 
 
In order to improve the BamHI qPCR at a single cells level I decided to 
test whether different combination of gDNA and water can alter the 
outcome of my reactions. Also, I decided to sort on live cells for the 
standard curve, instead of using only the physical parameters. The standard 
curve of Namalwa cells has been performed manually starting from 50’000 
cells and performing serial dilution till 19 cells. For 7, 2 and 1, the cells 
have been sorted. With a 10 µl final volume, the best results have been 
obtained when using water, a lower amount of template and when cells 












Figure 5.4. Optimization test on Namalwa cells to improve EBV BamHI DNA-
qPCR at single cell level: Comparison between limiting dilutions of Namalwa cells 
screened with different reaction mix. For conditions “4.5ul” with or without water 
and for “zombie gated” (live cells) VS “physical parameters” only 7,2 and 1 sorted 
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Experiment 0051: Increased Number of CD19+ and first evidence that 
proliferation of CD19+ B-cells is EBV driven and obtained in the 
presence of RA-FLS: 
 
At this point I needed to standardise my experiment and repeat it. As 
mentioned in research methodologies, I also modified some of the 
conditions, mostly to increase the probability to have EBV+CD19+ in my 
co-culture. 
 
Indeed, my first test with the new conditions, experiment 0051, has shown 
proliferation after only 14 days. Sorting has been performed at day 28 and 
cells have been tested with BamHIW EBVqPCR. Thanks to the presence of 
a control at time 0, it has been possible to check the increase in number of 
EBV copies compared to the beginning of the experiment, and also to 
esteem the average of copies for single cells (Fig 5.5). Limiting dilutions 
have been performed both for samples and controls, in order to identify the 
lowest point in which was possible to still obtain a positive signal. 
Results clearly show an increase in number of EBV copies compare to 
control (200’000 copies at 28 days Vs 10-1 copies at time 0) using the 
same number of cells. A low level of proliferation has been observed also 
in the B cell control but this data has to be revised since no alive B cells 
where present in this condition and most of the cells sorted were dead or 
dying. It is very likely that by adding DNAse to the cells -  before 
performing the sorting - this kind of background can be avoided. Data have 






Figure 5.5. Number of Copies versus Number of B cells in co-culture system: 
Results are showing an enormous increase of the infected cells and number of copies after co-
culture with RA-FLS compared to control. Each sample has been run in 4 biological replicates 
and each of the biological replicates has been further tested in 3 technical replicates for 








Comparison between co-culture of RA-FLS with HdCD19+ or 
RACD19+ 
 
Co-culture of RA-FLS with RACD19+ and HdCD19+ B cells shows 
increase of EBV infected cells 
 
In order to address one of the aims of this PhD I repeated the experiment 10 
times using 5 blood samples from ACPA+ RA patient and compared these 
results VS RA-FLS cultured with HdCD19+ obtained from 5 different healthy 
donor.  Each of these 10 co-cultures have been performed separately and not 
at the same time, as previously stated. After the last experiment have been 
performed data have been put together to create this graph. I confirmed that 
after 28 days, proliferation of B cells happens exclusively when cultured with 
RA-FLS and it is always due to the presence of EBV. I also demonstrated that 
this EBV-driven proliferation does not happen exclusively with RACD19+ but 
also with HdCD19+ (as this was expected since circulating EBV+ B cells are 
present at a very low frequency also in this group). Nevertheless HdCD19+ 
cells show slightly less proliferative potential compared to ACPA+RACD19+ 





Figure 5.6. Co-culture of RA-FLS with RACD19+ and HdCD19+ B cells shows 
increase of EBV+ infected cells: Comparison of number of EBV copies detected 
between RACD19+ (5 peripheral blood samples) and HdCD19+ (5 peripheral blood 
samples) co-cultured with RA-FLS at day 0 and day 28. After 28 days 
EBV-driven proliferation of B cells happens almost exclusively when cultured with 
RA-FLS. Nevertheless HdCD19+ cells show slightly less proliferative potential 
compared to ACPA+RACD19+. Samples that have not given any qPCR signal have 
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Increase in immunoglobulin and inflammatory cytokines production 
in presence of EBV -driven proliferation 
 
ELISA tests on SN showed a strong increase of IL-6 and IL-8 in all 
proliferative co-culture, when compared to controls, both at 14 and 28 days 
(Fig 5.7). As for previous results, production of IL-6 and IL-8 does not 
exclusively increase in co-cultures of RA-FLS and RACD19+ but also in 
all HdCD19+ experiments in which proliferation has been detected (fig 
5.7). There is no significant difference between the RA and HD group 
neither at  14 nor 28 days. 
Production of IgM and IgG follows a similar pattern, with IgG production 
slightly more marked in RA (Fig. 5.8). Nevertheless, these differences – 
both at 14 and 28 days – have resulted not significant between the RA and 
HD group.  
At least in one sample, considering the highest point reached in terms of 
production, I estimated an average of 34.50-fold increase for IL-6 and 




Figure 5.7. Increase of IL-6 and IL-8 production by co-culture system in the presence of EBV-driven proliferation: Results are showing Il-6 and Il-8 
increased production when EBV driven proliferation is observed in co-culture of RACD19+/HdCD19+ with RA-FLS (timepoint: day2, day14, day 28). Increase is already 
appreciable at 14 days (Data from experiment comparing 5 RACD19+ peripheral blood samples and 5 HdCD19+ peripheral blood samples co-cultured with RA-FLS). 









RA VS Hd CD19+B cells Cultured with RAFLS



































RA VS Hd CD19+B cells Cultured with RAFLS










Figure 5.8. Increase of IgM and gG production by co-culture system in the presence of EBV-driven proliferation: Results are showing IgM and IgG increased 
production when EBV driven proliferation is observed in co-culture of RACD19+/HdCD19+ with RA-FLS (timepoint: day2, day14, day 28). Increase is already appreciable 
at 14 days (Data from experiment comparing 5 RACD19+ peripheral blood samples and 5 HdCD19+ peripheral blood samples co-cultured with RA-FLS).











RA VS Hd CD19+B cells Cultured with RAFLS
















RA VS Hd CD19+B cells Cultured with RAFLS










Increase of CD38+ and IgM+ and switched IgG+ subsets during co-
culture in presence of EBV-driven proliferation 
 
I demonstrated by FACS analysis that in co-culture – during the EBV 
driven proliferation - there is a significant increase of proliferating CD38+ 
plasmablast. This increase of CD38+ is not present in ctrl B cells, so it is a 
further demonstration that this subset it is not affected by the stimuli. Also, 
IgM+ are significantly increased in co-culture, but a smaller - but still 
significant – increase is present also in the Ctrl B cells.  
A smaller, but not significant, increase of switched IgG has been detected 
in co-culture compared to control (Fig 5.9). 
Nevertheless, there is no significant difference about these markers when 







Figure 5.9 Increase of CD38+, IgM+ and switched IgG+ subsets during co-culture in presence of EBV-driven proliferation: Facs Results are showing CD38+ and 
IgM+ significant increase in proliferative co-culture. A milder increase of IgG has been detected. Graph are obtained from total CD19+CD20+ sorted B cell at the end of the 




CHAPTER 6 Specific patterns emerging in RACD19+ and RA-FLS 
co-culture when EBV is detected 
 
During experiment 0051 not all sorted B cells were needed to perform the 
qPCR, so the extra amount has been used to perform further experiment. 
These 30’000 “leftovers” lymphoblasts have been kept for 7 days in CM-B 
and then plated again a second time on RA-FLS without any kind of 
stimuli. Surprisingly cells were still proliferating at the end point of the 
second co-culture (day 36) (Fig. 3,1). Supernatant has then been collected 
every week and cells have been used to test reliability of the new 
CD58/CD23 Lymphoblast panel.  
 
 
Further characterization of subsets of EBV+CD19+ B cells obtained 
from co-culture  
 
Proliferating cells in co-culture are mainly CD58+/CD23low and 
CD58+/CD23hi B cells 
 
At the end of the experiment, all 0051 B cells have shown to belong to the 
main subsets described by Megyola, CD58+/CD23low and CD58+/CD23hi 
which are almost totally absent in a healthy control [205]. Also, compared 
to the positive control (Namalwa cells) my population appear highly 
skewed toward the proliferating compartment (CD23hi) (Fig 6.1, Table 
3.2). Interestingly, most of the co-culture at time 0 appear to have more 










Figure 6.1. Expression of CD58 and CD23 marker by FACS in experiment 0051 (previous pages): Results are showing presence of the two previously described 
population CD58+/CD23low and CD58+/CD23hi in EBV infected cells from 0051, which are absent in healthy donor PBMC and EBV- cell line (Ramos cells). Nevertheless, 
the two subsets clearly resemble an EBV+ cell line (Namalwa). Gating has been done on singlets, lymphocytes, live cells and then expression of CD19 and CD20. Cell have 








Figure. 6.2 Expression of CD58 and CD23 marker by FACS in all co-culture at time 0: 
Results are showing the expression for CD58 and CD23 markers at time 0 in co-culture, 
Interestingly, at the beginning of the experiment the majority of cells are CD58+/CD23low, 
while a very few CD58+/CD23hi cells are present (Data from experiment comparing 5 
RACD19+ peripheral blood samples and 5 HdCD19+ peripheral blood samples co-cultured 









Screening trough multiplex reveal a different pattern in cytokines and 
chemokines produced between B cells and lymphoblast 
 
Supernatants from experiment 0051 (first round: 28 day of co-culture; 
interphase with only LCL: 7 days ; second round of co-culture: 36 days)   
have been tested with a custom LEGENDplexTM assay panel and several 
different analytes were present (all analytes are present in table 6.1). In 
order to understand the mechanism and decide further approach analytes 
have been divided between those produced both in the presence of normal 
B cell and in the presence lymphoblast (Fig.6.3) and those produced only 
after lymphoblast proliferation (Fig 6.4). The entire panel analysed can be 
found in appendix (table 6.1) 
The analytes produced in the presence of both cells are MIP-1alfa, CCL2, 
BAFF and IL-6. 
The analytes produced only during lymphoblasts proliferation are CCL5, 













Figure 6.3. Analytes produced both in the presence of B cells and Lymphoblast: Results 
are showing analytes produced both in the presence of B cells and lymphoblast (data is 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6.4. Analytes produced only in the presence of Lymphoblast: Results are showing 
analytes produced only in the presence of lymphoblast (data is showing results for only the 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CD58+/CD23hi cells show an increased number of EBV EBNA-LP 
mRNA compared to CD58+/CD23lo cells when analysed at single cell 
level 
 
CD58+/CD23hi and CD58+/CD23low have been tested at single cells level 
for level of transcript from the BamHI W, repeated region: EBNA-LP. 
Intriguingly, CD58+/CD23hi showed a significant increase in transcript 
signal when compared to CD58+/CD23low (Fig.6.5). Since this 
compartment is the one proliferating the most it might be that is also the 








Figure 6.5. CD58+/CD23hi cells show an increased number of EBV EBNA-LP mRNA 
compared to CD58+/CD23low cells when analyzed at single cell level: Results are showing 
normalized relative expression values from qPCR for EBNA-LP RNA transcripts obtained 
from CD58+/23hi and CD58+/CD23low. values from CD58+/23hi cells appear to be 
significantly higher than CD58+/CD23low, meaning a higher content of the transcript. Number 














































After sorting, subsets CD58+/CD23hi  and CD58+/CD23low tend to 
merge again in a mixed population after 2 weeks in culture 
 
CD58+/CD23hi and CD58+/CD23low have been sorted separately and the 
same number of cells has been cultured for two weeks, in order to 
understand stability of these two subsets. Nevertheless, at the end point, 
cells showed again the same mixed population of 23 low and 23 hi (data not 
shown). The only main difference has been in the number of cells obtained 
from the double positive cells, but this is not surprising since it is known to 
be the one with the most proliferative power. Also, cells have been sorted 
again, serial diluted and screened for copy number with the BamHI gDNA 
qPCR. The result of this last experiment has not showed any significant 























Figure 6.6. EBV Copies from separation of subsets CD58+/CD23hi and CD58+/CD23low: 
Results are showing BamHI gDNA qPCR interpolated copies number from sorted population 
of CD58+/CD23hi and CD58+/CD23low. Merged subsets have been subsequently separated in 
relative CD23low and CD23hi in order to perform the qPCR.  No significant difference has been 











A putative lymphoblastoid cell line isolation: Carejavi 
 
Singles cells 10X genomics chromium sequencing and STRING 
analysis on lymphoblasts 0051 show presence of one main clonotype 
and typical proliferating blast phenotype 
 
Lymphoblasts from experiment 0051 were expanded without stimuli or a 
feeding layer of RA-FLS for 4 months. In order to get a better understanding 
of these cells, I decided to perform an analyse using 10X genomic chromium 
single cell sequencing platform for both V(D)J and 5’ total transcriptomic 
analysis. Ig sequences of the heavy chain are determined by a specific V(D)J 
rearrangement which defines a unique CDR3. Further diversity is introduced 
by N nucleotide addition during gene rearrangement and by point mutations 
through the process of SHM during clonal expansion of the B cells. The latter 
event brings to the formation of clonally related B cells. Thus, the Ig gene of 
these clonally related B cells derives from a single germline rearrangement 
and is characterised by the same V, D and J gene usage. Analysis of a set of 
IGH sequences from the lymphoblasts (experiment 0051) showed that almost 
all the cells were clonally related with a prevalence of one clonotype (Fig 6.7) 
This clonotype (isotype: IgM) was identified by Ig VH3-7, D2-8, JH4, 
CDR3=CARHRDQWAHW and Ig VL2-14, JL2, CDR3 = 
CSSYISNNILPVVL. Stability of this clonotype over time was confirmed after 
three months using a single cells nested PCR approach set up in my lab by 
Corsiero (data not shown) as alternative method to the 10X platform [110] . 
Moreover, 5’ total transcriptomic analysis showed that the three main clusters 
obtained by t-distributed stochastic neighbour embedding (t-SNE) shared most 
of the same upregulated genes (Fig.6.8). With STRING analysis was possible 
to confirm that the first 50 upregulated genes were related to process of cells 
undergoing active proliferation, i.e. DNA proliferation, chromosome and 
chromatin organization, DNA packaging, nucleosome organization. These are 
typical process present in proliferating lymphoblast (Fig 6.9). Of great interest 
is the fact that these cells have a strong signature for HLA-DRB1, the gene 
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connected to the shared epitope, and this might finally help me to connect 
these cells to an autoimmune mechanism (Fig.6.10). 
As a candidate for a possible cell line, these cells have been provisionally 
referred to as “Carejavi”. (characterization and potential commercial 
exploitation of this cell line is included in future plans). Since these cells are 
from an ACPA+ RA patient, naturally harbour the virus and have a strong 
signature in HLA-DRB1 they might be a powerful tool to be used in research 






















Figure 6.7. Barcode frequency (top) and heatmap (bottom) from 10X genomic single 
cells sequencing for V(D)J: Results are showing that almost all the cells analysed belong to a 










IGH: VH3-7, D2-8, JH4 IGM











Figure 6.8. t-SNE from 10x genomic single cells sequencing for 5’ transcriptomic: Results 
are showing 3 main cluster (1,2 and 3) obtained from 10 X t-SNE analysis. Cluster 4 and 5 
have been excluded from the analysis due to the presence of high background genes, such as 
ribosomal or mitochondrial genes). From 10X genomic: These are the assignments of each 
cell-barcode to clusters by an automated clustering algorithm. The clustering groups together 
cells that have similar expression profiles. The axes correspond to the 2-dimensional 
embedding produced by the t-SNE algorithm. In this space, pairs of cells that are close to 







Figure 6.9. STRING analysis for first 50 upregulated genes in Carejavi (with legend, starting from previous page): Results are showing the output obtained from 
STRING analysis for the first 50 upregulate genes from Carejavi. Output network is showing more significant interaction than expected, meaning that my proteins have more 
interaction among themselves than what would be expected for a random set of proteins of similar size, drawn from the genome. This enrichment indicates that the proteins 





Figure 6.10. Expression of HLA-DRB1 in Carejavi Results are showing the HLA-DRB1 gene expression output obtained from 10X single cells genomic sequencing. 




Seurat comparative analysis between Carejavi and two EBV+ cell line 
using online available single cells dataset: Carejavi express typical 
marker of LCLs. 
 
An alternative analysis using Seurat has been performed on lymphoblasts from 
experiment 0051 in order to compare them with two publicly available single 
cell dataset of EBV+ cell lines: GM18502 and GM12878. These datasets have 
been obtained from Osorio et al [247]. The 3 cell lines have been analysed in 
parallel and showed similar QC results, in term of RNA feature (genes), RNA 
count (absolute count of RNA), percentage of mitochondrial genes (which 
account for apoptic cells) despite the difference in absolutes numbers 
(GM18502: 5437 cells; GM12878: 7186 cells; Carejavi: 943 cells (fig 6.11). 
Next, the identification of highly variable feature (feature that exhibit high cell 
to cell variation) has highlighted several similarities in the top 20 genes 
between the Carejavi and the other two cell lines, with CCL3, CCL4, and 
CCL22 as the most homogenously genes represented (fig 6.12). After 
regression of genes related to the cell cycle, this list of features has been then 
used to calculate PCs (including dimensional heatmap, elbow plot and 
jackstraw plot, Supplementary figure 6.1 - 6.4) in order to perform clustering 
and create a Uniform Manifold Approximation and Projection (UMAP) for 
non -linear dimensionality. For this analysis the first 10 PCs have been used 
(fig 6.13).  The final expression heatmap of the 10 most representative genes 
has been generated for all the 3 cell lines according to the number of clusters 
and can be visualized in figure 6.14, 6.15 and 6.16. I particularly focused on 
the mutually exclusive compartmentalization of genes related to 
Immunoglobulin/differentiation versus activation/NFKBI (for this clustering 
list of genes suggested by Sorelle have been used [252], Fig.6.17-6.19). What 
is more interesting is that CD58 and CD23/FCER2 positive cells tends to be 
more closely clustered with the activation and NFKB targeted related genes. 
This is a further confirmation not just that the Carejavi are behaving like a 
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lymphoblastoid cell line but also that cells expressing CD23/FCER2 and 







(From previous page) Figure 6.11. Quality control results between the 3 cells lines: GM18502, GM12878 and Carejavi: Results are showing violin plots for RNA 
features (genes), count of absolute RNA molecules and mitochondrial genes percentage. Same data are expressed also as Scatter Feature plot. Absolute number of cells 






 Figure 6.12. Identification of highly variable features between the 3 cells lines:GM18502, GM12878 and Carejavi: Results are showing  















Figure 6.15. Expression heatmap for GM12878.
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Figure 6.17. Comparison between the 3 cells lines for differentiation and NFKB related genes: Results are showing mutually exclusive clustering of cells expressing 
genes related to differentiation (TNFRSF17, XBP1, MZB1, CD27) and genes related to NFkB cascade and activation (NFKB2, NFKBIA, EBI3, ICAM1, BCL2A1) between 




Figure 6.18. Comparison between the 3 cells lines for Immunoglobulin and NFKB related genes: Results are showing mutually exclusive clustering of cells expressing 
genes related to immunoglobulin (IGHM, IGHA1, IGHG1) and genes related to NFkB cascade and activation (NFKB2, NFKBIA, EBI3, ICAM1, BCL2A1) between the 3 
different cell lines. Red is for NFkB signature, while blue is for Immunoglobulin signature.
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Figure 6.19. Comparison between the 3 cells lines for CD58 and CD23/FCER2: Results are showing cells expressing CD58 and CD23/FCER2 genes. Red is for 
CD23/FCER2 signature, while green is for CD58 signature.
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Co-culture transcriptomic analysis: reciprocal effect of RACD19+ B 
cells on RA-FLS phenotype 
 
Singles cells 10X genomic sequencing and STRING analysis reveal 
RA-FLS phenotype switch when in co-culture with RA-CD19+ 
 
One co-culture experiment (RA-FLS and RA-CD19+ B cells) and control 
(RA-FLS alone) were screened using single cells 10X genomic platform. 
Preliminary data showed that RA-FLS cultured with RA-CD19+ B cells tend 
to switch from a proliferative and invasive phenotype to a more inflammatory 
one (Fig.6.20, 6.21). Specifically, RA-FLS in co-culture showed to 
downregulate genes related to cell proliferation pathways, while upregulate 
those ones relative to type I interferon signalling, cellular response to organic 




Figure 6.20. Differential gene expression between RA-FLS co-cultured with EBV+RACD19+ and control (downregulated) Results are showing that co-cultured RA-
FLS (on the left) tend to downregulate expression of genes as Cartilage Oligomeric Matrix Protein (COMP), Microfibril Associated Protein 4 (MFAP4), and Stimulator Of 
Chondrogenesis (SCRG1). Relative expression output obtained from 10X single cells genomic sequencing. Graphs has been obtained with 10Xsoftware LOUPE (10x 
genomic)  







Figure 6.21. Differential gene expression between RA-FLS co-cultured with EBV+RACD19+ and control (upregulated) Results are showing that co-cultured RA-FLS 
(on the left) tend to upregulate expression of genes  Interferon Alpha Inducible Protein 27 (IFI27), IL32, and Carbonic Anhydrase 12 (CA12). Relative expression output 
obtained from 10X single cells genomic sequencing. Graphs has been obtained with 10Xsoftware LOUPE (10x).







Figure 6.22. Upregulated and downregulated genes in co-culture vs control (starting from previous page). Heatmap obtained through single cells 10X genomic 5’ 




Type I interferon Signaling Pathway Cellular Response to organic substances Response to Cytokine
 219 
Type I interferon Signaling Pathway Cellular Response to organic substances Response to Cytokine
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Figure 6.23. Upregulated and downregulated genes in co-culture (previous pages): 
Results are showing the output obtained from STRING analysis for first 50 upregulate (Top 3 
) and downregulated (bottom e) genes for RA-FLS cultured with B cell, compared to RA-
FLS. Output network is showing more significant interaction than expected, meaning that my 
proteins have more interaction among themselves than what would be expected for a random 
set of proteins of similar size, drawn from the genome. This enrichment indicates that the 
proteins are at least partially biologically connected, as a group.
 225 
Singles cells 10X genomic sequencing analysis reveal that EBV+ 
RACD19+ co-cultured with RA-FLS express genes important in 
ectopic GC formation  
 
The EBV+RACD19+ cells cultured with the RA-FLS used in the previous 
experiment have been screened as well for VDJ and 5’ transcriptomic.  From 
the VDJ analysis a small group of clonotypes (mainly IgG and IgM) has 
emerged, (Fig.6.24). Regarding the transcriptomic analysis, the t-SNE plot 
obtained from the 10x analysis has divided these cells in 4 main clusters, 
which has given me the possibility to extrapolate an heatmap from LOUPE 
(Fig.6.25). From these graph it is possible to appreciate several genes 
important for the GC formation are, such as Epstein Barr  Virus Induced 3 
(EBI3), LTA and LTB (Fig.6.26). Also, several marker of proliferating B cells 
are upregulated, such as mki67 and also those ones connected to oncogenic 
viral transformation, like MYC . However, these are preliminary data and 




Figure 6.24. Barcode frequency from 10X genomic single cells sequencing for V(D)J: Results are showing emerging clonotypes from VDJ analysis of EBV+RACD19+ 
cultured with RA-FLS. 
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Figure 6.25. t-SNE from 10x genomic single cells sequencing for 5’ transcriptomic: Results are showing 4 main clusters obtained from 10 X t-SNE analysis. From 10X 
genomic: “These are the assignments of each cell-barcode to clusters by an automated clustering algorithm. The clustering groups together cells that have similar expression 
profiles. The axes correspond to the 2-dimensional embedding produced by the t-SNE algorithm. In this space, pairs of cells that are close to each other have more similar 




Figure 6.26. Upregulated and downregulated genes in of EBV+RACD19+ co-cultured with RA-FLS: Heatmap obtained through single cells 10X genomic 5’ 
transcriptomic analysis. The 4 clusters obtained are showing important genes for the ectopic GC formation, like LTA, LTB and EBI3. Also, genes important in oncogenic 




CHAPTER 7 DISCUSSION 
 
Significance of EBV infection in RA as a possible etiological factor  
 
In these PhD project I intended to clarify the intimate relationship between 
EBV, autoreactive B cells activation and the maintenance of autoimmunity 
against citrullinated antigens in the joints.  I have demonstrated that 
synovial fluid and synovial tissue FLS enhance the long-term survival of 
naturally occurring EBV infected B cells obtained from circulating B cells 
of both RA patients and healthy donors. This work has led to the 
generation of one RA-derived EBV+LCL cell line (obtained with the 
above-mentioned feeding layer) and suggest that the co-culture of B cells 
with RA-FLS might be a good experimental arrangement for the 
establishment of LCL, which are a powerful research tool. 
Also, I have investigated if - on the other hand - the co-cultured EBV 
infected B cells are able to enhance RA-FLS inflammatory response, which 
from my single-cell RNA seq data seems the case. 
For last, I have tried to investigate if these cells are bearing an autoreactive 
phenotype, but at the moment all results are negative and further 
investigation is needed. 
In order to obtain long-standing EBV-infected B cells, I have setup an in 
vitro co-culture system whereby RA-FLS obtained from synovial fluid and 
synovial tissue of ACPA+ patients were cultured with isolated CD19+ B 
cells from RA patients and HD controls for long-terms. RA-FLS were used 
as scaffolding and feeding environment for RACD19+ cells obtained from 
ACPA+ RA patients. CpG was added to the co-culture in order to induce 
EBV+ memory cells to plasma-cells differentiation for testing the presence 
of ACPA antibodies towards viral epitopes (total IgG, IgM and IgA; IgG-
ACPA, IgG-EBNA, IgG-VCA). The latter has been chosen following 
Lanzavecchia and Bernasconi’s protocol, where they showed that human 
memory B cells tend to proliferate and finally differentiate into plasmacells 
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in response to CpG, while Naïve B cell require simultaneously CpG and 
the BCR stimulation[241]. Other growth factors, cytokine and chemokine 
have been tested such as IL-6, IL-8, BAFF and APRIL. Furthermore, 
Interleukin-2 (IL-2) was added to the co-culture in order to stimulate cell 
survival. At the end of the co-culture single cell sorting was performed, 
genomic DNA was recovered to perform molecular biology analysis to 
detect and quantify specific EBV-related gene through the BAMHI W-
repeated region in RACD19+, while RNA was isolated to test it for 
inflammatory related genes in RA-FLS. 
 
In the first part of my PhD I focused on getting a better understanding on 
how to work with FLS from different sources (synovial fluid and synovial 
tissue) and to how the in vitro conditions can actually alter the phenotype 
of these cells. Apparently both fibroblast from synovial fluid and synovial 
tissue are behaving similarly - when cultured in the same conditions - and 
have been kept in culture without any sign of senescence.  
I decided then to perform preliminary experiments with total PBMCs and 
RA-FLS from ACPA+ RA patients in order to create the best protocol for 
my co-culture.  
Unfortunately, most of these experiments failed due to a strong immune 
reaction of the total PBMCs versus the RA-FLS, evidently caused by MHC 
mismatch detected by T cells. The heterologous nature of the assay has 
been an obstacle during this preliminary phase and, indeed, obtaining both 
FLS and B cells from the same patient has resulted challenging (and has 
been possible only in one case).  
After performing CD19+ positive bead purification to the PBMCS prior to 
the co-culture, my protocol greatly improved. Also, the fact that 
plasmacells almost do not express CD19 has allowed to perform a sort of 
“autozero” in my system, regarding CSR and antibody production. At this 
point I have been finally able to obtain some preliminary results. The first 
evidences showed that RA-FLS are able to nourish B cells and keep them 
alive up to a maximum of 123 days and to observe the first sign of 
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activation and proliferation.  Some of the mechanisms through which FLS 
helps different immune cells are well known:  CD19+ cells are protected 
from cell death when cultured with FLS from RA through a mechanism 
that requires VCAM-1 and α4β1 integrin (VLA-4) and this interaction has 
been shown to be associated with increased expression of apoptosis 
inhibitors like Bcl-X[253]. Also, different cytokines such as BAFF and 
APRIL are produced by FLS. The former is produced in RA after 
engagement α5 (VLA-5) and β1 (ITGB1) integrins on the cell surface  
[117].  Production of these two ligands in supernatant has already been 
proven in my lab by Bombardieri and Kam during a short co-culture 
experiment (1 to 3 days). In this experiment RA-FLS – upon a TLR-3 
stimulated pathways - were able to sustain tonsil naïve B cell SHM through 
the induction of AID expression and Ig class-switching [126]. At this point 
I decided to: i) standardise the protocol time and conditions; ii) increase the 
number of starting B cells (in order to have a greater chance of getting an 
EBV+ B cells); iii) test also B cells from healthy donor on the same RA-
FLS. Indeed, SHM and CSR were confirmed also in my experiments 
through ELISA and FACS.  
Specifically, FACS data have shown a significant increase of CD38+ and 
IgM+ subsets during co-culture in presence of EBV-driven proliferation 
and a smaller, but not significant, increase of switched IgG+ cells 
compared to control. Part of the increase in IgM+ might be due to the 
effect of the stimuli, since this subset is present also in the control B cells 
and CpG is known to induce also proliferation [241, 254]. Nevertheless, 
the difference between these two groups - when the cells are co-cultured - 
is significantly higher, so part of it is definitely induced by the RA-FLS. 
Interestingly, CpG does not seems to have any effect on CD38, therefore 
the result obtained can be genuinely connected to the presence of EBV. In 
fact, the increase of CD38 and IgM observed on the lymphoblast in my co-
cultures matches the LCL phenotype described in literature by several 
authors [255-257]. Since the typical isotype of RF is IgM and since all the 
patient used are ACPA positive, we performed several attempts to identify 
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if the antibodies produced were, in fact, autoreactive. Unfortunately, most 
of them failed and I am speculating that the assays I have used – which are 
usually used to test serum – do not have enough detectability power. Also, 
the more sensitive VCP1 and VCP2 assay was performed in Migliorini’s 
lab on the first batch of supernatant in 2016 and these experiments had a 
lower amount of B cells, thus were more diluted. Other experiments to 
investigate immunoreactivity have been scheduled.  
I later performed a wide array of experiments to rule out the possibility that 
my stimuli could have any sort of effect on the RA-FLS. Neither IL-2 nor 
CpG had any effect on the stromal cells in my system.  Namely Ospelt et al 
showed that TLR9 expression by FLS it is almost null [118].   
Following this exclusion procedure, I have researched the possibility that 
EBV can infect also the RA-FLS. This should not be the case, since RA-
FLS (and fibroblasts in general) do not express the surface markers 
necessary for viral infection, but cases of EBV identification in fibroblasts 
have been reported by a few authors [258]. Therefore, the sorted fibroblasts 
from my co-cultures experiment have been screened by qPCR for the 
presence of EBV and some of them resulted positive. Nevertheless, those 
who were positive for EBV were also positive for CD19 (data not shown). 
It is unlikely that this is the result of sorting errors, since the physical 
parameters used to sort FLS and B cells are quite different, but a scientific 
explanation might come from the evidences that B cell cultured for long 
time in vitro tend to actively migrate into the fibroblast cytoplasm, a 
fascinating mechanism called pseudoemperipolesis [259]. Hence, further 
investigation to understand if this event has happened in my system are 
ongoing, but the prospect that an EBV+ infected B cell can be internalized 
by RA-FLS is of great interest. 
Regarding the quantification of EBV using the BamHI W repeated regions 
gDNA qPCR, my results showed that both RACD19+ and HdCD19+ in co-
culture tend to exhibit an EBV-driven proliferation with a small significant 
difference between the two groups. The fact that also HdCD19+ have 
proliferate with the RA-FLS is not unexpected since – as above mentioned- 
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FLS can actively support B cells survival and anti-EBV T CD8+ specific 
cells are depleted from the system. It is important to mention that the 
results showed are an interpolation - through a standard curve - of the 
number of EBV copies on a given number of cells. In order to specifically 
quantify and determine the number of infected cells in our system we will 
need to use Poisson statistics, and work to generate these graphs is ongoing 
[260]. Moreover in 2017 Sanosyan et al have reported that reiterations of 
BamHI-W repeats sequence are also associated with a higher quantification 
variability when compared to LMP2A [261]. Nevertheless, this work was 
done to enhance clinical and therapeutic monitoring precision, which is 
beyond the scope of my project. 
Additionally, proliferation of EBV+ B cells has been already observed to 
be increased in the presence of fibroblast, as described by Wiesner et al 
[262]. Indeed, cells were kept alive for an outstanding record time of 1650 
days. However, these series of experiments were ran using murine 
fibroblastic L cells stably transfected with the human CD40 ligand and 
adding IL-4 to the co-culture. In my assay FLS cells are obtained from RA 
ACPA+ patient and neither irradiated nor modified, resembling more the 
pathological the patient and so are not biased as an artificial feeder cell 
line. 
As mentioned in the results, the LCL emerged from experiment 0051 have 
showed an outstanding proliferative behaviour, becoming a limitless 
resource of naturally EBV infected B cells from an RA patient and an 
advantageous tool for further experiments. After the 1st co-culture, these 
cells have been kept alone for a week in medium, and then cultured again a 
2nd time on RA-FLS without stimuli. The supernatants have been tested 
through LEGENDPLEX TM for several cytokines and chemokines. In this 
preliminary test Mip1-alfa seems to be the first molecule to be produced by 
the B cells despite presence of fibroblast or stimulation. It is possible that 
Mip1-alfa stimulates the FLS to produce high amount of IL-6 which in 
return can induce B cells, when infected, to proliferate. This subsequently 
leads to the production of CCL2 and IL8 in the first co-culture while 
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CXCL10, CCL5/RANTES and IL-12p70 are detected only when 
lymphoblasts are present. CCL5/RANTES increase might lead to the IL-8 
increase detected by ELISA in the 2nd co-culture [263]. These are just 
speculation and further experiments are needed to understand if any of 
these mechanisms are related to paracrine signalling or cell to cell contact. 
 
LCL 0051 have also been used to investigate in RA the EBV related subset 
reported by Megyola et al: CD58+/CD23hi and CD58+/CD23lo  where 
CD23, also known as Fc epsilon RII (FcεRII) is the "low-
affinity" receptor for IgE while CD58 or lymphocyte function-associated 
antigen 3 (LFA-3) is a cell adhesion molecule expressed on APC, 
(particularly macrophages) and is usually important for interaction between 
B and T cells[205]. My result showed that LCL 0051 have a strong 
presence of both CD58+/CD23hi and CD58+/CD23lo and that they are more 
likely different stages of the LCL rather that totally separated subsets with 
different functions. However, it is true that single cell sorted 
CD58+/CD23hi showed higher level of the BamHI transcript EBNA-LP 
compared to CD58+/CD23lo. Further experiments have started to 
investigate whether these cells are increased in autoimmune diseases (RA, 
SS or SLE) both in ectopic GC of synovia or salivary gland, but also at the 
periphery level. This is not unlikely since De Miguel et al have already 
reported activated CD23 hyperexpression in B cells from blood of RA 
patient, (but no connection to EBV were present in this work)[264]. 
Furthermore, these subsets might be used in order to predict those RA 
patients who are at risk of developing a lymphoma due to long use of 
immunosuppression drug, such as methotrexate or TNF blockers [64, 265]. 
 
After expanding the LCL 0051, it was clear that these cells were not losing 
their proliferative behaviour, so I formulated the hypothesis that they might 
be a possible cell line candidate.  In order to understand this, I started to 
perform a series of screening on the LCL 0051, referred from now on as 
“Carejavi”. I tested these cells for the production of immunoglobulin and 
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the result has showed that they produce low amounts of antibodies, mainly 
IgM, but not ACPA, or at least not detectable. 
The first evidence that these cells were all coming from a single related 
clonotype - IgH: VH3-7, D2-8, JH4; IgL: IGLV2-14, IGLJ2 - has been 
given by the VDJ analysis performed with the 10X sequencing. 
Intriguingly, the 5’ transcriptomic analysis has showed that the Carejavi 
overexpress the shared epitope related gene HLA-DRB1. This is of great 
interest because has made me speculate that rather than an autoantibody 
producing cells, the main role of the Carejavi might be of an APC. This is 
not unlikely since Hong et al have recently demonstrate in a very elegant in 
vivo work that B cells can be the dominant APC activating CD4+ T cells in 
response to virus-like particles[266]. Therefore, further investigation to 
understand if the Carejavi are able to present autoreactive antigens to other 
cells are already scheduled. The possibility of having a natural APC EBV+ 
infected B cells obtained from an ACPA+ patient is exciting, since it can 
become a model for a better understanding of possible EBV-RA related 
mechanisms: i) binding of the MHCII by gp42, ii) investigation of disease- 
related protein. Also, in connection with Trier et al work, it might elucidate 
EBV strain-specific characteristic in ACPA+RA patients [229]. It is 
imperative to mention, tough, that the possibility that the Carejavi preserve 
the identity of the originally infected cells is almost null. The original cell 
would have been in latency 0/I and, once activated, these cells are not 
known to revert back to proliferating latency III. It is much more likely that 
Carejavi are just bystander LCL cells after one cycle of lytic reactivation. 
Furthermore, the lack of any sign of autoreactivity so far may suggest that 
the rare EBV+ circulating cells are absolutely not more prone to be 
autoreactive nor representative of the situation in the RA synovium. 
Indeed, Tracy et al (as already mentioned in the introduction) have 
demonstrated that EBV can be found in self-reactive cells but does not 
preferentially survive in this compartment and so the possibility that the 
LCL in my possess will have any autoimmune potential is extremely low. 
One way to address this issue would necessarily require a different 
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approach and an increased number of samples, as suggested by Croia in 
2013: using explants from RA synovial tissue (or dissociated cultures) 
containing ectopic germinal centers (thus including both reactive 
fibroblasts and infiltrating lymphocytes) and using cyclosporin to inhibit T 
cell activation, could be used to immortalize the local EBV infected B cells 
and verify whether they indeed produce ACPA. Such an assay would be 
more difficult to control in term of all the different actors present in the 
explant (macrophages, perycites, endothelial cells, ecc ecc), but would 
definitely resemble more the synovial compartment in vivo, since the B 
cells would originate from the tissue and not from the peripheral blood. On 
a positive note, the alternative analysis performed with Seurat has shown 
that the Carejavi single cell dataset resemble very closely other similar 
LCL datasets available online: indeed, when compared to GM18502 and 
GM12878, the Carejavi seems to have the same mutually exclusive 
clustering of differentiation/immunoglobulin related genes compared to the 
NFkB targets. This is evident as well for  CD58 and CD23/FCER2, which 
mostly overlap with the same cells expressing the NFkB group. 
 
Regarding the investigation on the RA-FLS - after numerous attempts -
unfortunately part of the FACS data were inconclusive. It is true that I 
found the best condition of detachment, preservation of surface markers 
and staining for FLS, but the group of markers selected in my assay to 
identify different fibroblast subsets (following Mizoguchi’s work in 2017) 
have not allowed me to distinguish any possible pattern induced on the 
FLS by the B cells (data not shown) [149]. Also, reproducibility of a few 
positive experiments has been an issue. Conversely, the ELISA data on IL-
6 and IL-8 were reliable. Both RA-FLS and B cell can produce IL-6, but 
the IL-8 identified in my co-culture seems to be produced only by the RA-
FLS. I still need to elucidate whether this increase compared to control is 
directly related to some sort of active mechanism implying the virus or is 
an indirect consequence of only a higher number of cells. IL-6 is usually 
transiently produced in response to infective agents and trauma, but it also 
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involved host defence through the stimulation of acute phase reactions and 
immune responses. It is also involved in haematopoiesis[267].  
For what concern IL-8, this specific chemokine (C-X-C motif) has many 
roles, like inducing chemotaxis in target cells such as neutrophils and 
granulocytes. Also, IL-8 is strongly correlated to angiogenesis and a 
connection between EBV presence, stimulation of IL-8 and 
neovascularization in pathological conditions has been investigated by 
Yoshizaki et al [268]. It is not unlikely to speculate that EBV might induce 
a similar mechanism in the ectopic GC of an inflamed synovia - maybe in 
the early phase of the disease - acting as a trigger for IL-8 production by 
the stromal cells compartment, finally activating some of the events which 
have been quite often associated with a semi-neoplastic behaviour in RA. 
It is important to add that a slight increase in IL-6 production has been 
detected also in those samples which have not proliferated, and this sort of 
baseline enhancement is probably due to the feeding environment offered 
by the FLS.   
The availability of single cells 10x genomic sequencing has pushed me to 
screen a co-culture experiment with this assay. These data have just been 
recently produced, nevertheless some of the preliminary evidence are 
worth to be mentioned. 
The output has showed that RA-FLS co-cultured with EBV+ RACD19+ 
(without any stimuli) tend to switch from proliferative and invasive 
phenotype to a more inflammatory/cytokine producing one. Specifically, 
they tend to downregulate COMP, MFAP4, SCRG1 and Cadherin 11 (all 
genes related to the extracellular matrix and cell proliferation pathways) 
and to increase IFI27 or CA12 (more related to type I interferon signalling, 
cellular response to organic substances and response to cytokine). In 
particular this activation of the antiviral type 1 IFN pathway can be 
explained by the presence on FLS of TLR-3 and RIG-I, two PRR receptors 
which are known - as reported by Samanta et al - to be activated upon 
stimulation by EBER, which in my system is very likely to be present and 
have originated from the infected B cells [269]. On this topic, Stuhlmeier et 
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al have reported that the EBV is able to increase the production of 
hyaluronan on RA-FLS trough a similar mechanism [270]. Furthermore, 
Karpu et al have reported that triggering of the RIG-I, TLR-3 and MDA5 is 
able to induce the expression of CD55, but no such event was recorded in 
my experiment [271]. 
Of interest IL-32, one of the upregulated genes, is a chemokine who has 
been showed to prevent EBV lytic activation and has shown to have the 
potential to aggravate osteoclastogenesis in RA trough an IL-17 axis[272, 
273]. 
A possible mechanism of the above-mentioned interaction is summarised 
in figure 8.1. 
In conclusion, the relationship between EBV and RA is complex, and 
several mechanisms have been highlighted in this dissertation. With this 
work I aimed mainly to clarify the intimate relationship between EBV, 
autoreactive B cells activation and the maintenance of autoimmunity 
against citrullinated antigens in the joints. I provided evidence that 
synovial fluid and synovial tissue RA-FLS enhance the long-term survival 
of naturally occurring EBV infected B cells obtained from circulating B 
cells of RA patients and healthy donor and that, as a reciprocal mechanism, 




Figure 8.1. Possible mechanism of interaction between EBV+CD19+ co-cultured with RA-FLS: Scheme summarising the possible mechanism by which the interaction 
of RA-FLS and EBV+ infected CD19+ cells might promote RA pathology.  Upon activation of VLA-5 and ITGBI, RA-FLS upregulate April and BAFF production. Also, 
interaction between VLA4 and VCAM1 sustain survival of B cells and increase the expression of antiapoptic signals, such as Bcl-X. This mechanism just not leads to 
increased survival and proliferation of B cells but also an increase of CSR. Proliferating EBV+ B cell upregulate CD23, while the production of EBER can activate the type 1 





CHAPTER 8: PLAN OF FUTURE STUDIES  
 
Several plans for future work have been already highlighted in this 
manuscript. A summary is showed here: 
i) In order to replicates the co-culture results on a higher 
magnitude I will collect more RACD19+ from different donors 
and start a new set of co-culture experiments. Also, control co-
culture will be performed using: dermal fibroblast or FLS from 
different RA pathotypes; ACPA- patients, EBV- patients.  
ii) Confirming 10X data on RA-FLS repeating the experiment with 
different samples. 
iii) Continue characterization on Carejavi cells to understand 
scientific value and possible potential commercial exploitation: 
specifically investigate the possible APC role of Carejavi 
regarding autoimmune antigens. 
iv) In case of EBV driven proliferation an extra 96well plate will be 
single cell sorted in order to express the monoclonal antibody 
and, when possible, test them for autoreactivity. Preliminary 
data have already shown the feasibility of this approach. 
v) Investigate the role of the CD23/CD58 population by: FACS 
and immunofluorescence in RA and other autoimmune diseases 
vi) Increase ELISA and Legendplex panel in order to test other 
molecules relevant in inflammation, such as CXCL12 or 
RANK-L.  















Flask Size  Final 
Volume  
Seeding Density 
(Viable cells per 
flask) 
T25  5-7 ml  2.0 x 105 – 6.0 x 105 
T75  15 ml  8.5 x 105 – 1.3 x 106 
T175  20-25 ml  1.8 x 106 – 2.4 x 106 
 
Table 3.1. Seeding density for FLS: Note: The chart above is to be used as a guideline only. 
Basic seeding rule is 1.0-1.4 x 104 cells/cm2. Readapted from Coriell Institute for Medical 




Table 3.2. Purity, Characterization and Lymphoblast Panels for B Cell. Flow Cytometry Analysis panels for purity (Panel1), characterization (Panel2) 
and Lymphoblast (panel 3) for B cell.
Marker Fluruochrome Filter Marker Fluruochrome Filter
Only LSR Fortessa 1 Both Fortessa 1 and ARIA Fusion
CD3 BV785 V 780/60 CD3 PE Cy5 YG 670/30
CD19 PERCP.CY5.5 B 695/40 CD19 PERCP.CY5.5 B 695/40
CD20 AF488 B 530/30 CD20 AF488 B 530/30
CD27 APC R 670/14 CD27 APC R 670/14
CD38 BV711 V 710/50 CD38 BV711 V 710/50
IgD BV421 V 450/50 IgD PE YG 582/15
CD56 APC Cy7 R 780/60 IgG APC H7 R 780/60
CD14 PE YG 582/15 IgM BV421 V 450/50
LiveDead Zombie V 525/50 CD24 PE/Dazzle 594 YG 610/20
LiveDead Zombie V 525/50




























Name Cluster Cell Flurochrome
PTPRC CD45 Hematopoietic	lineage	cells BV510
MCAM CD146 Pericytes BV510
GYPA CD253a RedBloodCells BV510
PECAM1 CD31 Endothelial	cells BV510
Podo FLS AF647
Cadherin11 FLS	 PE
CD34 CD34 FLS BV785
THY-1 CD90 FLS BV	650




















Table 3.4. Primer and probe for EBV BamHI W gDNA qPCR. Fl All probes are 























GAPDH F ACAGTCCATGCCATCACTGCC 
GAPDH R GCCTGCTTCACCACCTTCTTG 
CD19 F AGAACCAGTACGGGAACGTG 
CD 19 R CTGCTCGGGTTTCCATAAGA 
LMP2A F TTCTGGCTCTTCTGGGAACA 
LMP2A R ATTGCCCCAATCTGAGTCCT 
EBER F AAAACATGCGGACCACCAGCC 
EBER R AGGACCTACGCTGCCCTAGA 
EBNA 1 F GGAGCCTGACCTGTGATCGT 
EBNA 1 R TAGGCCATTTCCAGGTCCTGTA  
   EBNA2F             TGGAAACCCGTCACTCTC 
    EBNA2I TAATGGCATAGGTGGAATG 
EBNA2C AGGGATGCCTGGACACAAGA  
EBNA2G  GCCTCGGTTGTGACAGAG  
EBNA2B  TTGAAGAGTATGTCCTAAGG  
 
 




Patient Code Diagnosis Sample Sex Age at Collection 
RA 
Qmul-Rbb  057/11 RA Synovial tissue Male N/A 
 Qmul-Rbb 040/2016 RA Synovial Fluid Female 48 
Qmul-Rbb 2018/003 RA Synovial Tissue Male 27 
Qmul-Rbb 034/2016 RA Synovial Fluid Female 57 
Qmul-Rbb 023/2015 RA Synovial Fluid Male N/A 
Qmul-Rbb 099/2016 RA Peripheral Blood Female 74 
EMR-RTB 0051 RA Peripheral Blood Male 46 
EMR-RTB 0060 RA Peripheral Blood Female 75 
EMR-RTB 0160 RA Peripheral Blood Male 28 
EMR-RTB 0190 RA Peripheral Blood Female 66 
EMR-RTB 0195 RA Peripheral Blood Female 32 
EMR-RTB 0022 RA Peripheral Blood N/A N/A 
EMR-RTB 0023 RA Peripheral Blood N/A N/A 
EMR-RTB 0029 RA Peripheral Blood N/A N/A 
EMRRTB 0050 RA Peripheral Blood N/A N/A 
       
OA Qmul-Rbb 099/2017  OA Synovial Tissue Female 74 
Qmul-Rbb 109/2017 OA Synovial Tissue Female 63 
       
 248 
PsA Qmul-Rbb 026/2015 Psoriatic Arthritis Synovial Tissue N/A N/A 
       
HD 
EMR-RTB-HD 0040 Healthy Peripheral Blood Male 31 
EMR-RTB-HD 0041 Healthy Peripheral Blood Female 32 
EMR-RTB-HD 0047 Healthy Peripheral Blood Female 42 
EMR-RTB-HD 0048 Healthy Peripheral Blood Female 48 
EMR-RTB-HD 0049 Healthy Peripheral Blood Female 32 
EMR-RTB-HD 0050 Healthy Peripheral Blood Female 42 
 





Patient Code DX Sample Source Cell  
Experiment 















• 8 • 8 • Sample have been 















• 1 • 8 • Sample have been 
















• 2 • 8 • Sample have been 














• 1 • 8 • Sample have been 














• 2 • 8 • Sample have been 















• 2 • 8 • Sample have been 














• 2 • 8 • Sample have been 











• FACS comparison using 
different detaching 
agents 
• 1 • 1 flask • Sample used for FACS 
analysis 
• FACS Comparison 
between RA-FLS and 
OA-FLS at different 
passages  
• 1 • 1 flask • Sample used for FACS 
analysis 
• IL-6 and IL-8 production 
in RA-FLS stimulated 
with CpG and IL-2  
• 1 • 2 wells of a 12 
well  plate 
• SN tested on ELISA for IL-6 
and IL-8 
• Relative Expression of 
co-culture related genes 
after 28 days 
stimulation with IL-2 
and CpG on RA-FLS  
• 1 • 3 • Extracted RNA has been 
retrotranscribed and 
cDNA used for qPCR 
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• FACS Comparison 
between RA-FLS and 
PsA-FLS  












• FACS comparison 
using different 
detaching agents 
• 1 • 1 flask • Sample used for 
FACS analysis 
• Co-Culture • 4 • 2 wells of 




• SN tested on ELISA 
(IL-6, IL-8, IgG, IgM, 
IgA) 












• FACS comparison 
using different 
detaching agents 
• 1 • 1 flask • Sample used for 
FACS analysis 
• Co-Culture • 6 • 2 wells of 




• SN tested on ELISA 
(IL-6, IL-8, IgG, IgM, 
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Supplementary Figure 6.1. Elbow plot and Jackstraw plot for Carejavi, GM18502, GM12878. Graph are showing Elbow plot ( a ranking of principle 
components based on the percentage of variance explained by each one) and Jackstraw plot (visualization tool for comparing the distribution of p-values for 









Supplementary Figure 6.3. Dimensional Heatmap of the first 10 PCs for GM12878 (4 genes).  
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